Identification of response pathways of prostate cancer cell lines in Hans Clevers Media by Hutchinson, Alexander B.
 
 
 
 
Identification of Response Pathways of Prostate 
Cancer Cell Lines in Hans Clevers Media 
 
 
 
 
 
 
 
 
 
 
 
 Alexander Hutchinson 
 
 
Submitted in fulfilment of the requirements for the degree of 
 Master of Applied Science (Research) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Australian Prostate Cancer Research Centre - Queensland 
School of Biomedical Science 
Institute of Health and Biomedical Innovations 
Faculty of Health 
Queensland University of Technology 
2017 
 
  
i 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ii 
Key words 
 
Prostate cancer 
In vitro cell culturing  
Stem cell media 
Cell culturing systems  
RNA sequencing 
Androgen sensitive prostate cancer cells 
Pathway analysis 
Transcriptomic analysis 
Androgen Receptor  
Neuroendocrine 
Lipid Metabolism  
 
 
  
iii 
Abstract 
Prostate cancer is a significant public health concern, with its latter stages remaining 
incurable. The development of a more diverse in vitro prostate cancer cell model is vital to 
advancing research into this disease. The creation of a novel prostate cell culturing system 
by Hans Clevers and colleagues, termed Hans Clevers Media (HCM), is a move towards this 
more complete model, however, the detailed mechanism of action within this media 
remains undefined. This study aimed to uncover these media specific responses within this 
novel culture media, through transcriptomic analysis. RNA sequencing data from LNCaP 
and VCaP prostate cancer cell lines, cultured with HCM, underwent pathway analysis, 
thereby identifying the differentially expressed genes and pathways. These pathways were 
investigated on the transcriptome level, in both LNCaP and VCaP cells cultured in HCM, 
compared to standard RPMI media, which was used as a control. The androgenic response 
of these cell lines was stimulated using DHT, so to investigate the effect of HCM on 
androgen regulated pathways. Results showed that HCM influences the activation of 
androgen receptor signalling in both cell lines, via multiple mechanisms. Additionally, an 
increased expression of neuroendocrine related genes was found, suggesting a possible 
neuroendocrine-like response to growth in HCM. These results together suggested that 
HCM potentially enables prostate cancer cell’s ability to bypass the androgen receptor, 
allowing for proliferation, even in androgen-deprived environments and the transition to 
treatment resistant prostate cancer. A further finding indicated that HCM has a significant 
impact on the lipid metabolism at the transcriptome and cellular level, suggesting a 
possible process behind its ability to facilitate self-organisation of cells in vitro. These 
findings will inform future research through the greater clarity regarding the interactions of 
HCM on cell function and its potential interaction with specific treatment responses. 
Further research on pathways affected by the use of HCM on primary prostate cancer cells 
and prostate cancer circulating tumour cells is recommended.  
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Chapter 1: Introduction 
1.1 Context for Thesis  
Prostate cancer (PCa) represents one of the largest health challenges facing both 
the healthcare community and general public. Adenocarcinoma of the prostate is the most 
commonly diagnosed solid organ malignancy and the second most common cause of 
cancer related deaths among men in Australia, with an increased risk of diagnosis present 
for those above the age of 60 (Cancer Council Australia, 2016). Although the causes of PCa 
are not fully understood, research suggests that factors such as the patient’s age, family 
history, ethnicity, lifestyle and environmental factors are risk factors (Attard et al., 2016). 
The National Cancer Institute in the United States asserts that the 5-year survival rate for 
metastatic prostate cancer is only 28.7% (National Cancer Institute, 2016). Metastatic 
prostate cancer poses significant life threatening risks that can be only temporarily 
controlled with current therapeutic interventions. Further investigation into the processes 
and pathways involved in development of these therapeutic resistant stages of the disease, 
also known as Castrate Resistant Prostate Cancer (CRPC), is required (Attard et al., 2016). 
With the development of transcriptional analyses, along with pathway analysis, comes the 
possibility of precision medicine at the genomic level (Mirnezami, Nicholson, & Darzi, 
2012). This deeper understanding is necessary for more precise patient specific treatments 
and diagnoses (Attard et al., 2016). Using these genomic profiles integrated with diverse 
PCa cell models opens the possibility of precision patient specific drug treatments, not 
achievable in the past (Gao et al., 2014). 
An ongoing issue in using transcriptional analyses as a tool for cancer research is 
the ability to cultivate primary PCa cell lines in vitro (Gao et al., 2014). With the recent 
advancement of cell specific culture systems, this limitation has been overcome, creating 
more representative in vitro models for PCa research (Drost et al., 2016). However, even 
with these innovations, PCa cells have remained problematic to propagate in vitro (Gao et 
al., 2014). In hopes of creating a more representative model, Gao and colleagues (2014) 
successfully utilised a novel culture media, tailored to support the growth of PCa cells in 
particular. HCM (Hans Clevers Media) has successfully facilitated continuous propagation of 
primary PCa cell lines at rates not seen using standard RPMI growth media (Gao et al., 
2014).  
This critical research has now made it easier to establish and culture novel PCa cell 
lines in vitro. However, there still remains many uncertainties in regards to the complex 
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mechanisms of this media and its specific effects on the cell. This insight is key in the 
development of more effective diagnostic and therapeutic research, leading to future 
clinical applications.  
1.2 Aims and Significance  
This thesis aims to uncover HCM promoted effects on PCa cell lines at the 
transcriptome level, utilising pathway analysis, creating more clarity within this new in vitro 
model system. Specifically, this project will focus on HCM’s impact on the Androgen 
Receptor (AR) pathway, in comparison to the standard RPMI media, and on the 
mechanisms behind HCM’s success supporting PCa cell growth. These interactions will be 
explored across two AR positive PCa cell lines, LNCaP and VCaP.   
1.2.1 Research Significance   
It is hoped that knowledge found from these investigations will assist future 
researchers to distinguish between the effects of applied treatments and possible 
underlying effects of the culture system, allowing more accurate experimental 
interpretation. Additionally, this greater awareness is anticipated to inform research into 
these new culturing techniques with more detailed information on the mechanism of their 
success, in order to allow further evolution of the media, as well as the ability to create 
patient tailored systems and treatments. This will therefore, improve both novel 
methodology and assist towards a future of precision based medicine in PCa research. 
1.2.2 Aims and Key Objectives Outline  
 
  
 
 
 
Figure 1.1 Diagram of aims and objectives with the current study   
Uncover transcriptome wide changes/effects of HCM on 
PCa cell lines 
HCM impact on the Androgen 
Receptor  pathway in PCa 
Mechanisms behind HCM’s 
success at PCa cell growth 
Investigate pathways 
of potential 
therapeutic resistance 
with HCM 
Investigate HCM effects 
on metabolic pathways, 
with androgen and PCa 
associations 
Investigate androgen 
responsive pathways 
regulated in HCM 
 
Through Cell Growth and Pathway Analysis 
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Chapter 2: Literature Review  
2.1 Prostate Cancer - Mechanisms and Course  
2.1.1 Androgen Receptor  
The AR plays a crucial role in the normal physiological development and 
maintenance of the prostate as well as in the male phenotype development (Cunha et al., 
1992). Studies show that PCa cells require the AR for growth and proliferation and even in 
CRPC a functional AR remains a key regulator (Tan, Li, Xu, Melcher, & Yong, 2015). 
The AR belongs to the nuclear receptor superfamily and contains three functional 
domains; the N-terminal transactivation domain, the DNA-binding domain (DBD) and the C-
terminal ligand-binding domain (LBD) (Tian, He, & Zhou, 2015). 
The natural ligands for AR are androgens, which are steroid hormones produced 
primarily in the testis by Leydig cells (Ellis, Desjardins, & Fraser, 1983). A study of post-
castration 69 to 80-year-old men showed the testes to be responsible for 97% of the serum 
testosterone with the remainder produced by the adrenals and intra-prostatic 
steroidogenesis (Labrie et al., 2009). The androgen most responsible for AR activity is 
dihydrotestosterone (DHT) and 5α reductase is the enzyme that converts testosterone to 
the more potent DHT. The importance of DHT in male physiology is highlighted by the 
autosomal recessive disorder 5α-Reductase deficiency. Males with this deficiency have 
abnormally developed male external genitalia as well as rudimentary prostates (Wilson, 
1996).   
The dependency of PCa on AR activity in response to androgen provides hormone 
dependent pathway therapeutic targeting. In their landmark paper, Huggins, Stevens and 
Hodges (1941) demonstrated 75 years ago that castration in cases of advanced PCa leads to 
palliation of symptoms, whereas androgen administration aggravated the disease. Since 
that time, androgen deprivation therapy (ADT) has remained the standard treatment for 
certain types of localized PCa as well as metastatic PCa (Attard et al., 2016). ADT may be 
surgical or pharmaceutical induced. Pharmaceutical intervention is categorized into; 
pituitary hormone analogues, which lead to downstream reduction in testosterone; direct 
targeting of the AR; and inhibiting de novo steroidogenesis (Sharifi, Gulley, & Dahut, 2005).   
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2.1.2 Lipid metabolism and PCa  
Lipid metabolism is strikingly affected by androgens and lipid metabolism 
dysregulation is a key feature of PCa development (Butler et al., 2016; Wu, Daniels, Lee, & 
Monaco, 2014). As lipid metabolism is regulated by androgens, lipids have the potential to 
be effected by elements in certain media systems that would regulate the AR.  
Lipids are necessary molecules for life and nearly all cells possess the ability to 
obtain and amass lipids. To utilise lipids and meet cellular demands cells use lipid droplets 
(LDs), a specialized intracellular organelle with a phospholipid monolayer exterior 
containing a neutral lipid core (Wilfling, Haas, Walther, & Jr, 2014). The normal LD cellular 
functions including storing metabolic energy, storage of fat soluble vitamins, serving as a 
lipid buffer and providing components to both the cell membrane and organelle 
membranes, are found to be amplified in PCa cells (Baenke, Peck, Miess, & Schulze, 2013). 
Despite both the important cellular functions and near ubiquity of LDs, many aspects of LD 
biology are not fully understood, particularly in regards to their effect on PCa growth 
(Walther & Farese, 2012; Wilfling et al., 2014).  
 The majority of LD formation likely occurs de novo (Walther & Farese, 2012). 
Although not fully understood, a possible model for LD formation is neutral lipid synthesis 
in the endoplasmic reticulum (ER), intra-membrane lipid accumulation and LD formation or 
budding from the ER (Wilfling et al., 2014). The LDs can be located throughout the cell, 
however, LDs associate with mitochondria during increased cellular demands for energy. It 
has been suggested that LD and mitochondrial fusion facilitates the neutral lipids transfer 
to the mitochondria matrix for beta-oxidation in order to achieve cellular energy 
requirements (Gao & Goodman, 2015). 
Androgens drive lipid metabolism primarily through the promotion of de novo 
lipogenesis and fatty acid (FA) uptake (Butler et al., 2016).  Most metabolized cellular FA 
are either synthesized into neural triglycerides (TAG) for energy storage within LDs or into 
phospholipids for cell/organelle membrane growth or maintenance. The cellular 
requirements determine which metabolic pathway is activated (Chen & Li, 2016). During 
energy surplus FAs are converted into storage fats. If cellular energy demands are not being 
met FAs breakdown via ketogenesis as required (Foster & McGarry 1982). If rapid cell 
growth is ongoing, FA are synthesised into new phospholipid membranes and this process 
transpires primarily in smooth ER (Chen & Li, 2016). Phospholipid synthesis is either de 
novo by the Kennedy Pathway or through lipid modification via the Lands Cycle (Pol, Gross, 
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& Parton, 2014; Appendix Figure 1). Phosphatidylcholine is the most prominent 
phospholipid used in membrane synthesis.  
When considering the pathways behind the development of PCa, it is valuable to 
identify lipid metabolic pathways, as their dysregulation is required for PCa growth and 
metastasis (Wu et al., 2014). Cancer cells amplify the synthesis of phosphatidylcholine 
through the dysregulation of the Kennedy Pathway and FA metabolism, and this 
amplification potentially may result in increased tumour cell growth. (Awwad, Geisel, & 
Obeid, 2012; Chen & Li, 2016).  
2.1.3  PCa Diagnosis  
PCa occurs in male patients, generally aged between 55-69. A clinical examination 
involving a Digital Rectal Examination (DRE) and investigation of the Prostate Specific 
Antigen (PSA) levels in the patient’s serum are the initial steps towards diagnosis (Attard et 
al., 2016; Cancer Council Australia & Prostate Cancer Foundation of Australia, 2015). PSA is 
a nearly universally accepted serum tumour marker for PCa (Attard et al., 2016). If the free 
PSA levels in the blood increase above 3ng/ml or 0.35 ng/mL per year, it may be indicative 
of the need for biopsy of the prostate to investigate the presence of PCa (Attard et al., 
2016; Cancer Council Australia & Prostate Cancer Foundation of Australia, 2015).  
DRE may be used to identify abnormalities such as swellings, lumps, hardening 
and/or tenderness of the prostate, which can indicate the presence of tumours as well 
other prostate pathologies. Although not all tumours are palpable, a DRE may identify 
tumours that do not produce abnormally high PSA levels and therefore may not be 
identified testing serum PSA levels alone (Katafigiotis et al., 2016). If a patient has a positive 
DRE and/or elevated PSA, a transrectal ultrasound guided biopsy is indicated to obtain 
tissue for histological examination and definitive diagnosis. If the biopsy confirms the 
presence of a tumour, the sample is graded to assist in determining the patient’s 
treatment, management and prognosis. The system used in the diagnosis and management 
of PCa is the Gleason grading system. This system is a measure of cellular morphology, 
differentiation and tissue architecture obtained by microscopic examination of biopsy 
specimens. Tissue samples are assessed in respect to certain ‘Gleason Patterns’ giving 
scores 1-5 (see Figure 2.1), then grades are assigned to; the dominate pattern seen, 
primary grade (>50% of total pattern); and the next most common pattern, secondary 
grade. The primary grade score is then added to the secondary score, creating a total 
Gleason score. This score indicates the potential aggressiveness of the PCa (Brimo et al., 
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2013). A high Gleason Score indicates a less differentiated and therefore more aggressive 
cancer, with an increasing likelihood of metastases and thus progression to the lethal stage 
of the disease (Brimo et al., 2013; Table 2.1).  
 
 
 
Figure 2.1 Gleason Pattern Scale Diagram 
 
 
Table 2.1 Gleason Score for Metastatic Prostate Cancer (Brimo et al., 2013) 
Gleason Score WHO Risk Category Interpretation 
< 6 1 indicates a slow-growing, less aggressive cancer 
(3 + 4) 7 2 indicates a faster-growing and 
moderately aggressive cancer 
(4 + 3) 7 3 
(4 + 4) 8 4 
indicates a fast-growing, aggressive 
cancer 
9 & 10 5 
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2.1.4 Metastatic Prostate Cancer, Progression and Treatment 
Many low grade localised prostate cancers are considered relatively harmless 
requiring only active surveillance. However, if of a higher grade and requiring treatment 
radical prostatectomy, external-beam radiotherapy, and brachytherapy are all standard 
treatments for localised PCa (Attard et al., 2016). If after this local treatment, a rise in PSA 
is observed, local recurrence or metastatic disease may be indicated. Often at this stage 
ADT is commenced (Attard et al., 2016). 
ADT can be achieved via different approaches. These include castration, anti-
androgen treatment and intracellular steroidogenesis inhibition. The development of 
Leuprolide, a Gonadotropin-releasing hormone (GnRH) analogue, which continuously 
stimulates the pituitary gland resulting in chemical castration suppressing the production of 
testosterone, created an alternative to orchiectomy (Karantanos, Corn, & Thompson, 
2013).  
Bicalutamide (BIC), a non-steroidal anti-androgen, competes with circulating 
androgens for binding sites on the AR, promoting apoptosis, inhibiting gene expression and 
inhibiting PCa cell growth (Waller, Sharrard, Berthon, & Maitland, 2000). A drawback with 
bicalutamide treatment is that CRPC possess the ability to turn the antagonist activity into 
an agonist by way of a LBD mutation on the AR (Tian et al., 2015). 
Enzalutamide (ENZ) is a second generation anti-androgen, a rationally designed 
competitive inhibitor of the AR impairing the AR pathway through three established 
mechanisms; inhibition of AR ligand binding, nuclear translocation and DNA binding 
(Bambury & Scher, 2015; Schalken & Fitzpatrick, 2016). ENZ has eight times the affinity for 
the AR than bicalutamide (Ramadan, Kabbara, & Al Basiouni Al Masri, 2015). Unlike 
bicalutamide, ENZ remains an antagonist of the AR even in instances of high AR expression 
(Katsogiannou et al., 2015). One mechanism of resistance to ENZ is amplification of the 
constitutively active AR splice variant, AR-V7 (Bryce & Antonarakis, 2016).  
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Abiraterone is a CYP17 inhibitor used to inhibit intracellular steroidogenesis 
(Antonarakis et al., 2014). CYP17 is an important enzyme mediating the production of 
androgens from progestins and its role in steroidogenesis pathway can be observed in 
Figure 2.2 (Montgomery et al., 2008). Like ENZ, amplification of constitutively active splice 
variants, like AR-V7, leads to resistance to abiraterone treatment (Bryce & Antonarakis, 
2016). 
Figure 2.2 Steroidogenesis pathway and AKR1C3 involvement  
Note: (Δ5-Adiol, 5-Androstene-3β,17β-diol; Δ4-Adione, 4-Androstene-3,17-dione; 5α-Dione, 5α-Androstane-
3,17-dione; AR, Androgen receptor; ARE, Androgen response element; DHEA, Dehydroepiandrosterone; 5α-
DHT, 5α-Dihydrotestosterone; HSD3B, 3β-Hydroxysteroid dehydrogenase; PREG, Pregnenolone; SRD5A, 5α-
Reductase); enzymes are also listed as their gene names (Adeniji et al., 2013) 
 
2.1.5 Castration Resistant Prostate Cancer  
Of the patients who are administered ADT, more than 84% will have progressed to 
a treatment resistant stage in the disease within 5 years of starting treatment, however the 
mechanisms behind CRPC are still poorly understood (Kirby, Hirst, & Crawford, 2011; 
Nelson, De Marzo, & Isaacs, 2003; Tian et al., 2015). ADT resistant PCa, known as CRPC, 
may be independent of circulating androgen but it is not independent of AR signalling 
(Longo, 2010; Tian et al., 2015).  
The majority of deaths due to PCa are during the CRPC stage in the disease. 
According to one US study, the mortality of patients over the age of 65 diagnosed with 
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early stages of PCa was 7.6%, similar to the all-cause mortality rate of 5.7%, and most of 
the patients in this group die with the disease not from it (Scher, Solo, Valant, Todd, & 
Mehra, 2015). In striking contrast, 90% of the deaths from patients diagnosed with CRPC 
were directly attributed to the disease (Scher et al., 2015). Currently available therapies are 
rarely curative or able to produce long term remission. Current treatments generally have 
modest effects and according to one meta-analysis the median survival rates for CRPC are 
between 9 to 30 months (Kirby et al., 2011). As CRPC is considered essentially incurable 
and the mechanisms of resistance incompletely defined, this represents a significant and 
clear gap in the understanding of PCa (Kirby et al., 2011; Tian et al., 2015). Further research 
is needed to identify new pathways of resistance and to develop new agents to treat CRPC.   
2.1.6 Mechanisms of Development of CRPC 
CRPC is indicated by the presence of patient AR activity while undergoing ADT. This 
aberrant AR activation is denoted by rising levels of PSA and/or disease progression despite 
serum testosterone at castrate levels (<50 ng/dL) (Cookson, Lowrance, Murad, & Kibel, 
2015; Crona et al., 2015). At a transcriptomic level, this AR activation is determined by the 
expression of Kallikrein-Related Peptidase 3 (KLK3), a gene that codes for PSA (Knudsen & 
Penning, 2010). AR amplification or overexpression with consequent AR activation, despite 
serum castrate levels of testosterone, is one possible mechanism leading to CRPC (Graham 
& Schweizer, 2016; Tian et al., 2015).  
AR mutations are implicated in the development of CRPC and to date over 1,000 
AR mutations have been reported (Eisermann, Wang, Jing, Pascal, & Wang, 2013). One 
example of an AR mutation is the AR point mutation of the LBD. Normally, androgen 
ligands bind to the LBD of AR causing a translocation into the nucleus to dimerize with 
another AR. After dimerizing the complex binds to a regulatory region to regulate 
transcription of androgen dependent genes, such as KLK3, resulting in PCa cell survival and 
proliferation (Crona, Milowsky, & Whang, 2015). A mutated LBD non-specifically activated 
by atypical ligands such as adrenal androgens, non-adrenal steroid hormones or even 
antiandrogen drugs leading to uncontrolled AR activation is a proposed mechanism behind 
CRPC development (Crona et al., 2015).  
Another AR mutation potentially leading to CRPC is the expression of constitutively 
active splice variants such as AR-V7 (AR3). The AR3 splice variants are predominantly 
localised in the nucleus and do not require androgen ligand activation to promote the 
transcription of AR target genes (Crona et al., 2015). 
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Under normal conditions the AR recruits co-activator and co-repressor molecules 
to alter transcription, amplification, and dysregulation of these molecules potentially 
underlies a cause of CRPC (Chandrasekar, Yang, Gao, & Evans, 2015). Cytokines such as 
Interleukin 6 (IL6) or Interleukin 8 (IL8) are known co-activators of AR (Katzenwadel & Wolf, 
2015). IL6 activates the AR independent of androgens, promoting PCa cell growth, through 
activation of the AR gene promoter and through the MAPK (Mitogen-Activated Protein 
Kinase) signalling cascade (Malinowska et al., 2009).  
Tyrosine kinase receptor-activating ligands, such as insulin-like growth-factor-1 
(IGF1) and epidermal growth factor (EGF) potentially activate the AR through ligand-
independent mechanisms, creating an ‘outlaw AR’, through a number of pathways 
including MAPK signalling cascade ultimately resulting in CRPC (Liao, R., et al. 2013; Tan, Li, 
Xu, Melcher, & Yong, 2015) 
One general mechanism by which PCa cells potentially become castrate resistant is 
through intra-tumoural steroidogenesis (Graham & Schweizer, 2016). PCa cells in some 
studies have demonstrated the ability to produce androgens using several pathways. Weak 
androgens such as dehydroepiandrosterone (DHEA) produced by the adrenals, are utilized 
for the production of testosterone and DHT by PCa cells (Hamid 2013; Penning, 2014). The 
percentage of androgen metabolites (weak androgens, such as DHEA) remains high post-
castration due to adrenal and intra-prostate steroidogenesis (Kumagai et al., 2013; Labrie 
et al., 2009). Another means of intracellular steroidogenesis is progesterone precursor de 
novo androgen synthesis from circulating cholesterol (Cai 2011b; Lu et al., 2006; 
Montgomery et al., 2008). The rate limiting step in cholesterol synthesis is controlled by 
HMG-CoA reductase, and that enzyme along with the isoprenoids, lipid signalling 
molecules, are inhibited by the drug simvastatin (Kim, Cox, & Wasan, 2014; Luu-The, 2013; 
Pedersen & Tobert, 2004). A study using C4-2 cells, a castrate resistant subline of LNCaP 
cells, showed decreased cell viability and decreased PSA secretion following simvastatin 
treatment, however, whether or not statins inhibited intracellular steroidogenesis was not 
determined (Kim, Cox, & Wasan, 2014). Steroidogenesis is the production of steroids and 
this process is reflected by a change in expression of transcripts coding for key enzymes 
responsible for the synthesis of androgens, demonstrating a potential mechanism for the 
development of CRPC (Armandari, Hamid, Verhaegh, & Schalken, 2014). The increased 
expression of alto-keto reductase family 1 member C3 (AKR1C3) is one such transcript that 
encodes a protein implicated in intracellular steroidogenesis and controls several pathways 
of androgen synthesis (Figure 2.2) (Adeniji et al., 2013). AKR1C3 is amplified by ERG, which 
 11 
itself is overexpressed in up to 50% of PCa through a gene fusion with the androgen 
regulated Transmembrane protease, serine 2 (TMPRSS2) gene (Fenner, 2015).   
In summation, possible causes of CRPC derive from the selective pressures during 
ADT, which activate adaptive cellular processes leading to reactivation of AR signalling by 
activation or amplification of AR and/or AR mutants, co-activator/repressor dysregulation 
and intracellular steroidogenesis (Crona et al., 2015; Robinson et al., 2015).  
2.1.7 Neuroendocrine Prostate Cancer 
A therapeutically unresponsive and terminal stage in PCa is neuroendocrine 
prostate cancer (NEPCa). NEPCa ranges from the rare pure neuroendocrine tumour such as 
small cell carcinoma of the prostate to the much more common mixed neuroendocrine-
adenocarcinoma tumour. (Terry & Beltran, 2014). Neuroendocrine cells are found in 
normal prostate tissue localised to major ducts, however, the proportion of normal 
neuroendocrine prostate cells to epithelial prostate cells is very small and as such purely 
neuroendocrine tumours of the prostate are rare (Terry & Beltran, 2014). Most 
neuroendocrine tumours of the prostate arise from neuroendocrine differentiation (NED) 
from epithelial tumour cells (Terry & Beltran, 2014). The rate of occurrence of NED is 
increased after initiation of ADT and its association with CRPC has been postulated to be a 
potential adaptive mechanism behind the disease (Li, Zhang, & Zhang, 2016; Priemer et al., 
2016; Terry & Beltran, 2014). In LNCaP cells androgen deprivation results in an increase in 
the expression of NED related genes (Li et al., 2016; Terry & Beltran, 2014; Volante et al., 
2016). The percentage of histological NED tissue after ADT treated PCa ranges from 10 to 
100% of the cancer (Parimi, Goyal, Poropatich, & Yang, 2014). Despite ongoing research of 
NEPCa, the molecular alterations involved in the NED of prostatic adenocarcinomas are not 
well understood, perhaps due the many variations in the NEPCa genome (Beltran, 
Mosquera, & Rubin, 2013; Grigore, Ben-Jacob, & Farach-Carson, 2015; Li et al., 2016). As 
there is a varied NEPCa genome, there are a number of hypothesised molecular variations 
behind the development of NEPCa. 
Patients found to have co-amplification of the gene Aurora kinase A (AURKA) and 
N-myc (MYCN) in the primary PCa tumour are frequently later diagnosed with NEPCa 
(Beltran et al., 2013). To determine if these molecules are markers of or mechanisms 
behind NED, LNCaP cells were transfected with MYCN and the cells subsequently displayed 
neuroendocrine-related profiles (Beltran et al., 2013). NEPCa is also associated with 
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amplification of the AR and ETS gene family fusions (Priemer et al., 2016). Other noted 
molecular alterations are that patients with CRPC and metastatic PCa express significantly 
higher levels of IL-6, which suppresses RE-1 silencing transcription factor (REST), a 
suggested major inhibitor of NED (Santoni et al., 2014). Another interleukin implicated in 
the development of NEPCa is IL-8 coded by the gene CXCL8. IL-8 could potentially 
contribute to NED and play a role in androgen-independent proliferation of ADT treated 
PCa tissue (Santoni et al., 2014). 
Biomarkers to identify NED commonly used in clinical practice include 
chromogranin A (CgA), Synaptophysin (Syp), neuron specific enolase (NSE) and neural-cell 
adhesion molecule (NCAM) (Beltran et al., 2013). The CHGA gene codes for CgA whose 
expression levels correlate with a poor prognosis.  Syp is a protein coded by the SYP gene in 
neuroendocrine cells (Surcel et al., 2015). NCAM coded by the gene NCAM1 is a sensitive 
marker to establishing NED. NCAM contributes to cell-to-cell adhesion and cell-matrix 
interactions during the development and differentiation of the nervous system (Li et al., 
2016). In addition to the biomarkers discussed above, gene expression changes with 
corresponding NED characteristic are listed in Table 2.2.  
Table 2.2 Gene Expression Neuroendocrine Differentiation Markers in Prostate Cancer 
(Attard et al., 2016; Li et al., 2016; Surcel et al., 2015) 
Gene Characteristic 
SYP Overexpression 
CHGA Overexpression 
CD44  Strong and diffuse membrane staining 
TMPRSS2–ERG Gene Fusion 
NCAM1 Overexpression 
ENO2 Overexpression 
SV2B Overexpression 
SNAP25 Overexpression 
RAB3GAP1 Overexpression 
AURKA Overexpression 
TIMP-1 Overexpression 
CCND1 Overexpression 
ASCL1 Overexpression 
MYCN Overexpression 
RB1 loss 
REST Under expression 
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2.2 Current Models in PCa Research 
2.2.1 PCa Cell Lines   
An impediment to PCa research is that relatively few cell lines exist with which to 
conduct research in vitro. The exact mechanisms as to why prostate cells are so hard to 
culture are unknown, it can only be said that unlike other cancers standard culture 
conditions are not suited to PCa (Cunningham & You, 2015; Gao et al., 2014).  One available 
PCa cell line is the LNCaP cell line which originates from a prostate adenocarcinoma lymph 
node metastasis isolated in 1977 and is one of only a small number of AR positive PCa cell 
lines (Cunningham & You, 2015). AR positive PCa cell lines are responsive to androgens. 
The androgen sensitivity of LNCaP cells allows for in vitro investigation of the molecular 
mechanisms by which AR activity modulates the PCa cells (Tan, Li, Xu, Melcher, & Yong, 
2015). A potential limitation of the LNCaP cell line is that the AR of the cell is mutated and 
this mutation has been shown to effect steroid binding allowing non-androgen 
activation (Veldscholte et al., 1992).   
VCaP cells are an AR positive cell line that is not yet as widely used by the research 
community as LNCaP cells.  VCaP are a cell line resulting from xenografting of metastatic 
lesions taken from a lumbar vertebra from a patient with CRPC (Lee et al., 2001). VCaP cells 
have a wild-type AR that binds DHT with higher specificity than the LNCaP AR. VCaP cells 
also contain an approximate 10-fold higher AR mRNA and protein level than LNCaP cells, 
and there is a TMPRSS2- ETS-related gene (ERG) fusion which creates a more diverse model 
than using LNCaP cells alone (Makkonen, Kauhanen, Jääskeläinen, & Palvimo, 2011). 
Additionally, VCaP cells have the ability to proliferate and survive androgen deprivation, 
making them ideal for analysing the transcriptomic response of ADT and occurrence of 
CRPC (Makkonen et al., 2011). This castration resistant nature of VCaP cell line was 
observed by researchers, finding enhanced levels of mRNA for PSA, AR, ERG and other 
genes enhancing certain metabolic functions such as lipid synthesis (Cai et al., 2011a). 
Unlike castrate sensitive cells there was no subsequent rise in suppressor elements of 
genes that negatively regulate AR signalling, androgen synthesis, DNA synthesis and cell 
proliferation (Cai et al., 2011b). 
2.2.2 Cell Culture Systems 
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Cell culture media enables the in vitro growth of cancer cells. To some degree the 
media provides an environment similar to the in vivo conditions, however, consistencies of 
culture media differ with respect to cellular or experimental requirements. Due to the 
difficulty of in vitro propagation of certain cell lines, additives are required to assist in this 
process (Gao et al., 2014). The specific additions to a media may individually or in 
combination influence the cells resulting in divergent analytics within a single cell line. Cell 
culture media is generally grouped with respect to how specifically the additives are 
defined, creating two categories; undefined media, using complex biologically derived 
serum to assist in cell growth; and defined media, using isolated individual compounds that 
are catalogued and defined prior to addition (Brunner et al., 2010; van der Valk et al., 
2010). While undefined media has shown efficacy in cell growth in vitro, the ultimately 
unknown and variable composition of the serums risk the addition of confounding variables 
during use in experimentation (van der Valk et al., 2010). Despite these significant 
methodical issues, undefined media using biologically derived supplements, such as Fetal 
Bovine Serum (FBS), remain the standard media system for cell culturing (Brunner et al., 
2010).  
With the recent advancements in biochemistry, the identification of specific in vivo 
growth factors has become possible. This knowledge has facilitated the development of 
defined media from individual components, removing many of the methodical 
complications seen in the traditional undefined media systems (Brunner et al., 2010). In 
addition to the clearer and more controllable parameters that these medias provide, they 
are also able to be tailored to specific cell types. This has resulted, in some cases, in the 
efficacy of these novel defined media being superior to that of traditional undefined media 
in regards to cell growth (Drost et al., 2016; Gao et al., 2014).  While these defined media 
provide more control and information, the novel nature of these additives means many of 
the media specific effects on cell lines, as well as any potential interaction with other 
treatments, often remains unknown. However, unlike undefined medias, the very nature of 
defined media systems allows for exploration of these effects and interactions, leading to 
the possibility of a more robust and informative model. Whilst these interactions could be 
categorized through a number of differing techniques, the potential efficacy of genomic 
data in developing patient specific treatments, supports the use of transcriptomic and 
pathway analyses for this purpose, as used in the current study (Barretina et al., 2012).     
The innovations within cell culture systems are particularly relevant in the research 
of PCa, due to primary PCa cell lines proving very problematic to propagate in traditional 
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media. Gao and his colleagues (2014) utilised a novel defined culturing system, termed by 
our group HCM, tailored to the growth of PCa cell lines. HCM is a defined culture media 
with 34 separate additives capable of driving cell cycle proliferation and survival of novel 
PCa cell lines, PCa cell xenografts previously never before cultured in vitro and patient 
derived PCa circulating tumour cells (CTCs) (Gao et al., 2014). One of the prominent 
features of this media is its ability to promote early stage self-organisation of PCa cells in 
vitro. This ability allows for efficacy in organoid production with the addition of a culturing 
matrix. An organoid is the 3 dimensional self-organisation of cells in vitro (Sato et at., 
2009). This organoid process has the potential to more closely replicate in vivo cellular 
development and therefore allow for more accurate research into PCa (Gao et al., 2014).  
Despite the abilities of HCM to facilitate primary tumour culture in vitro, a caveat 
regarding the interpretation of transcriptomic results from HCM cultured cells should be 
raised, as a number of additives within HCM have potential to greatly influence cellular 
pathways and functions. However, through the exploration of these pathways, these 
effects can be accounted for in future application of this novel system.  
2.2.3 RNA Sequencing  
Quantifying RNA expression levels is a useful technique to determine how the 
transcriptional activity of the cell is altered by the presence or absence of external 
influences. RNA sequencing (RNAseq) demonstrates clinical application, for example in 
2010 researchers at the Mayo Clinic used RNAseq to identify differentially expressed 
transcripts between oral cancer and normal tissue cells. RNAseq was able to accurately 
evaluate the allelic imbalance (AI) and associate known oncogenic genes to a cancer not 
known to have an association with those particular oncogenes (Tuch et al., 2010).  RNAseq 
has another major advantage in that a large number of RNA transcript data can be analysed 
simultaneously compared to qPCR and other traditional technologies (Chu & Corey, 2012). 
RNAseq enables the detection of novel transcripts and transcript variants while both 
microarrays and qPCR require prior knowledge about the transcript composition to design 
probes and primers. 
2.3 Literature Summary  
Metastatic PCa poses significant life threatening risks that can be only temporarily 
controlled with current therapeutic interventions, before the development of CRPC. While 
several mechanisms behind this therapeutic-resistant stage of PCa have been proposed, 
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they are still not fully understood. PCa progression, even after depletion of systemic 
androgen supply, can be influenced by mutations within the cell, as well as by possible use 
of certain alternative pathways to derive androgens. The complexity of the human system 
is difficult to understand and research, using in vitro conditions. However, with the 
development of the defined HCM, containing specific additives supporting PCa cell 
proliferation, a more representative model may be becoming available. This novel culturing 
system has been shown to facilitate the propagation of primary PCa cell lines, enabling the 
possibility of a more representative in vitro model of PCa. Thus allowing for a move 
towards patient specific precision treatments of PCa, vital for combating the complex 
process of PCa advancement.  
However, many of the complex and specific effects of this novel media on PCa cells 
still remain unknown. A greater clarity within the processes that allow for this media’s 
efficacy in the growth of PCa cells and the possible media specific interactions it has on 
these cells is needed in order to advance the field.  
2.4 Aims and Objectives  
In light of this literature, this thesis aims to explore the effects of HCM on the 
transcriptome of PCa cell lines. As the AR pathway is crucial to PCa growth and 
development, a primary focus and aim will be to understand the HCM’s impact on this 
pathway in PCa cell lines. Additionally, the transcriptomic processes behind HCM’s ability to 
enhance in vitro PCa cell growth will also be a major aim. To achieve these aims, the 
following objectives will be undertaken using functional and pathway analysis of 
differentially expressed genes identified in PCa cell lines cultured in HCM; 
• Investigate androgen responsive pathways regulated in HCM 
• Investigate pathways of potential therapeutic resistance with HCM 
• Investigate HCM’s effects on metabolic pathways, with androgen and PCa associations 
These investigations will be conducted using two androgen positive PCa cell lines, LNCaP 
and VCaP.  The AR mediated pathways will be studied using an androgen depleted (no DHT) 
and androgen enriched condition (DHT) across both PCa cell lines in HCM. An undefined-
type media containing serum (RPMI+ Charcoal stripped serum (CSS)) will be used as the 
control in each condition. Affected cellular pathways and biological processes will then be 
examined between the two conditions in each media type in order to complete the 
objectives. 
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 Chapter 3: Methodology  
3.1  Materials and Software  
3.1.1 LNCaP and VCaP Cell lines 
The LNCaP and VCaP prostate cell lines were obtained by the Australia Prostate 
Cancer Research Centre, Queensland (APCRC-Q) from the American Type Culture Collection 
(ATCC; Manassus, VA) and established and proliferated in vitro using Roswell Park 
Memorial Institute (RPMI) medium supplemented with 5% and 10% FBS respectively. 
Both established cell lines were cultured in 75cm2 plastic flasks Corning using 10-15 
mL of RPMI supplement with 5% or 10% FBS medium for the LNCaP and VCaP cells 
respectively. The cells contained on average 6-8 million cells/ml at confluence for LNCaP 
and 20-30 million cell/ml at confluence for the VCaP cells. To detach the cells for re-seeding 
a 0.1% Trypsin solution (Thermo Fisher Scientific) was applied and the cells were counted 
and assessed for viability by Trypan Blue staining using the TC20 automated cell counter 
Bio-Rad. To re-seed the cells were placed into T-75 flasks at a density of 9,000 cells/cm2 for 
LNCaP cells and 80,000 cells/cm2 for VCaP cells. Newly seeded cell culture flasks were 
incubated for 48 hours undisturbed (37°C, 21% O2, 5% CO2) to allow settling and 
attachment.  Refeeding with fresh medium was undertaken at 2-3 day intervals.  The 
passage numbers of the cells used for experiments were LNCaP cells between the 25th and 
45th passage and VCaP cells less than 25 passages.  
3.1.2 HCM and RPMI Media 
RPMI-1640 medium (Gibco, Life Technologies) was supplemented with 5% FBS or 
10% FBS (Thermo Fisher Scientific) as instructed by APCRC-Q and ATCC protocols.  
HCM is a serum free media reported to be capable of culturing primary prostate 
cell lines and xenografts never before cultured in vitro (Gao et al., 2014). The HCM has a 
number of growth factors (e.g. Fibroblast growth factor (FGF2), Fibroblast growth factor 
(FGF10), Epithelial Growth Factor (EGF)) for cell survival. Noggin is an additive that reduces 
cell differentiation and inactivated the cytokine transforming growth factor beta (TGF-β). 
The specific additives and components of additives are listed in Tables 3.1 and 3.2 
opposite.  
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Table 3.1. Additives in HCM 
Additive Supplier Concentration Role 
EGF Sigma  50ng/ml Mitogenic growth factor 
R-spondin 1  *  5% v/v Regulate Wnt/beta-catenin signalling 
Noggin  *  10% v/v 
Inactivates transforming growth factor-
beta (TGF-B) 
Pleiotropic effects. 
FGF10  Peprotech  10ng/ml Mitogenic and survival activation 
FGF2  Peprotech  1ng/ml Mitogenic and survival activation 
Nicotinamide  Acros  10mM Vitamin B3 and a PARP inhibitor 
A83-01  Tocris  0.5mM 
TGF-B kinase/activin receptor like kinase 
inhibitor 
Inhibition of epithelial-mesenchymal 
transition 
SB202190  Sigma-Aldrich  10mM Cell permeable inhibitor of p38 MAP kinase 
Y-27632  Selleck 
Chemical  10mM 
Rho-associated kinase p160ROCK 
inhibitor – inhibition of apoptosis of stem 
cells 
B27 Additive**  Invitrogen  1X Cocktail of vitamin A, antioxidant and 
insulin for stem cell growth 
N-Acetyl-L-cysteine  Sigma-Aldrich  1.25mM 
Antioxidant with anti-inflammatory 
activity through NF-kB and HIF-1alpha 
and modulation of ROS 
Glutamax  Invitrogen  2mM 
Substitute for L-glutamine which is used 
for energy and protein. Nucleic acid 
synthesis 
HEPES  Sigma-Aldrich  10mM Buffering agent 
Primocin  Invivogen  1% v/v Antibiotic mixture 
(source Dr Ian Vela) 
Note: *The R-spondin 1 and Noggin conditioned media are made by Dr. Handoo Rhee from transfected cells obtained through 
the Memorial Sloan Kettering Cancer Center Research Laboratory. HEK-293 cells over expressing R-spondin 1 and Noggin 
protiens were cultured in Dulbecco's Modified Eagle Medium (DMEM) with 10% FBS and glutamax. The supernatated was 
harvested and stored in a -80 C freezer.  **B27 Components listed in Table 4. Fibroblast growth factor (FGF2), Fibroblast 
growth factor (FGF10), Epithelial Growth Factor (EGF), Reactive Oxygen Species (ROS), nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-kB), transforming growth factor beta (TGF-B)  
 
Table 3.2. Components of B27 
Vitamins Other Components 
Biotin Corticosterone 
DL Alpha Tocopherol Acetate D-Galactose 
DL Alpha-Tocopherol Ethanolamine HCl 
Proteins Glutathione (reduced) 
BSA, fatty acid free Fraction V L-Carnitine HCl 
Catalase Linoleic Acid 
Human Recombinant Insulin Linolenic Acid 
Human Transferrin Progesterone 
Superoxide Dismutase Putrescine 2HCl 
Note: Bovine Serum Albumine (BSA); Hydrochloric Acid 
(HCL) (Thermo Fisher Scientific 2016) 
Sodium Selenite 
T3 (triodo-I-thyronine) 
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3.1.3 Ingenuity Pathway Analysis (IPA) 
IPA analysis of differentially expressed genes in a dataset identifies and assigns p-
values, ratio and z-scores to pathways, functions, diseases and upstream regulators based 
on IPA previously generated knowledge banks (Ingenuity Systems, 2016a.).  
The p-value associated with those transcriptomic visualisation tools compares the 
number of genes in a dataset to those that are present in IPA database defined pathways, 
functions, diseases or upstream regulators. The smaller the p-value the greater the 
likelihood the association is statistically significant and not a random association. IPA p-
value is calculated using the right-tailed Fisher Exact Test. The calculation of the p-value 
was determined by accounting for the number of genes present in the experimental 
dataset as compared to the number of genes in the IPA background dataset for a specific 
pathway. The ratio is the percentage of target genes from the experimental dataset 
identified in a background Ingenuity produced pathway and is indicated in the relevant 
figures with an orange line. The z-score is a metric that uses the differential expression of 
genes in the sample dataset that are present to predict the activation state of the identified 
pathway, function, disease or upstream regulator. The activity state of a specific pathway is 
based on the expression of key genes identified by the IPA curated data base and the 
inherent knowledge of the effect of said genes on pathway activity. Therefore, the 
expression status of those genes in response to a treatment may be predicted to affect the 
overall activity of a pathway, with the validity of this prediction indicated by the z-score. As 
defined by IPA, z-score greater or less than (+/-2) indicates a statistically significant 
activation/inactivation state. Positive z-score displayed in the colour orange, indicate 
activated state. A negative z-score indicate inactivated state and are displayed as blue in 
colour. A 0 z-score indicates the pathway is neither activated nor inactivated and are 
displayed in the colour white. If an activation state is listed as NaN, IPA is not able to 
predict the activation state, and the activation state is displayed in the colour gray 
(Ingenuity Systems, 2016a). 
Ingenuity uses a knowledge bank to define the pathways and the statistical 
significance of the association of target genes to IPA defined pathway genes measured with 
–log (p-value). The pathway is listed in the figure as a bar graph and the height of the bar 
graph corresponds to the magnitude of the –log (p-value). This analysis, and all subsequent 
IPA analyses in this report, determined a significant association to have a –log (p-value) 
significance greater than 1.3, unless stated otherwise 
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IPA determines activated upstream regulators based on interpretation of the 
molecular networks observed in the dataset and assigns direction, activation z-score, based 
on available literature. P-value significance for Upstream Regulators is determined to be 
<0.01 by IPA. Like the analysis of the canonical pathways, an activation z-score, like z-score, 
greater or less than (+/-2) indicates a statistically significant activation/inactivation state. 
Positive z-score indicate activated state, a negative z-score indicate inactivated state and a 
0 z-score indicates the pathway is neither activated nor inactivated. If an activation state is 
listed as NaN IPA is not able to predict the activation state. 
IPA possesses Pathway Exploration tools capable of exploring potential 
relationships between individual genes. The relationship between two genes is listed as 
direct or indirect and assigned an activation state based on the curated knowledge of the 
IPA literature bank. 
3.1.4 Gene Ontology Enrichment Analysis and Visualization Tool (GOrilla) 
GOrilla is a software package that searches for enriched gene ontology terms in a 
target dataset compared to the background dataset using standard hyper geometric 
statistics and visually presents the findings. Biological processes, molecular functions and 
cellular components are identified using this tool (Eden et al., 2009). 
3.1.5  Additional Datasets 
Insulin 1 is a microarray dataset generated within the laboratory/research group 
using LNCaP cells treated with insulin in RPMI media. The Insulin 1 dataset was used to 
identify insulin regulated genes. Despite the Insulin 1 dataset identifying a list of insulin-
regulated genes in LNCaP cells, it provides an accessible tool to investigate insulin response 
in VCaP cells.  
The datasets were compared against a list of lipid-related genes to identify genes 
involved in lipid metabolism compiled by Martin Sadowski and Jennifer Gunter of APRC-Q. 
3.2 Procedure  
3.2.1 Treatment of Prostate Cell lines In Vitro 
The PCa cell lines LNCaP and VCaP cells were seeded in 6 well plates at 
concentrations of 3000 or 20,000 cells/cm2 respectively were initially plated in 2mL of 
RPMI with 5% or 10% FBS for the LNCaP or VCaP cells respectively which was replaced after 
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72 hours with RPMI + Charcoal stripped serum (CSS; 5 or 10% respectively.) After 48 hours 
media was replaced with fresh CSS and treatments added. Cells were treated with vehicle, 
(Dimethoxy Sulfoxide (DMSO)), or 10nM DHT in the presence and absence of 10µM 
Enzalutamide (ENZ) with three technical repeats per experiment. Samples were collected 
for RNA extraction 48 hours post-application. Experiments were repeated to provide two 
biological repeats. 
3.2.2 RNA Extraction   
Total RNA was extracted from samples using the Norgen Biotek Purification Kit 
(Norgen Biotek; Ontario, Canada) as per manufacturer’s instructions. RNA was treated with 
on-column DNAse 1 treatment (Norgen) to remove genomic contamination during RNA 
isolation as per manufacturer’s instructions. 
3.2.3  Quality control 
 Real-time polymerase chain reaction (qPCR) was performed for quality control. An 
increased expression of KLK3, FK506 binding protein 5 (FKBP5) and TEMPRSS2 was 
monitored in order to verify an appropriate androgen response. A decrease in expression 
of dopa decarboxylase (DDC) was monitored in order to verify an appropriate androgen 
response.   
3.2.4 In Vitro Transcriptomic Analyses 
After initial screening to confirm cellular response to DHT and ENZ, isolated RNA 
was sent to the Kinghorn Cancer Centre (TKCC) Garvin Institute. Briefly Illumina TruSeq 
library preparation kits were utilized for sample preparation followed by paired-end 
sequencing on the Illumina HiSeq 2500 sequencer at the clinical-grade sequencing facility 
at TKCC. The established RNAseq analysis pipeline, built in collaboration with a 
bioinformatics team at the Garvan Institute, uses open-source and in-house tools including 
de novo transcriptome assembly (Trinity), quantification (RSEM), and differential 
expression analyses (edgeR). Using the high performance computing power and 
bioinformatics expertise from the Garvan and QUT together with data mining and 
visualization tools including; IPA, GOrilla, integration of the RNAseq data was generated. 
Additionally, genes were compared and contrasted using the online Venn diagram tool 
Venny (Oliveros, 2015). This was then compared APCRC-Q generated RNAseq data related 
to androgen response, data from publicly available large international sequencing projects 
(including ICGC and TCGA) as well as the micro-array generated Insulin 1 dataset.  
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In silico exploration and data-driven prioritization of candidate markers of 
treatment response/resistance was then undertaken. This analysis, and all subsequent 
analyses in this thesis, determined a significant change in gene expression to require a fold 
change (FC) less or greater than 1.5 times compared to the baseline, with a p-value 
significance level set at less than 0.05, unless stated otherwise.  
Comparison of the differential expression (DE) of transcripts for LNCaP and VCaP 
cells treated with vehicle control (DMSO + EtOH) in HCM to LNCaP and VCaP cells treated in 
RPMI media supplemented with CSS, treated with vehicle control (DMSO + EtOH) (LNCaP 
HCM vs RPMI dataset and VCaP HCM vs RPMI) was finally performed. In this analysis, when 
referring to RPMI media treated sample, it is implied that the RPMI is supplemented with 
CSS at the previous stated concentrations specific for each PCa cell line. 
As alluded to earlier the datasets require some interpretation. The dataset LNCaP 
(HCM vs RPMI) was a comparison measuring the difference in expression between the non-
androgen treated HCM and RPMI samples for LNCaP cells. 
3.2.5 Fatty Acid Uptake and Lipid Droplet Analysis  
This experiment measured the exogenous fatty acid uptake and storage, in the 
form of lipid droplets, and was conducted in collaboration with Martin Sadowski of the 
APCRC-Q. LNCaP cells were seeded in a 96-well optical µ-plate (IBIDI, Germany) with at 
densities of 4.0 x 103 cells per well. Cells were seeded into 150µL of phenol-red free RPMI-
1640 supplemented with 5% CSS. After 72 hours’ media was removed and replaced with 
150uL of appropriate base. 24 hours after the media was replaced with 150µL of each 
respective treatment in Table 3.3. The cell response was analysed 48 hours after 
treatment.  
 
 Table 3.3. Lipid Droplet Treatments Used on LNCaP cells 
FBS HCM FBS + Orlistat 
CSS + R1881 CSS - 
 
The 5% CSS supplemented in RPMI was the control and was free of androgens. The 
androgen response was represented by culturing cells in 5% CSS supplemented RPMI and 
subsequently treating with 1nM R1881 (androgen). To represent a state of increased lipid 
uptake cells cultured in 5% FBS supplemented RPMI were treated with Orlistat. Orlistat was 
a dual lipogenesis (DNL) and lipolysis inhibitor, leading to increased uptake of FAs into LDs. 
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The number of LDs and size of LDs increases in the absence of DNL from exogenous FA and 
intracellular FA mobilization from phospholipids. To determine if fatty acid uptake and lipid 
droplets were altered by the presence of HCM, cells were cultured and treated in the 
media.  
LNCaP cells were treated with the indicated concentrations for 48 hours. Cells were 
fixed in 4% paraformaldehyde, processed and stained with DAPI and Nile Red as described 
previously (Sadowski, 2014). Imaging was then conducted in the DAPI, Cy3 (neutral lipids, 
(NLs)) and Cy5 channels (phospholipids, (PLs)) on an IN Cell Analyser 2200 (GE Healthcare) 
with a 10x objective and automatic image acquisition of 750 cells/well. Cellular mean 
fluorescence intensities of PLs and NLs and number and total area of lipid droplets were 
quantitated from of 750 cells per treatment with three repeats with Cell Profiler software 
(Broad Institute). 
To analyse fatty acid uptake, the cells were treated for 48 hr with indicated 
treatments.  The media was then replaced with serum-free media supplemented with 0.2% 
BSA and C1-Bodipy-C12 (5 µM, D-3823, Thermo Fisher Scientific) and MitoTracker Organe 
(0.4 µM, Thermo Fisher Scientific. The cells were incubated for 45 min, washed with PBS, 
fixed in 4% paraformaldehyde for 15 min at room temperature, and DNA and F-actin was 
counterstained with DAPI (1 µg/ml) and Alexa Fluor Phalloidin (Thermo Fisher Scientific) as 
per manufacturer’s instructions. Cells were imaged in the DAPI, FITC (C1-Bodipy-C12), Cy3 
(MitoTracker Orange) and Cy5 channels (F-actin) on an IN Cell Analyser 2200 (GE 
Healthcare) with a 10x objective and automatic image acquisition of 750 cells per well. 
Mean fluorescence intensities of C1-Bodipy-C12 (FITC) of 750 cells per treatment in 
triplicate were quantitated with CellProfiler software (Broad Institute). Statistical 
significance was analysed with GraphPad Prism (GraphPad Software) by one-way ANOVA 
with Dunnett’s multiple comparison test.   
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Chapter 4: Results 
4.1 Data Presentation and comparisons  
In line with bioinformatics practises, subsequent results will be referring to the 
ratio, or fold change, of gene expression between a chosen condition (ie.  HCM with no 
DHT treatment) to the base line (unless otherwise stated, the androgen depleted control; 
RPMI).  If the fold change of these compared conditions was greater than 1.5 or lesser than 
- 1.5, and the p-value was less than 0.05, the gene was considered to be significantly 
differentially expressed. The differentially expressed genes from each comparison were 
then compiled into a dataset. When a single dataset is referred to without reference to its 
baseline comparison, a baseline of the control (RPMI androgen deplete) is assumed. 
Two main figures were utilised to present the subsequent results, each using these 
previously explained datasets.  Bar graphs were used to visually display pathways present 
within certain datasets. These graphs display both the likelihood of a pathway being 
present within the chosen dataset (- log p-value) and the proportion of genes in each 
canonical pathway that were present within the analysed dataset (ratio). Within each 
analysis, z-scores were also included, with positive indicating pathway activation, negative 
indicating deactivation and zero indicating no change to the baseline. A further figure was 
used when a dataset (ie. HCM vs RPMI) was compared to another such dataset (ie. 
RPMI+DHT vs RPMI), with this data displayed in a Venn diagram. 
4.2 Transcriptome analysis of LNCaP cells cultured in HCM 
Initial transcriptome analysis of the HCM cultured LNCaP dataset identified 1554 
genes that were differentially expressed, of which 624 were upregulated and 930 
downregulated. To achieve a perspective on the biological processes for the LNCaP cells 
cultured in HCM, gene ontology analysis of differentially expressed genes identified 
enriched biological processes, which included insulin signalling, neuroendocrine-like 
profiles, lipid metabolism, the MAPK cascade, amino acid transport and structural 
development (Figure 4.1, Appendix Table 1).   
4.2.1  Canonical Pathways affected by culturing LNCaP cells in HCM 
To examine the impact of HCM in greater detail, functional analysis of differentially 
expressed genes in LNCaP cells cultured in HCM was undertaken. This analysis identified a 
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number of canonical pathways, with the top 10 listed in Figure 4.2. The top identified 
pathway was, “Superpathway of Cholesterol Biosynthesis,” which had the highest ratio of 
differentially expressed genes for a pathway (Figure 4.2). Despite the identification of these 
pathways, none were predicted to be significantly activated or inactivated (z-score +/- 2). 
However, based on the differential expression of certain genes several pathways did show 
indications of potential direction of activity (Figure 4.2, Appendix Table 2). One pathway 
that was activated was the lipid-related “Liver X Receptor/Retinoid X Receptor Activation” 
(LXR/RXR) pathway, which is involved in the regulation of lipid metabolism, inflammation, 
and the conversion of cholesterol to bile acid catabolism (Ingenuity, 2016). The “LXR/RXR 
Activation” pathway had a positive z-score suggesting the pathway was activated in HCM 
treated LNCaP cells; however, the z-score did not reach a level to indicate a statistically 
significant level of activity.  Despite the uncertainty in direction of activity for a number of 
lipid-related pathways in Figure 4.2, their detection reflects the observations in the gene 
ontology analysis map (Figure 4.1; Appendix Table 1).  
To further determine the influences of HCM on LNCaP cells, exploration using 
functional analysis was undertaken and three canonical pathways that were significantly or 
near significantly activated/inactivated were identified (Figure 4.3). Both identified 
pathways that were significant have been reported to be inactivated by glutamate and 
Noggin, which were present in HCM (Table 3.1; Krause, Guzman & Knaus, 2010). Although 
not statistically significant, a third pathway, “Triggering Receptor Expressed on Myeloid 
Cells 1 (TREM1) Signalling” pathway appeared likely to be activated by culturing in HCM 
(Figure 4.3).  
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Figure 4.2. Top 10* IPA Canonical Pathways for LNCaP cells cultured in HCM 
compared to RPMI (HCM vs RPMI) 
Note: Exact values for figure given in Appendix Table 3, *Appendix Table 4. Canonical Pathways 
for LNCaP cells treated in HCM that share all genes with 'Superpathway of Cholesterol 
Biosynthesis,' The height of the bar corresponds to the enrichment –log (p-value) and the colour 
indicates the predicted activation state of the pathway. The ratio represents the percentage of 
genes within a pathway that are present and differentially expressed in the experimental dataset. 
Values over -log (p-value) 1.3 were statistically significant.  
 
Figure 4.3. IPA Canonical Pathways LNCaP cells cultured in HCM compared to 
RPMI (HCM vs RPMI) with significant or near significant z-scores 
Note: Exact values for figure given in Appendix Table 5, The height of the bar corresponds to the 
enrichment –log (p-value) and the colour indicates the predicted activation state of the pathway. 
The ratio represents the percentage of genes in a pathway that are differentially expressed in the 
experimental dataset. Values over 1.3 -log (p-value) are statistically significant.  
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4.2.2 LNCaP Canonical Pathway comparison of the HCM to the androgen-enriched RPMI 
treatment  
Due to the importance androgens play in the regulation of PCa cells, a comparison 
of the HCM cultured and androgen treated control LNCaP cells was made. Beginning with 
the analysis of the androgen-enriched RPMI treated LNCaP dataset, there were 1209 DE 
genes identified, of which 598 of those genes were upregulated and 611 were 
downregulated. Functional analysis of this dataset identified a number of canonical 
pathways (Appendix Table 6), with the top 10 ranked by –log (p-value) listed in Figure 4.4. 
Comparing these pathways to those identified following HCM treatment revealed two 
pathways in the top 10 shared by both the androgen enriched control and non-androgen 
HCM treatment, “Superpathway of Cholesterol Biosynthesis” and “Sperm Motility” with 47 
shared pathways overall. Interestingly, the gene expression ratio for the pathway, 
“Superpathway of Cholesterol Biosynthesis” was 25% after the addition of androgen 
treatment to RPMI, whereas the ratio for that lipid-related pathway was 61% in HCM 
(Figure 4.4), and included all seven of the androgen-enriched genes.   
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Figure 4.4. Top 10 IPA Canonical Pathways for LNCaP cells grown in RPMI+DHT 
as compared to RPMI grown cells 
Note: Exact values for figures in Appendix Table 7, The height of the bar corresponds to the 
enrichment –log (p-value) and the colour indicates the predicted activation state of the pathway. 
The ratio represents the percentage of genes within a pathway that are present and differentially 
expressed in the experimental dataset. Values over -log (p-value) 1.3 are statistically significant. 
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Table 4.1. Top 30 Upstream Regulators for LNCaP cells grown in HCM  
Upstream 
Regulator 
Exp Fold 
Change Molecule Type 
Predicted 
Activation State 
Activation 
z-score 
p-value of 
overlap 
DHT - chemical - endogenous Activated 5.513 3.95E-17 
Vegf - group Activated 4.999 6.02E-21 
HGF - growth factor Activated 4.868 1.09E-15 
metribolone - chemical reagent Activated 4.401 2.69E-16 
EGF 1.798 growth factor Activated 4.301 2.42E-10 
IL2 - cytokine Activated 4.266 3.37E-10 
AR -4.328 ligand-dependent nuclear receptor Activated 4.078 1.34E-11 
PDGF BB - complex Activated 4.077 3.92E-11 
SREBF2 1.95 transcription regulator Activated 4.01 2.11E-19 
SREBF1 - transcription regulator Activated 3.999 1.80E-13 
Ins1 - other Activated 3.887 2.35E-09 
TICAM1 - other Activated 3.883 1.28E-04 
SCAP 1.504 other Activated 3.866 4.39E-14 
NFkB (complex) - complex Activated 3.697 2.62E-04 
F2 1.795 peptidase Activated 3.658 1.53E-06 
beta-estradiol - chemical - endogenous Activated 3.625 2.26E-28 
IL5 31.199 cytokine Activated 3.584 3.76E-12 
PTGS2 - enzyme Activated 3.561 3.04E-04 
RABL6 - other Activated 3.441 2.73E-09 
hydrogen 
peroxide - 
chemical - 
endogenous Activated 3.419 4.58E-13 
KRAS - enzyme Activated 3.383 1.63E-07 
Insulin - group Activated 3.383 4.75E-08 
TNF 53.537 cytokine Activated 3.355 5.07E-15 
ERK - group Activated 3.338 4.01E-09 
CD40LG - cytokine Activated 3.32 3.49E-07 
CSF2 - cytokine Activated 3.227 8.35E-12 
FGF2 33.344 growth factor Activated 3.168 1.11E-05 
Jnk - group Activated 3.161 2.22E-05 
AGT -4.841 growth factor Activated 3.152 8.86E-12 
TBK1 - kinase Activated 3.144 7.67E-03 
Note: Ranked determined by activation z-score. A positive activation z-score indicates the pathway is predicted to 
be activated, p-val >0.01, Expression Fold Change (Exp FC) listed if the gene is DE in the dataset. 
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4.3 HCM Treated LNCaP Upstream Regulators 
In order to determine the regulatory effects, the additives exert transcriptionally, 
the downstream expression of genes was used to identify potential up-stream regulators 
that may be influencing gene expression. In addition, the identification of known HCM 
additives as upstream regulators would give validation for transcriptomic analysis. The top 
30 Upstream Regulators ranked by predicted level of activity for LNCaP cells treated with 
HCM are presented in Table 4.1 (opposite). There was a wide diversity in these molecules 
with the largest group being cytokines (Table 4.1). Of the top 30 upstream regulators 
identified in LNCaP cells grown in androgen-enriched RPMI (Appendix Table 8); eight were 
predicted to be active in androgen deplete HCM (Table 4.2) and the top regulator in both 
cases was predicted to be DHT. 
 
Table 4.2. The androgen-enriched RPMI media treated LNCaP Upstream Regulators* 
shared with the Top 30 HCM treated LNCaP Upstream Regulators.  
Upstream 
Regulator Molecule Type 
Predicted 
Activation State 
Activation 
z-score overlapping p-value 
DHT chemical - endogenous  Activated 6.963 2.37E-23 
AR 
ligand-
dependent 
nuclear receptor 
Activated 5.982 4.75E-22 
SREBF2 transcription regulator Activated 2.742 3.49E-6 
SREBF1 transcription regulator Activated 2.444 3.55E-6 
SCAP other Activated 2.608 9.5E-3 
beta-oestradiol chemical - endogenous  Activated 2.471 4.56E-11 
KRAS enzyme Activated 2.304 4.69E-3 
Insulin group Activated 2.206 3.68E-6 
Note: Ranked determined by activation z-score. A positive activation z-score indicates the pathway is 
predicted to be activated, p-val >0.01, Expression Fold Change (Exp FC) listed if the gene is DE in the dataset. 
* The exhaustive list of significant Upstream Regulators for DHT+RPMI treated LNCaP is located in Appendix 
Table 8.   
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4.4 Androgen Regulated Genes in HCM Treated LNCaP Cells 
To investigate the potential LNCaP androgen response to androgen-free HCM 
treatment, a number of well-characterised direct targets of AR signalling were identified 
including KLK3, FKBP5, TPMRSS2 and DDC. (Makkonen et al., 2011). Based on these genes 
both the androgen-enriched RPMI and HCM treated LNCaP cells expressed an androgenic 
response profile (Table 4.3). 
Further analysis of a potential LNCaP androgen-like response to HCM treatment 
revealed there were 1553 and 1209 genes significantly DE in the (HCM vs RPMI) and 
(DHT+RPMI vs RPMI) datasets respectively, and the datasets shared 499 DE genes (Figure 
4.5). Of the 499, only 5 genes were expressed in different directions (Table 4.4). To further 
explore an androgen-like response, the 10 top upregulated DE genes (as assessed by FC) in 
common between both datasets are listed in Table 4.5.  
When LNCaP cells cultured in HCM were exposed to androgens (HCM+DHT vs 
HCM) there was a dramatic reduction in the sensitivity of those genes to further 
stimulation by androgen, as demonstrated by the fact that only 136 genes showed DE 
compared to androgen-deplete HCM, whereas 1209 genes displayed differential expression 
in response to the addition of DHT to RPMI (DHT+RPMI vs RPMI) (Figure 4.6). 
Figure 4.5. LNCaP genes DE by HCM and DHT+RPMI 
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Table 4.5. Top 10 shared DE genes between LNCaP cells treated in HCM and androgen-
enriched RPMI media.  
Table 4.3. Expression of genes of interest for LNCaP cells treated with HCM or 
RPMI+DHT.  
 Gene HCM vs RPMI  RPMI+DHT vs RPMI  
KLK3 9.057 139.918 
FKBP5 14.73 21.575 
DDC -24.027 -15.282 
TMPRSS2 3.991  14.716 
Table 4.4. Shared Genes between HCM and androgen-enriched RPMI media treated 
LNCaP androgen regulated genes with different directionality in expression.  
Gene HCM vs RPMI  RPMI+DHT vs RPMI 
TNIK 2.54 -2.349 
FAT1 -1.905 1.801 
ALAD -1.91 1.645 
RLN1 -4.055 2.849 
CWH43 -4.085 3.094 
Note:  Listed with FC 
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Gene HCM vs RPMI RPMI+DHT vs RPMI 
 
STEAP4 6026.611 6715.628  
VCY1B 1474.666 2331.293  
SLC38A4 603.814 670.584  
CTB-167B5.2 505.778 661.578  
XAGE1B 482.486 179.986  
RP11-618G20.1 354.879 256.892  
OLAH 337.361 84.761  
AKAP12 220.97 158.446  
ORM2 207.084 3109.568  
SLC2A3 170.142 709.388  
Note: Ranked by HCM vs RPMI FC  
 
 
Figure 4.6. HCM cultured LNCaP cells muted genomic response to DHT 
 
4.4.1 LNCaP Neuroendocrine Response in HCM  
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The results of gene ontology analysis identified the enrichment of biological 
processes that were neuroendocrine related in LNCaP cells treated cultured in HCM (Figure 
4.1; Appendix Table 9). To further explore this finding, functional analysis identified 2 
neuroendocrine-like related pathways, both of which were predicted be inactivated (Figure 
4.7).  
To better understand if these results were suggestive of NED, analysis of NED gene 
expression was assessed in LNCaP cells treated with HCM (Table 4.6). HCM treatment 
resulted in the expression of a number of genes used in the diagnosis of NEPCa. Androgen 
treatment of LNCaP cells culture in RPMI or HCM showed no effect on the differential 
expression on the neuroendocrine genes identified in Table 4.6 as none of the genes were 
differentially expressed by DHT in either the control or HCM+DHT treatment. 
 
 
 
 
 
 
  
Figure 4.7. HCM cultured LNCaP Canonical Pathways with Neuroendocrine 
Association. 
Note: Exact values for figure in Appendix 10, The height of the bar corresponds to the enrichment 
–log (p-value) and the colour indicates the predicted activation state of the pathway. The ratio 
represents the percentage of genes within a pathway that are present and differentially 
expressed in the experimental dataset. Values over -log (p-value) 1.3 were statistically significant. 
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 Table 4.6 DE of neuroendocrine associated genes (FC) for LNCaP cells cultured in HCM 
compared to both HCM and RPMI media treated with DHT. 
Gene HCM vs RPMI RPMI+DHT vs RPMI HCM+DHT vs HCM 
SYP 2.349 - - 
CHGA - - - 
NCAM1 4.045* - - 
ENO2 - - - 
SV2B 27.004 - - 
SNAP25 49.857 - - 
CYB561 - - - 
AURKA 2.807 - - 
TIMP-1 121.484 - - 
ASH-1 - - - 
MYCN - - - 
RB1 - - - 
Note: (*NCAM1 p-value is 0.0558, (-) indicates the gene is not differentially expressed), Ranked by FC 
 
4.5 HCM effects on LNCaP cells Excluding Androgen Regulated Genes 
Despite the differential expression of a large number of androgen-regulated genes 
from HCM treatment in an absence of exogenous androgens, approximately 2/3 of the 
differentially expressed genes cells were not regulated by androgens (Figure 4.8). Initial 
analysis of HCM revealed 1054 non-androgen regulated genes, with 445 genes that were 
upregulated and 609 genes that were downregulated. The top 10 upregulated and 
downregulated non-androgen HCM treated genes are listed in Tables 4.7a and 4.7b 
respectively.  
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Table 4.7a. Top upregulated DE genes for 
HCM treated LNCaP cells excluding DHT 
regulated genes 
 Table 4.7b. Top downregulated DE genes for 
HCM treated LNCaP cells excluding DHT 
regulated genes 
Gene FC  Gene FC 
PNLIPRP3 726.813  PLA2G2F -741.323 
CXCL8 429.028  ATOH8 -733.609 
PLEKHA4 269.604  LDLRAD4 -285.436 
TNFRSF9 266.321  FBLN7 -262.137 
ETV4 231.306  CTC-340A15.2 -253.485 
THEG 214.367  GGT6 -205.44 
RP11-483I13.5 180.799  MROH7 -189.404 
PHGR1 164.305  FPR3 -184.526 
MMP1 161.573  CSPG4P12 -174.6 
EGR1 154.849  RP11-1415C14.4 -155.419 
Note: Ranked by FC 
 
In order to gain an understanding of the processes the HCM non-androgen gene 
influenced, ontology analysis was performed on the subset of HCM genes with the 
androgen regulated genes excluded. From these non-androgen regulated genes 82 
statically significantly enriched biological processes were identified (Appendix Table 11). 
Out of these 82 processes, 12 processes were lipid related and 11 processes were 
neuroendocrine-like related (Figure 4.9). The proportion of identified NED-like processes 
Figure 4.8. DE genes for HCM cultured LNCaP cells excluding DHT regulated genes  
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detected by gene ontology analysis increased relative to the total dataset after the 
exclusion of androgen regulated genes. The neuroendocrine-like enriched processes for 
LNCaP non-androgen regulated genes in HCM are listed in Table 4.8.  
 
 
Table 4.8. Gene Ontology Analysis identified Neuroendocrine-like Biological Processes for 
HCM treated LNCaP cells excluding DHT regulated genes 
Neurological System Process 
Positive Regulation of Synaptic Transmission 
Learning of Memory 
Learning 
Associative Learning 
Synapse Organization 
Synapse Assembly 
Synaptic Vesicle Exocytosis 
Cognition 
Modulation of Inhibitory Postsynaptic Potential 
Positive Regulation of Inhibitory Postsynaptic Potential 
 
  
Figure 4.9. The gene ontology analysis process types for LNCaP cells cultured in 
HCM excluding androgen regulated genes  
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4.5.1 Non-Androgen regulated Lipid-Related Effects of HCM on LNCaP cells 
Analysis was conducted to determine to what extent excluding androgen regulated 
genes from the LNCaP HCM dataset altered lipid-related pathways. Pathway analysis of this 
subset of genes, identified lipid-related pathways in the absence of androgen regulated 
genes, for instance the pathway “Superpathway of Cholesterol Biosynthesis” again was 
identified as the top pathway. However, the ratio, which determining the overlap between 
the target and IPA determined dataset, dropped from 61% to 39% (Figure 4.10).  
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Figure 4.10. Top 10 Canonical Pathways for HCM treated LNCaP cells 
excluding androgen regulated genes 
Note: Exact values for figure in Appendix Table 12, The height of the bar corresponds 
to the enrichment –log (p-value) and the colour indicates the predicted activation 
state of the pathway. The ratio represents the percentage of genes within a pathway 
that are present and differentially expressed in the experimental dataset. Values over 
-log (p-value) 1.3 are statistically significant. 
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4.5.2 Non-Androgenic Effects of HCM on LNCaP cells – Neuroendocrine Differentiation.   
Functional analysis identified three Canonical Pathways with significant activation 
or inactivation from the HCM treated LNCaP dataset (Figure 4.2). The “TREM1 Signalling” 
pathway, which was approaching significance in the LNCaP cell dataset (HCM vs RPMI) 
(Figure 4.3), with the exclusion of androgen regulated genes reached a significant 
activation state (Figure 4.11). This pathway increases the expression of genes that code for 
cytokines involved in NED (Ford, J. & McVicar, 2009). 
Functional analysis of upstream regulators from the non-androgen regulated HCM 
treated LNCaP genes ((HCM vs RPMI) vs (RPMI+DHT vs RPMI)) identified that nearly a 
quarter were identified to be cytokines correlating with what was observed in Figure 4.11 
with the identification of the TREM1 Signalling Pathway (Table 4.9). 
 
 
 
 
 
 
 
Figure 4.11 Canonical Pathways with significant z-scores for LNCaP cells treated with HCM 
excluding DHT regulated genes ((HCM vs RPMI) vs (RPMI+DHT vs RPMI)) 
Note: Exact values for figure in Appendix Table 13, The height of the bar corresponds to the enrichment –log 
(p-value) and the colour indicates the predicted activation state of the pathway. The ratio represents the 
percentage of genes within a pathway that are present and differentially expressed in the experimental 
dataset. Values over -log (p-value) 1.3 are  statistically significant. 
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Table 4.9 IPA Top 30 upstream regulators for HCM treated LNCaP cells excluding DHT regulated 
genes ((HCM vs RPMI) vs (RPMI+DHT vs RPMI)  
Upstream Regulator Molecule Type Activation z-score 
Vegf group 5.144 
HGF growth factor 4.798 
CSF2 cytokine 4.683 
NFkB (complex) complex 4.342 
IL6 cytokine 4.329 
IL2 cytokine 4.225 
TNF cytokine 4.089 
EGF growth factor 3.918 
ATF4 transcription regulator 3.883 
PDGF BB complex 3.858 
F2 peptidase 3.83 
IL5 cytokine 3.764 
P38 MAPK group 3.729 
IL1B cytokine 3.692 
KRAS enzyme 3.625 
beta-oestradiol chemical - endogenous mammalian 3.573 
IKBKB kinase 3.512 
PRKCD kinase 3.507 
RABL6 other 3.5 
Jnk group 3.48 
TICAM1 other 3.475 
SPP1 cytokine 3.471 
CD40LG cytokine 3.4 
ERK group 3.363 
PTGS2 enzyme 3.336 
ERK1/2 group 3.306 
TREM1 transmembrane receptor 3.288 
TNFSF12 cytokine 3.274 
IL3 cytokine 3.262 
Tnf (family) group 3.261 
Note: ranked by activation z-scores; bolded upstream regulators are identified DHT treated regulators. 
(RPMI+DHT vs RPMI) upstream regulators (Appendix Table 8).  A positive activation z-score indicates the 
pathway is predicted to be activated, p-val >0.01, Expression Fold Change (Exp FC) listed if the gene is DE 
in the dataset. 
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4.6 Insulin mediated effects of HCM on LNCaP Genes 
To determine what impact the powerful regulatory hormone insulin, a HCM 
component, had on the expression of LNCaP genes, the HCM dataset was compared to list 
of previously identified insulin regulated genes identified from insulin treated LNCaP cells 
(Insulin 1). Analysis identified 713 of the 1554 HCM genes were insulin regulated genes 
(Figure 4.12). The top upregulated and downregulated insulin regulated DE genes from the 
HCM dataset are listed in Tables 4.10a and 4.10b.  
 
 
 
Table 4.10a. Top upregulated DE genes for HCM treated LNCaP cells that were regulated 
by insulin ((HCM vs RPMI) & Insulin 1) 
Gene FC 
AKAP12 220.97 
EGR1 154.849 
CXCL3 70.424 
CCDC141 68.902 
DIRAS3 46.961 
TRIM9 42.897 
RP11-443P15.2 42.262 
LHFP 35.294 
THSD7A 28.231 
SIPA1L2 28.078 
Note: Ranked by FC. 
 
  
Figure 4.12 DE gene for HCM cultured LNCaP cells regulated by insulin 
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Table 4.10b. Top downregulated DE genes for HCM treated LNCaP cells that were 
regulated by insulin ((HCM vs RPMI) & Insulin 1) 
Gene FC 
SLC6A19 -2876.05 
PLA2G2F -741.323 
ATOH8 -733.609 
LDLRAD4 -285.436 
IGHD -247.827 
MEGF10 -159.406 
SLC6A4 -132.699 
SSTR5-AS1 -124.332 
TFCP2 -118.813 
EDNRA -115.417 
Note: Ranked by FC 
4.7 Non-Insulin Regulated gene expression in HCM treated LNCaP cells 
Over half of the DE genes detected (839/1552) in LNCaP cells treated with HCM 
showed no regulation by insulin ((HCM vs RPMI) vs Insulin 1) as determined by lack of 
overlap between datasets (Figure 4.13). Of these 839 genes, 339 were upregulated and 500 
were downregulated with the top up and downregulated DE genes listed in Tables 4.11a & 
4.11b.  
 
Figure 4.13. DE gene for HCM culture LNCaP cells not regulated by insulin (Insulin 1) 
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Table 4.11a. Top upregulated DE genes for HCM treated LNCaP cells that were not 
regulated by insulin ((HCM vs RPMI) vs Insulin 1) 
Gene FC 
STEAP4 6026.611 
VCY1B 1474.666 
PNLIPRP3 726.813 
SLC38A4 603.814 
CTB-167B5.2 505.778 
XAGE1B 482.486 
CXCL8 429.028 
RP11-618G20.1 354.879 
OLAH 337.361 
PLEKHA4 269.604 
Note: Ranked by FC 
 
Table 4.11b. Top downregulated DE genes for HCM treated LNCaP cells that were not 
regulated by insulin ((HCM vs RPMI) vs Insulin 1) 
Gene FC 
IGHG3 -767.297 
CPAMD8 -280.074 
PARVG -278.66 
FBLN7 -262.137 
CTC-340A15.2 -253.485 
LINC01279 -222.603 
GGT6 -205.44 
MROH7 -189.404 
FPR3 -184.526 
RP11-231E6.1 -180.807 
Note: Ranked by FC 
 
4.8 Non-Androgen & Insulin Regulated genes in HCM treated LNCaP cells  
In order to determine which LNCaP genes were not regulated by either androgen 
or insulin in HCM, a comparison was made excluding identified androgen and insulin genes. 
After comparing the total 1554 DE genes with those from the androgen-enriched RPMI and 
the Insulin 1 datasets, it was found that 576 DE genes displayed no regulation by either 
androgens or insulin (Figure 4.14). Of these genes, the top up and downregulated genes are 
listed in Table 4.12a & 4.12b. These genes represent the HCM response in the absence of 
the androgen and insulin regulation. 
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Figure 4.14. DE genes for HCM cultured LNCaP cells excluding androgen and insulin 
regulated genes 
 
Table 4.12a. Top upregulated genes for HCM cultured LNCaP cells excluding 
genes regulated by androgen or insulin 
Gene FC 
PNLIPRP3 726.813 
CXCL8 429.028 
PLEKHA4 269.604 
TNFRSF9 266.321 
ETV4 231.306 
THEG 214.367 
RP11-483I13.5 180.799 
PHGR1 164.305 
MMP1 161.573 
ICAM1 143.537 
ARL14 137.129 
Note: Listed with FC 
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Table 4.12b. Top downregulated genes for HCM cultured LNCaP cells 
excluding genes regulated by androgen or insulin 
Gene FC 
FBLN7 -262.137 
CTC-340A15.2 -253.485 
GGT6 -205.44 
MROH7 -189.404 
FPR3 -184.526 
CSPG4P12 -174.6 
RP11-1415C14.4 -155.419 
OR7E128P -151.869 
RP3-467K16.2 -139.009 
TRIM49 -126.247 
RP11-666A20.4 -122.245 
Note: Listed with FC 
 
4.8.1 Lipid-Related effects in HCM treated LNCaP cells excluding androgen and insulin 
regulated genes 
 
To determine what effects HCM had on LNCaP lipid metabolism in the absence of 
androgen and insulin regulated genes, analysis of this population of 576 genes was 
conducted. Gene ontology analysis identified 22 statistically significant enriched biological 
processes (Appendix Table 13). By excluding the genes regulated by androgens and insulin 
from those DE by HCM, the lipid-related process previously identified were no longer 
detected (Figure 4.15). This change was also observed with pathway analysis as the only 
remaining lipid-related canonical pathway identified was the “LXR/RXR Activation” pathway 
and the identification of this pathway could be due the non-lipid related function of this 
pathway (Figure 4.16). 
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Figure 4.15 Gene Otology Analysis Identified Remaining Biology Processes for HCM treated 
LNCaP cells excluding androgen and insulin regulated genes 
  
 
Figure 4.16. Top 10 Canonical Pathways for LNCaP cells treated in HCM excluding androgen 
and insulin regulated genes  
Note: Exact values for figure in Appendix Table 14, The height of the bar corresponds to the enrichment –log (p-
value) and the colour indicates the predicted activation state of the pathway. The ratio represents the 
percentage of genes within a pathway that are present and differentially expressed in the experimental dataset. 
Values over -log (p-value) 1.3 are statistically significant. 
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4.8.2 NED-like effects in HCM treated LNCaP cells excluding androgen and insulin 
regulated genes 
To determine the neuroendocrine-like related processes independent of androgens 
or insulin regulation, genes regulated by either of those were excluded.  Gene ontology 
analysis revealed of the non-androgen and non-insulin regulated subset, 22 enriched 
processes, which accounted for over half, were related to neuroendocrine processes 
(Figure 4.15). Five of the top ten upregulated non-androgen and non-insulin regulated HCM 
treated genes were found to encode for cytokines (CXCL8, ICAM1, ARL14, MMP1 and 
TNFRSF9) (Table 4.12a). From this non-androgen and non-insulin regulated dataset, 
functional analysis identified canonical pathways related to cytokine regulation i.e. “Role of 
Hypercytokinemia/hyperchemokinemia in the Pathogenesis of Influenza” “IL-6 Signalling” 
(Figure 4.16).  
4.9 Transcriptome analysis of VCaP cells cultured in HCM 
In order to determine if the HCM effects identified in the LNCaP cells were 
influenced by AR promiscuity the VCaP cells were treated and the harvested RNAseq 
analysed identical to LNCaP cells/RNAseq data. Unlike LNCaP cells, gene ontology analysis 
of the HCM cultured VCaP dataset displayed a greater proportion of enriched biological 
processes relating to DNA metabolism, repair or replication (Figure 4.17 & Appendix Table 
15).  Similarly, to the HCM treated LNCaP cells, there were a number of neuroendocrine 
and lipid-related biological processes enriched in VCaP cells grown in HCM 
Reflecting what was observed with gene ontology analysis, pathway analysis of the 
HCM treated VCaP data identified a number of canonical pathways that involved cell cycle 
and DNA regulation, repair and metabolism (Figure 4.18; Appendix Table 16). The DNA and 
cell cycle related pathways were uniquely identified in the VCaP dataset, as compared to 
the LNCaP data, suggesting a cell line specific response.  
Ranking the enriched pathways by z-scores, the top activated pathway was “Ataxia 
telangiectasia mutated (ATM) signalling”, which is related to DNA repair or apoptosis 
(Figure 4.19). The predicted activation state of the pathways “Role of BRCA1 in DNA 
Damage Response” and “Estrogen-mediated S-phase Entry” correlates well with the 
findings from the gene ontology analysis, which indicate an enrichment of “DNA 
metabolism, replication or repair” processes.   
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Figure 4.18. Top 10* Canonical Pathways for HCM cultured VCaP cells  
Note: Exact values for figure in Appendix Table 17. *Pathways that share all genes in common 
with 'Superpathway of Cholesterol Biosynthesis' in Appendix Table 18, Ranked by -log (p-
value), The height of the bar corresponds to the enrichment –log (p-value) and the colour 
indicates the predicted activation state of the pathway. The ratio represents the percentage 
of genes within a pathway that are present and differentially expressed in the experimental 
dataset. Values over -log (p-value) 1.3 are statistically significant. 
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Figure 4.19. Canonical Pathways for HCM cultured VCaP cells with significant or near 
significant z-scores. 
Note: Exact values for figure in Appendix Table 19, The height of the bar corresponds to the enrichment 
–log (p-value) and the colour indicates the predicted activation state of the pathway. The ratio 
represents the percentage of genes within a pathway that are present and differentially expressed in 
the experimental dataset. Values over -log (p-value) 1.3 are statistically significant. 
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4.9.1 Lipid-Related Effects of HCM Treated VCaP cells 
Functional analysis identified a lipid-metabolism-related response with HCM 
treatment in the VCaP data comparable to the LNCaP lipid-related response. The pathway 
“Superpathway of Cholesterol Biosynthesis” identified in the HCM treated LNCaP dataset, 
was also identified in the HCM treated VCaP dataset, suggesting regulation of this pathway 
was a HCM specific response (Figure 4.18). Two of the three canonical pathways showed a 
trend towards inactivation with HCM treatment were lipid-related, “AMPK Signalling” and 
“Protein Kinase A Signalling” (Figure 4.19). Furthermore, “Ketogenesis” was a significantly 
enriched lipid-related pathway; however, the pathway was not assigned an activation state 
(Table Appendix 10). To investigate a possible activation state, the individual genes in the 
pathway were analysed. The differentially expressed genes involved in this pathway are 
listed in Table 4.13 with each gene’s respective fold change. As seen in Table 4.13 the 
genes involved in FA breakdown were downregulated.  
 
Table 4.13. Ketogenesis associated genes differentially expressed in HCM treat VCaP cells  
Gene Fold Change Association 
BDH1 -2.43 FA catabolism 
ACAT2 3.163 Cholesterol Synthesis 
HADHB -2.096 Beta-Oxidation 
HMGCS1 -8.257 Ketogenesis and Cholesterol Synthesis 
HMGCS2 7.867 Ketogenesis in the Mitochondria 
 
4.9.2 Analysis of the Androgenic Effects of HCM on VCaP Cells 
 
In order to determine if HCM additives could have a regulatory impact on the AR, 
analysis was performed using the IPA pathway exploration tool. Using this function, 
experimental gene expression data was overlayed with the database of IPA-curated 
knowledge to identify potential relationships that could exist and act directly or indirectly 
on a target, in this case AR. This analysis predicted the VCaP AR to be inactivated with HCM 
treatment, implying there was an ongoing androgen regulation effect through different 
mechanisms (Figure 4.20). For example, FGF2, a HCM additive, could influence the AR 
signalling pathway. To further analyse the VCaP response to HCM, the response to well-
characterized androgen response genes was analysed (Table 4.14).  
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Figure 4.20 Identified potential mechanisms of regulation of AR activity in VCaP cells 
cultured in HCM via FGF2  
 
Table 4.14. Differential expression of well characterised androgen responsive 
genes in VCaP cells grown in HCM and RPMI+DHT 
 Genes HCM vs RPMI RPMI+DHT vs RPMI 
KLK3 -5.28 82.121 
FKBP5 - 50.666 
DDC -4.433 -31.617 
TMPRSS2 - 22.365 
AR - -4.537 
4.9.3  Analysis of the Upstream Regulators for HCM Treated VCaP Cells  
In order to determine the HCM additives regulatory influences on a PCa cell with 
low promiscuous binding potential, functional analysis was performed on the HCM treated 
VCaP dataset. Unlike the HCM treated LNCaP cells, analysis of the dataset no longer 
identified DHT as the top upstream regulator, or even a regulator for this dataset (Table 
4.15). When the top 30 upstream regulators of VCaP response to HCM were compared to 
LNCaP data, a number of common upstream activators were identified including Vegf, HGF 
and EGF (Table 4.15), potentially validating the transcriptional analysis as EGF was an 
additive in HCM (Table 3.1). 
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Table 4.15. Top 30 Predicted Upstream Regulators for VCaP cells cultured in HCM 
Upstream 
Regulator Exp FC Molecule Type 
Predicted 
Activation 
State 
Activation z-
score P-Value 
Vegf - group Activated 5.823 7.01E-19 
HGF -9.633 growth factor Activated 5.56 1.12E-11 
E2F1 10.76 transcription regulator Activated 5.485 5.13E-20 
CCND1 3.408 transcription regulator Activated 5.452 8.85E-25 
TBX2 - transcription regulator Activated 5.199 3.55E-14 
CSF2 - cytokine Activated 4.866 3.19E-12 
E2f - group Activated 4.78 6.92E-13 
SREBF1 - transcription regulator Activated 4.485 4.43E-03 
EGF - growth factor Activated 4.398 5.45E-09 
Jnk - group Activated 4.243 3.55E-03 
E2F3 - transcription regulator Activated 4.082 7.60E-13 
SREBF2 - transcription regulator Activated 4.054 5.00E-06 
SCAP - other Activated 3.959 7.60E-06 
CHUK - kinase Activated 3.858 9.38E-04 
VEGFA - growth factor Activated 3.847 2.62E-06 
RABL6 - other Activated 3.78 1.75E-13 
FOXM1 3.809 transcription regulator Activated 3.685 2.85E-05 
IKBKG - kinase Activated 3.65 2.13E-03 
PDGF BB - complex Activated 3.459 4.00E-12 
IL6 - cytokine Activated 3.41 2.37E-10 
BCL2L1 - other Activated 3.406 9.29E-04 
RETNLB - other Activated 3.357 2.60E-03 
AGT - growth factor Activated 3.322 6.83E-09 
FOXO1 - transcription regulator Activated 3.322 1.15E-04 
beta-oestradiol - chemical - endogenous mammalian Activated 3.307 4.55E-23 
TREM1 - transmembrane receptor Activated 3.291 7.05E-10 
hydrogen 
peroxide - 
chemical - endogenous 
mammalian Activated 3.264 8.08E-06 
Cg - complex Activated 3.24 1.09E-08 
EGFR - kinase Activated 3.24 2.45E-06 
F2 - peptidase Activated 3.198 1.82E-04 
Note: a positive z-score indicates the pathway is activated, the higher or lower the z-score the great activation 
or inactivation; Bolded upstream regulators shared with HCM treated LNCaP upstream regulators, Ranked by 
Activation z-score 
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4.9.4 Analysis of DE gene for VCaP cells treated in androgen enriched or depleted HCM, 
and androgen enriched RPMI 
There was a different response to androgen-enrichment for HCM treated VCaP 
cells as compared to the LNCaP cells. To investigate the differences and commonalities 
between these two responses, the three androgen regulated subsets for androgen-free 
HCM were analysed. The three subsets were; those genes unique to HCM in androgen or 
non-androgen treatment, those genes unique to non-androgen HCM and androgen 
enriched RPMI, and lastly those genes common between non-androgen and androgen 
treated HCM and androgen enriched RPMI. 
There were 268 common DE genes identified between the VCaP cells cultured in 
HCM (with or without DHT) and the VCaP cells cultured in RPMI+DHT (Figure 4.21). Overall, 
the direction of DE between the androgen-enriched RPMI and HCM treatments was 
congruent, implying that androgen stimulation had a similar effect in the direction of 
expression for both medias in this subset. However, the overall androgenic effect in both 
androgen treatments was generally different to the direction of expression in the non-
androgen HCM media (Table 4.16 & Table 4.17).  Functional analysis for the genes 
differential expressed across all three treatments identified pathways associated with DNA 
and cell cycle regulation (Figure 4.22). In general, functional analysis did not determine an 
activation state for most pathways in this data subset, therefore an additional analysis 
enrichment analysis, was performed to determine an activation state.  Enrichment analysis 
indicated there was an increase in the predicted activation state of cellular proliferation, 
together with a decrease in the predicted activation state for cell death and genome 
instability for HCM treated VCaP cells indicating overall cell survival (Table 4.18). The 
enrichment analysis of the activating biology functions identified by IPA from the 
experimental data did not definitively infer an activation state on a specific pathway; 
nevertheless, the less specific but greater perspective achieved through enrichment 
analysis predicts the potential activation states of pathways.  
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Figure 4.21. DE genes shared between VCaP cells cultured in HCM and treated +/- DHT and 
RPMI+DHT  
 
Table 4.16. The Similarity in the Directionality of Expression for the 268 genes differentially 
expressed between VCaP cells cultured in HCM and treated +/- DHT and the RPMI+DHT 
treatment  
 HCM vs RPMI RPMI+DHT vs RPMI HCM+DHT vs RPMI 
HCM vs RPMI - 153/268 159/268 
RPMI+DHT vs RPMI 153/268 - 263/268 
HCM+DHT vs RPMI 159/268 263/268 - 
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Table 4.17: The top upregulated genes between VCaP cells cultured in HCM treated with 
+/- DHT and VCaP cells cultured in RPMI+DHT 
Genes HCM vs RPMI   RPMI+DHT vs RPMI HCM+DHT vs HCM 
RP1-69M21.2 51.966 808.34 21.249 
NXPH3 44.315 5.917 -8.853 
KIAA1462 24.088 -4.901 -75.038 
NT5E 15.272 20.423 -6.379 
NOVA1 13.88 -6.402 -11.905 
PLCXD3 10.313 -102.556 -43.527 
SYNPO 9.199 -13.087 -21.677 
BRCA2 8.248 -4.833 -7.162 
RAD54L 7.978 -4.126 -10.275 
EXO1 7.065 -3.654 -9.945 
ESCO2 6.899 -4.038 -7.942 
NCAM1 6.548 -8.163 -3.217 
CDCA7L 6.463 -8.944 -2.298 
MALL 6.262 4.048 -3.411 
TYMS 6.167 -3.922 -9.555 
Note: Ranked by VCaP HCM vs RPMI FC 
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Table 4.18. IPA Functions Activation State for VCaP cells cultured in HCM treated with +/- 
DHT and RPMI+DHT 
Functions 
Diseases or 
Functions 
Annotation 
 p-Value 
Predicted 
Activation 
State 
Activation z-
score 
Cellular Growth and Proliferation proliferation of cells 6.26E-13 Increased 3.727 
Tissue Morphology quantity of cells 6.00E-12 Increased 3.189 
DNA Replication, Recombination, 
and Repair 
chromosomal 
instability 6.38E-06 Decreased -2.219 
DNA Replication, Recombination, 
and Repair 
chromosomal 
aberration 8.85E-04 Decreased -2.219 
Cell Death and Survival cell death 5.45E-03 Decreased -2.661 
DNA Replication, Recombination, 
and Repair DNA damage 5.46E-03 Decreased -2.804 
Cell Death and Survival apoptosis 1.46E-04 Decreased -3.083 
Note: a positive activation z-score indicates the function is activated, a negative activation z-score indicates the 
pathway is inactivated, NaN indicates it is unknown to IPA pathway activation or inactivation state, the higher 
or lower the z-score the great activation or inactivation, significance is determined by p-Value > 0.01, Ranked by 
Activation z-score 
  
 
0.00
0.10
0.20
0.30
0.40
0.50
0.60
0
1
2
3
4
5
6
Ra
tio
 
-lo
g 
(p
-v
al
ue
) 
   Inactivated 
                  
 
 
   No activity  
Pattern Available 
 
 
      
        Ratio 
Figure 4.22. Top 10 IPA Canonical Pathways between VCaP cells cultured in HCM 
with +/- DHT and RPMI+DHT.  
Note: Exact values for figure in Appendix Table 22. Ranked by HCM vs RPMI –log (p-value), The 
height of the bar corresponds to the enrichment –log (p-value) and the colour indicates the 
predicted activation state of the pathway. The ratio represents the percentage of genes within a 
pathway that are present and differentially expressed in the experimental dataset. Values over -log 
(p-value) 1.3 are statistically significant. 
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4.9.5 Analysis of DE gene found in VCaP datasets treated with HCM and RPMI+DHT 
excluding HCM+DHT treated genes 
 To determine if there was AR signalling activity in VCaP cells treated in androgen-
free HCM, comparative analysis of this dataset with RPMI+DHT dataset was performed. 
There were 497 genes differentially expressed that were common to HCM (without DHT) 
and RPMI+DHT treated VCaP cells.  The genes from this data subset were not further 
differentially expressed with the addition of androgen to HCM (Figure 4.23). These genes 
displayed over an 89% similarity in the directionality of expression (Table 4.19; Appendix 
Table 21). Functional analysis identified the “Superpathway of Cholesterol Biosynthesis” in 
this data subset (Figure 4.24)., indicating lipid-like regulation was androgen regulated.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.23. Genes in common between VCaP cells cultured in HCM and RPMI+DHT, 
excluding genes regulated HCM+DHT.  
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Table 4.19. Top 10 VCaP Androgen Sensitive Genes Upregulated in HCM that are 
insensitive to additional DHT Treatment.  
Gene HCM vs RPMI RPMI+DHT vs RPMI 
RP11-599B13.9 136.824 191.641 
ETV5 120.125 -39.125 
HSD17B2 84.979 57.502 
SLC5A1 78.302 48.814 
PLA2G4E 69.21 492.483 
RP1-69M21.2 51.966 808.34 
ITGB3 49.112 28.826 
NXPH3 44.315 5.917 
PSORS1C1 34.765 28.117 
KIAA1462 24.088 -4.901 
Note: DE with upregulation highlighted   ; DE with downregulation highlighted ; Ranked by 
HCM vs RPMI FC. 
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Figure 4.24. Top 10 Canonical Pathways of DHT responsive pathways in VCaP cells 
cultured in (HCM w/out DHT) & RPMI+DHT.  
Note: Exact values for figure in Appendix Table 22. Ranked by HCM vs RPMI –log (p-value), The 
height of the bar corresponds to the enrichment –log (p-value) and the colour indicates the 
predicted activation state of the pathway. The ratio represents the percentage of genes within a 
pathway that are present and differentially expressed in the experimental dataset. Values over -log 
(p-value) 1.3 are statistically significant. 
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4.9.6 Analysis of DE gene found in VCaP Cells treated in HCM with either androgen 
deplete or enriched treatment, excluding androgen-enriched RPMI genes 
To determine which genes were differentially expressed in the absence of 
androgens that were unique to HCM, analysis of the differentially expressed genes 
between androgen-enriched or deplete HCM was investigated, excluding those genes DE in 
the androgen-enriched RPMI. Of the 337 genes commonly DE genes between HCM 
treatments (Figure 4.25) 313 were DE in opposite directions (Tables 4.20). Enrichment 
analysis of the functions of this subset of genes showed an increase in activation of 
functions associated with cell survival, proliferation and repair and a corresponding 
decrease in activation of functions associated with cell death (Table 4.21a & 4.21b). 
 
 
Table 4.20. The Top 10 Upregulated Genes common between HCM +/- DHT and sensitive 
only to HCM treatment 
Gene HCM vs RPMI DHT vs RPMI 
A2M 7126.989 -16.963 
CLDN2 5504.492 -184.809 
CTLA4 558.733 -558.733 
CYTIP 518.01 -518.01 
HNF4A 442.344 -442.344 
HTR4 211.324 -211.324 
ADAMTS6 191.38 -191.38 
ETV4 187.333 -13.524 
KRT20 146.499 -146.499 
EGR2 120.082 -5.594 
Note: DE with upregulation highlighted    DE with downregulation highlighted   ; Ranked by 
HCM vs RPMI FC 
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Figure 4.25. Gene commonly differentially expressed between VCaP cells cultured in HCM 
+/-  DHT treatment, excluding androgen-enriched RPMI media treated genes 
 
Table 4.21a. The Top 10 Predicted VCaP Activated Diseases or Functions unique to HCM 
+/- DHT treatment, excluding RPMI+DHT regulated genes  
Diseases or Functions Annotation Predicted Activation State Activation z-score 
cell viability Increased 3.96 
cell survival Increased 3.958 
cell viability of tumour cell lines Increased 3.872 
repair of DNA Increased 3.756 
proliferation of cells Increased 3.727 
quantity of cells Increased 3.189 
repair of cells Increased 2.921 
cell proliferation of tumour cell lines Increased 2.905 
growth of embryo Increased 2.892 
repair of tumour cell lines Increased 2.747 
DNA replication Increased 2.695 
cell spreading Increased 2.618 
Note: Ranked by VCaP HCM vs RPMI (+) Activation z-score 
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Table 4.21b. The Top 10 Predicted VCaP Inactivated Diseases or Functions 
unique to HCM in either +/- DHT excluding RPMI+DHT regulated genes  
Diseases or Functions Annotation Predicted Activation State Activation z-score 
organismal death Decreased -6.46 
death of embryo Decreased -3.575 
lymphocytic cancer Decreased -3.284 
incidence of lymphoma Decreased -3.12 
cell death Decreased -3.076 
anaemia Decreased -2.906 
Growth Failure Decreased -2.869 
perinatal death Decreased -2.793 
incidence of tumour Decreased -2.767 
incidence of malignant tumour Decreased -2.675 
inflammation of secretory structure Decreased -2.626 
inflammation of organ Decreased -2.625 
Note: Ranked by VCaP HCM vs RPMI (-) Activation z-score 
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4.9.7 Analysis of DE gene found in VCaP datasets treated with DMSO in HCM and DHT in 
RPMI media excluding HCM+DHT treated genes and insulin regulated genes 
To determine what effects insulin had on the androgen-like response observed in 
androgen-deplete HCM, an analysis that compared VCaP cells cultured in HCM with the 
androgen-enriched RPMI was undertaken, after excluding genes regulated by androgen-
enriched HCM and insulin (Figure 4.26). Analysis identified 275 DE genes common to these 
two datasets with over 92% of the genes expressed in the same direction. Table 4.22 is an 
example of this congruent directionality in expression, between HCM treatment and 
androgen-enriched RPMI dataset (Appendix Table 23). 
 
 
 
Figure 4.26 DE genes in common between VCaP cells cultured in HCM (w/out DHT) and 
RPMI+DHT, excluding the genes regulated by insulin and HCM+DHT 
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Table 4.22. Top upregulated Genes between VCaP cells treated in HCM and RPMI+DHT and 
excluding insulin and HCM+DHT regulated genes  
Gene HCM vs RPMI RPMI+DHT vs RPMI 
RP11-599B13.9 136.824 191.641 
ETV5 120.125 -39.125 
HSD17B2 84.979 57.502 
SLC5A1 78.302 48.814 
PLA2G4E 69.21 492.483 
ITGB3 49.112 28.826 
NRGN 23.876 -5.737 
DNAH7 15.113 8.163 
CDKN2B 14.657 5.839 
PHOSPHO1 13.4 48.51 
EPHA7 11.721 8.564 
LINC00883 11.455 3.235 
EFEMP1 11.31 17.472 
LMO2 10.909 -12.343 
CPM 9.865 5.728 
PLEKHD1 9.7 8.533 
C3orf14 9.69 51.46 
NPPC 9.038 19.646 
TBXAS1 7.832 6.216 
Note: DE with upregulation highlighted DE with downregulation highlighted , Ranked by 
HCM vs RPMI FC 
 
4.10 LNCaP and VCaP Cell Side by Side Comparison 
To compare whether culture in HCM had similar or different response in each cell 
line, the datasets derived from LNCaP and VCaP HCM cultures were overlayed. 468 genes 
showed differential expression in both HCM treated LNCaP and VCaP cells (Figure 4.27). 
The top upregulated and downregulated genes for this dataset were expressed 
overwhelmingly in a congruent direction (Table 4.23a & b; Appendix Table 24). For the 
majority of genes changes, the effects were cell type specific for VCaP and LNCaP cells.  
Androgen and insulin genes were excluded from the HCM PCa cells to identify 
genes common between both HCM treatments that were not regulated by those 
molecules. There were 121 DE in that data subset (Figure 4.28). The top upregulated and 
downregulated genes were expressed overwhelmingly in a congruent direction (Table 
4.24a & b).  
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Table 4.23a. Top 15 upregulated gene between LNCaP and VCaP cells cultured in HCM 
base media.  
Gene LNCaP HCM vs RPMI VCaP HCM vs RPMI 
CXCL8 428.028 18.474 
PLEKHA4 269.604 16.509 
ETV4 231.306 187.333 
EGR1 154.849 88.494 
TIMP1 121.484 32.455 
ADAMTS6 101.484 191.38 
GSDMA 88.847 459.48 
TRGV9 84.696 -6.637 
MMP10 81.394 6.235 
A2M 76.792 7126.989 
DACT1 74.538 13.824 
PLA2G4E 72.724 69.21 
RP1-69M21.2 61.903 51.966 
EGR2 58.305 120.082 
DIRAS3 46.961 83.947 
Note: DE with upregulation highlighted DE with downregulation highlighted ; Bolded 
genes found in both tables 4.24a & 4.24b. Ranked by LNCaP HCM vs RPMI 
 
Table 4.23b. Top 15 upregulated gene between LNCaP and VCaP cells cultured in HCM 
base media.  
Gene LNCaP HCM vs RPMI VCaP HCM vs RPMI 
A2M 76.792 7126.989 
METTL7B 41.427 1196.6 
CHRM3 15.758 960.34 
GSDMA 88.847 459.48 
ADAMTS6 101.484 191.38 
ETV4 231.306 187.333 
RP11-599B13.9 14.017 136.824 
ETV5 24.888 120.125 
EGR2 58.305 120.082 
CXCR4 9.003 118.855 
EGR1 154.849 88.494 
CDKN2B-AS1 7.748 88.123 
DIRAS3 46.961 83.947 
PLA2G4E 72.724 69.21 
POU3F2 -9.876 65.559 
Note: DE with upregulation highlighted DE with downregulation highlighted ; Bolded 
genes found in both tables 4.24a & 4.24b. Ranked by VCaP HCM vs RPMI 
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Figure 4.27. DE genes in common between LNCaP and VCaP cells treated with HCM 
 
 
Figure 4.28. DE genes in common between LNCaP and VCaP cells treated with HCM 
excluding androgen and insulin regulated genes 
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Table 4.24a. Top 15 upregulated gene between LNCaP and VCaP cells cultured in HCM 
base media excluding androgen and insulin regulated genes 
Gene LNCaP HCM vs RPMI VCaP HCM vs RPMI 
CXCL8 429.028 18.474 
PLEKHA4 269.604 16.509 
ETV4 231.306 187.333 
TIMP1 121.484 32.455 
ADAMTS6 101.484 191.38 
GSDMA 88.847 459.48 
MMP10 81.394 6.235 
A2M 76.792 7126.989 
DACT1 74.538 13.824 
EGR2 58.305 120.082 
METTL7B 41.427 1196.6 
EGR3 26.618 14.33 
FOS 24.194 10.088 
GCNT3 20.451 12.252 
DUSP6 16.543 41.913 
Note: DE with upregulation highlighted DE with downregulation highlighted ; Bolded 
genes found in both tables 4.34a & 4.34b, Ranked by LNCaP HCM vs RPMI 
 
Table 4.24b. Top 15 upregulated gene between LNCaP and VCaP cells cultured in HCM 
base media excluding androgen and insulin regulated genes.  
Gene LNCaP HCM vs RPMI VCaP HCM vs RPMI 
A2M 76.792 7126.989 
METTL7B 41.427 1196.6 
CHRM3 15.758 960.34 
GSDMA 88.847 459.48 
ADAMTS6 101.484 191.38 
ETV4 231.306 187.333 
EGR2 58.305 120.082 
CDKN2B-AS1 7.748 88.123 
POU3F2 -9.876 65.559 
DUSP6 16.543 41.913 
TIMP1 121.484 32.455 
PIP5K1B 12.964 29.213 
LY6G6C 6.374 28.316 
CXCL8 429.028 18.474 
PLEKHA4 269.604 16.509 
Note: DE with upregulation highlighted DE with downregulation highlighted ; Bolded 
genes found in both tables 4.34a & 4.34b; Ranked by VCaP HCM vs RPMI FC 
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4.10.1 HCM Androgen effects between LNCaP and VCaP Cells 
Using the IPA Pathway Exploration tool, androgen-like activation was detected in 
both HCM treated LNCaP and VCaP datasets in the absence of androgens. Figure 4.29 
illustrates a mechanism by which FGF2, an HCM additive could regulate AR activity in both 
LNCaP and VCaP cells. The response to the addition of androgens to HCM varied between 
LNCaP and VCaP cells. For example, there were 136 differentially expressed androgen-
enriched HCM LNCaP cells and in VCaP cells that same comparison revealed 2217 DE genes 
(Figure 4.30).  
Figure 4.29. Analysis showing AR regulation in VCaP and LNCaP cells cultured in HCM via 
FGF2 
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Figure 4.30. The Difference in Genom
ic response betw
een VCaP and LN
CaP cells treated in HCM
 +/- DHT or RPM
I+DHT 
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4.10.2 Neuroendocrine effects between LNCaP and VCaP Cells 
To compare the neuroendocrine response between LNCaP and VCaP cells treated 
with HCM, the expression levels of a number of NED markers used to diagnose NEPCa were 
investigated and compared (Table 4.25). Unlike LNCaP cells, genes DE by VCaP treated with 
HCM displayed regulation by DHT. To determine what effects NED had on baseline levels of 
expression the gene, CHGA was analysed. CHGA, a well-established neuroendocrine gene, 
was expressed in androgen-deplete RPMI media treated VCaP cells 47756.65 greater than 
its respective LNCaP counterpart (Figure 4.31).  
 
Table 4.25.  Neuroendocrine Markers expressed following HCM treatment of LNCaP and 
VCaP cells 
PCa Type VCaP Cells LNCaP Cells 
Gene HCM vs RPMI    DHT+RPMI vs RPMI HCM vs RPMI DHT+RPMI vs RPMI 
SYP - - 2.349 - 
CHGA 14.438 - - - 
NCAM1 6.548 -8.163 4.045* - 
ENO2 - - - - 
SV2B - - 27.004 - 
SNAP25 - - 49.857 - 
RAB3GAP1 - - - - 
AURKA - - 2.807 - 
TIMP-1 32.455 - 121.484 - 
CCND1 3.408 2.842 - - 
ASCL1 9.421 - - - 
MYCN - - - - 
RB1 - - - - 
REST 1.939 - - - 
Note: listed with FC. *NCAM1 p-value is 0.0558, (-) implies the gene is not differentially expressed 
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4.11 HCM Effects on Lipids  
In order to determine the effects of HCM on lipids analysis was performed and 
functional analysis of the LNCaP cells grown in HCM revealed four of the identified 
canonical pathways to be lipid-related (Figure 4.2). However, the activation status of these 
pathways could not be determined. This was despite 40 genes known to be directly 
involved in lipid droplet metabolism being differentially expressed in the LNCaP dataset 
(Table 4.26).  
As the canonical pathway analysis identified cholesterol and lipid biosynthesis as 
major functional pathways in LNCaP cells with HCM treatment, expression of genes 
associated with these pathways was specifically examined (Figure 4.32 and Figure 4.33 
respectively). The results of this examination can be seen superimposed over pathway 
diagrams in Figure 4.32 and 4.33 in order to visualise the pathway directions and 
outcomes. The specific genes coding for the steps of the cholesterol synthesis were 
upregulated and the genes that code for lipid extracellular transport were downregulated. 
  
Figure 4.31. Chromogranin A (CHGA) Transcripts per Million (TPM) for VCaP & LNCaP cells cultured 
androgen-free HCM or RPMI   
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Figure 4.32. Cholesterol Synthesis Pathway. (modified from Salomonis et al., 2016). 
Note: DE with upregulation highlighted orange; DE with downregulation highlighted blue. Enzyme 
abbreviations: ABCA1, ATP-binding cassette transporter 1; ABCG5 & 8, ATP-binding cassette sub-family G 
member 5 & 8; APOA1, Apolipoprotein A-1; CETP, Cholesteryl ester transfer protein; DAG, Dystrophin-
Associated Glycoprotein; FDFT1, Farnesyl-diphosphate farnesyltransferase; HDL, High-Density Lipoprotein; 
LCAT, Lecithin-cholesterol acyltransferase; LDL, Low-Density Lipoprotein; LPL, Lipoprotein lipase; PDIA2, Protein 
disulphide-isomerase A2; PLTP, Phospholipid Transfer Protein; LIPC, Lipase C; SCARB1, Scavenger receptor class 
B member 1; SQLE, squalene epoxidase; VLDL, Very Low-Density Lipoprotein. 
  
DE UP 
DE Down 
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Table 4.26. Lipid metabolism associated genes for HCM treated LNCaP cells. Bolded gene 
also found in Figure 20 highlighting role in lipid metabolism.  
 Gene Fold Change Lipid Association 
METTL7B 41.427 Lipid Metabolism 
CYP11A1 12.837 Cholesterol Metabolism 
INSIG1 8.596 Cholesterol Metabolism 
AGPAT5 7.07 Fatty Acid (FA) Metabolism 
FADS1 6.983 Arachidonic Acid (AA) Metabolism 
FDFT1 6.737 Cholesterol Metabolism 
FADS2 4.884 Arachidonic Acid Metabolism 
HMGCR 4.2 Cholesterol Metabolism 
TRIB3 3.984 Insulin Signalling 
LDLR 3.856 Arachidonic Acid Metabolism 
FASN 3.679 FA Synthesis 
SQLE 3.561 Cholesterol Metabolism 
ELOVL7 3.221 FA Synthesis 
SCD 3.205 FA Synthesis 
ACAT2 3.071 Cholesterol Metabolism 
ELOVL6 2.841 FA synthesis 
ACSS2 2.839 Lipid Metabolism 
PRKCH 2.712 Lipid Metabolism 
LRP8 2.624 Lipid Transport 
ACSL1 2.389 FA Transport 
SLC27A2 1.887 FA Transport 
PLA2G12A 1.658 Arachidonic Acid Metabolism 
SCP2 -1.654 Lipid Metabolism 
CERS4 -2.212 Ceramide/Sphingolipid Signalling/Metabolism 
CELSR2 -2.256 - 
DGAT2 -2.591 FA metabolism 
ACAT1 -2.618 Cholesterol Metabolism 
LRP1 -2.933 Lipid Metabolism 
ACSS1 -3.2 Lipid Metabolism 
ACSL5 -3.537 FA Transport 
ACSL6 -5.278 FA Transport 
PLIN4 -5.95 Lipid Metabolism 
ABCG1 -12.574 Cholesterol Metabolism 
PLA2G2A -13.182 Arachidonic Acid Metabolism 
UCP2 -17.082 FA Oxidation 
LCAT -18.453 Cholesterol Metabolism 
DEGS2 -18.547 Ceramide/Sphingolipid Signalling/Metabolism 
ABCA1 -20.732 Cholesterol Metabolism 
PTGS1 -52.694 AA/Prostaglandin Metabolism 
CYP7A1 -82.599 Cholesterol Metabolism 
Note: DE with upregulation highlighted   ; DE with downregulation highlighted ; Ranked by FC 
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Figure 4.33. Lipid biosynthesis. (modified from Baenke et al., 2013) 
Note: DE with upregulation highlighted orange; DE with downregulation highlighted blue. Red highlights – Lipid 
uptake (essential FAs from B27 components and GlutaMax). Schematic overview of the pathways involved in 
the synthesis of fatty acids (FAs), cholesterol, phosphoglycerides, eicosanoids and sphingolipids. The enzymes 
involved in catalysing steps in lipid biosynthetic pathways are indicated in red. (a) Glucose- or glutamine-
derived citrate is first converted to Acetyl-CoA by ACLY. (b) For FA biosynthesis, Acetyl-CoA is converted into 
malonyl-CoA. The repeated condensation of Acetyl-CoA and malonyl-CoA by the multifunctional enzyme FASN 
leads to the generation of palmitic acid, a fully saturated 16-carbon FA. The introduction of a double bond in 
the Δ9 position of the acyl chain by SCD generates mono-unsaturated FAs. (c) Subsequent elongation and 
further desaturation produces the repertoire of FAs with different saturation levels. (d) Essential FAs (ω3 and 
ω6 FAs) cannot be synthesised by human cells and need to be provided from dietary sources. (e, f) Saturated 
and unsaturated FAs are combined with glycerol-3-phosphate (glycerol-3-P) to generate (e) phosphoglycerides 
and (f) phosphoinositides. (g) Arachidonic acid, a long-chain polyunsaturated FA, is used for the synthesis of 
eicosanoids. (h) Sphingolipids contain acyl chains and polar head groups derived from serine, phosphocholine 
or phosphoethanolamine. (i) Cholesterol biosynthesis is initiated by the conversion of Acetyl-CoA to 
acetoacetyl-CoA. Addition of another acyl group by HMGCS produces 3-methylglutaryl-3-hydroxy-CoA, which is 
converted to mevalonate by HMGCR. Subsequent reactions result in the production of farnesyl-pyrophosphate, 
an essential intermediate for protein prenylation. Cholesterol also forms the structural backbone for steroid 
hormone biosynthesis. Enzyme abbreviations: ACAT, acetyl-CoA acetyltransferase; ACC, acetyl-CoA carboxylase; 
ACLY, ATP citrate lyase; AGPAT, 1-acylglycerol-3-phosphate Oacyltransferase; COX1/2, prostaglandin-
endoperoxide synthase (PTGS); DGAT, diacylglycerol O-acyltransferase; ELOVL, fatty acid elongase; FADS, fatty 
acid desaturase; FASN, fatty acid synthase; GPAT, glycerol-3-phosphate acyltransferase; HMGCR, 3-hydroxy-3-
methylglutaryl-CoA reductase; HMGCS, 3-hydroxy-3- methylglutaryl-CoA synthase; PPAP, phosphatidic acid 
phosphatase; SCD, stearoyl-CoA desaturase; SPHK, sphingosine-1-kinase. Metabolite abbreviations: α-KG, α-
ketoglutarate; CDP-DAG, cytidine diphosphate-diacylglycerol; CER, ceramide; DAG, diacylglycerol; FA, fatty acid; 
LPA, lysophosphatidic acid; PA, phosphatidic acid; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PG, 
phosphatidylglycerol; PGE2, prostaglandin E2; PGH2, prostaglandin H2; PI, phosphatidylinositol; PIPx, 
phosphatidylinositol phosphate; PS, phosphatidylserine; S1P, sphingosine-1-phosphate; SPH, sphingosine; TAG, 
triacylglyceride  
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4.11.1 HCM effects on Phospholipid Synthesis 
To determine if the phospholipid synthesis pathway was activated those genes 
involved in the Kennedy Pathway were identified. It was found that two of the three 
transcripts in that pathway Kennedy Pathway were upregulated, including the rate limiting 
step in the HCM treated LNCaP cells (Figure 4.34 & Table 4.27).  
 
Figure 4.34. Phospholipid Synthesis. Kennedy Pathway Blue outline, Land Cycle Green Outline 
Note: *Rate Limiting Step in the Kennedy Pathway, Red upregulated with HCM treatment, Blue 
downregulated with HCM Treatment, Green mixed response to HCM treatment, Bolded Black no DE but 
expressed, Purple IPA predicted amplification with HCM treatment. CCT, CTP-phosphocholine 
cytidylyltransferase, CK: Choline kinase, FA: Fatty Acid, LPA: Lysophosphatic Acid, LPC: 
Lycophosphatidylcholine, LPCAT: Lysophosphatidylcholine acyltransferase, Lyso PLD: lysophospholipase D, 
PA: Phosphatidic Acid, PC: Phosphatidylcholine, PLA2: Phospholipase A2, PLD: Phospholipase (Pol et al., 
2014) 
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Table 4.27. Phospholipid Synthesis genes in Kennedy Pathway and Lands Cycle  
Enzyme Gene LNCaP HCM vs RPMI 
CCT* CTPS1 2.495 
CK CHKA 2.238 
AGPAT AGPAT5 7.07 
PLA2 PLA2G4E 72.724 
PLA2 PLA2G4C 6.558 
PLA2 PLA2G12A 1.658 
PLA2 PLA2G2F -741.323 
PLA2 PLA2G2A -13.182 
PLD PLD1 -19.286 
Note*Rate Limiting Step in the Kennedy Pathway  
4.11.2 Analysis of Fatty Acid Uptake and Lipid Droplet Status (Cellular Level) 
To support the transcriptional analysis findings of significant lipid pathway 
identification, lipid assays were conducted. In the LNCaP lipid droplet experiment, 
androgen (R1881) treatment caused an increase in FA uptake (Figure 4.35a) and an 
increase in the number of LDs via lipogenesis (Figure 4.35b) compared to the androgen-free 
CSS treatment. HCM, which contains insulin (part of B27), had little positive effect on FA 
uptake and LD size, though a relative increase in LD number (Figure 4.35a & b). The LNCaP 
cells grown in HCM were shown to have a reduced fatty acid uptake and reduction in the 
number and cellular area of LDs in LNCaP cells compared to (CSS + R1881); however, there 
was increased FA uptake and an increased number of lipid droplets relative to the CSS 
sample, although LD area was reduced.  
Mitochondrial membrane potential, indicative of oxidative-phosphorylation, was 
equivalent for LNCaP cells grown in HCM and FBS (Figure 4.35d). There was an increased 
number of mitochondria (Figure 4.35e) and decreased mitochondrial total area (Figure 
4.35f) were observed in HCM treatment compared to the (CSS + R1881) treatment.  
4.11.3 Analysis of lipid droplet parameters (organelle level) 
At an organelle level, HCM appears to promote localisation of LDs away from the 
nucleus, indicating a possible energy deplete environment (Herms et al., 2015) (Figure 
36b). To explore possible pathways that may be response for this pattern of LD localisation 
from the nucleus, the transcriptomic data was revisited looking for pathways that were 
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involved in lipid and energy metabolism. Within the dataset, AMPK Signalling was identified 
and its role in this process was explored as AMPK is a key controller of the intracellular 
metabolic process and activates in response to stress signalling (Herms et al., 2015; Tong, 
2005). Results of IPA gene expression analysis predicted the “AMPK Signalling” pathway in 
LNCaP cells grown in HCM was inactivated, suggesting the media was in fact not energy 
deplete, and subsequently another process may be responsible for the localisation of the 
LDs away from the nucleus (Table 4.28). Further indicating an energy enriched 
environment, the lack of LDs and mitochondria contact in the HCM treatment relative to 
the nutrient deplete Orlistat sample indicated a potential energy satiated environment 
(Figure 4.36f) (Herms et al., 2015). Identification of organelles and the nucleus was 
visualised in Figure 37. 
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Figure 4.37 Representative image of multiplex assay. Yellow indicates lipid droplets (LD), 
Green indicates mitochondria M, Blue indicates a nucleus 
 
Table 4.28. The AMPK Signalling Pathways for HCM treated LNCaP DE* genes 
Canonical Pathways  -log (p-value) z-score ratio 
AMPK Signalling 1.47 -2.183 19/188 
Note: -log (p-value) > 1.3 is significant, Ratio (target genes/IPA identified pathway genes) 
A positive z-score indicates the pathway is activated, a negative z-score indicates the pathway is inactivated, a 0 
z-score indicates the pathway is neither activated or inactivated, NaN indicates it is unknown to IPA pathway 
activation or inactivation state. 
*p-value > 0.055 
   
C16-Bodipy MitoTracker 
DNA F-actin 
X 
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Chapter: 5 Discussion 
The primary aim of this study was to identify any media specific transcriptomic 
interactions between HCM and PCa cell lines, with emphasis on androgenic pathways and 
the media’s efficacy in enhancing in vitro PCa cell growth. This was achieved through 
pathway analysis of RNAseq data from two AR expressing PCa cell lines, LNCaP and VCaP, 
cultured in HCM. This study’s key objectives were to investigate the HCM’s effects on; 
androgen response, possible pathways towards treatment resistance, and metabolic 
pathways associated with PCa and androgens. Results of each of these investigations will 
be addressed throughout this discussion. 
A notable media-specific impact was found on the AR activity of both cell lines. This 
effect was observed in HCM treated LNCaP cells, which showed a significant androgen-like 
response in androgen-deplete culture (HCM) and a muted response with additional 
androgen treatment (HCM+DHT) however in RPMI media, LNCaP cells only displayed a 
profound androgenic response when treated with androgen (RPMI+DHT). The VCaP cells 
cultured in HCM displayed an androgenic response in an androgen enriched culture, 
somewhat mirroring the control condition using RPMI media (RPMI+DHT). However, in the 
HCM cultured VCaP cell lines, a media specific effect was also found in the androgen 
depleted medium, where an androgen response was partially observed, whereas no such 
response was observed under the RPMI androgen deplete conditions.  
Additional noteworthy findings suggest media specific transcriptomic effects of 
HCM on insulin regulated pathways and lipid metabolism pathways of PCa cell lines, 
suggesting a potential mechanism for the HCM’s ‘organoid’ promoting potential. A possible 
further media specific effect was also observed in the expression of neuroendocrine 
related genes. While the potential simulation of neuroendocrine-like differentiation effects 
is by no means definitive, they provide potential mechanisms to further investigate as to 
how PCa cells could develop NED in an androgen deplete environment. These findings and 
their possible implications will both be further clarified later in this discussion.  
5.1 HCM & androgen response 
As predicted by previous research, the androgen treatment in both LNCaP and 
VCaP cell lines treated in RPMI with serum supplements (controls), induced a ‘classic’ 
androgen response, as documented in Table 4.3 & 4.14, with the predictable expression of 
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certain well-characterized androgen regulated genes (Makkonen et al., 2011). However, in 
contrast, it was found that the androgen-free HCM also had an androgenic-like effect on 
the expression of a number of androgen responsive genes in both cell lines. This finding 
was contrary to the literature, as the HCM is deplete of androgens and therefore should 
not active an androgenic response (Makkonen et al., 2011). This androgen response varied 
between the two cell lines and as such the predicted potential mechanisms inducing that 
response are different.  
5.1.1 HCM specific androgen response in LNCaP Cells 
 At the transcriptomic level, an androgen-like response was observed in HCM 
cultured LNCaP cells, in the absence of DHT, relative to the similarly treated control in 
RPMI. While this is counter-intuitive given HCM is an androgen deplete media, this result is 
potentially explained by the literature, due to the LNCaP cell lines mutated AR (Veldscholte 
et al., 1992; Katzenwadel & Wolf, 2015). The mutated AR present in LNCaP cells is 
susceptible to activation or stimulation by certain non-androgenic ligands as a result of 
reduced ligand specificity and selectivity, and therefore the androgenic-like response 
observed in the HCM treatment could have resulted from the non-specific activation of the 
AR by certain HCM additives, such as corticosterone (Veldscholte et al., 1992; Katzenwadel 
& Wolf, 2015). This ligand promiscuity can result in androgen binding resulting in AR 
activation from steroids other than DHT, and even some AR-targeting therapies and is 
therefore one of the mechanisms behind the potential development of CRPC (Tan et al., 
2015).  
 There was nearly nine-fold increase in the number of genes differentially expressed 
with the addition of DHT to the RPMI media versus to HCM, suggesting the basal level of 
expression of androgen responsive genes was abnormally elevated in HCM and that 
sensitivity to further androgenic stimulation may be limited (Figure 4.31). This finding 
suggests HCM produced a media specific androgen-like response, similar to DHT treatment 
in LNCaP cells using RPMI media. 
 A HCM media-specific androgen-like response in the LNCaP cells was further 
suggested by the similarity in directionality of gene expression, and in many cases 
amplitude, between the androgen deplete HCM treatment and androgen enriched RPMI 
media, in commonly differentially expressed genes (Table 4.3 & 4.5). Functional analysis 
identified the enrichment of common pathways in both HCM and androgen-enriched RPMI 
media, adding more evidence to the potential androgen-like activation of HCM. Further 
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supporting this finding, the highest activated upstream regulator for the androgen-deplete 
HCM was identified as DHT (Table 4.1). 
 HCM has previously shown outstanding potential for growing primary PCa cells and 
furthering precision medicine (Gao et al., 2014). However, due to the potential HCM 
specific androgen-like response observed in cells with a mutated AR, when requiring an 
androgen deplete environment, additional consideration is needed prior to analysis.  
5.1.2 HCM specific androgen response in VCaP Cells 
 Similar to the transcriptomic response observed with LNCaP cells cultured in HCM, 
there was an androgen-like response observed in VCaP cells cultured in androgen-deprived 
HCM. However, unlike the LNCaP cells, VCaP cells have a wild-type AR thus the observed 
androgen-like response was unlikely to be due to promiscuous AR binding of additives 
within HCM (Makkonen et al., 2011). The VCaP androgen response differed from the LNCaP 
response, and could be considered a ‘partial’ androgen-like response, as compared to the 
more ‘classical’ androgen-like response observed in the LNCaP cells. The VCaP AR response 
to HCM treatment resulted in an androgen-deprived expression profile for some well-
characterized androgen regulated genes (KLK3, FKPB5, TPMRSS2; Table 4.14). However, 
overall the androgen-deprived HCM and androgen enriched control (RPMI+DHT) were 
found to commonly regulate a number of DE genes with congruent directionality (Table 
4.19). This ‘partial’ response suggests that although a ‘classic’ androgen response was not 
identified, the upregulation of genes in the AR signalling pathway was consistent with AR 
signalling pathway activation even in an androgen deprived environment.  
Potential activators of the AR signalling pathway include insulin, a component 
within B27 a HCM additive. Androgen and insulin share regulatory control of numerous 
pathways including lipid metabolism (Butler et al., 2016; Saltiel et al., 2016). Pathway 
analysis identified lipid metabolism pathways in both the HCM and androgen-enriched 
RPMI VCaP cells suggesting the androgen-like effects of HCM could potential be explained 
by the presence of insulin in HCM. However, even excluding insulin and HCM+DHT 
regulated genes, an androgen-like response was still observed (Table 4.22). This indicates 
that while insulin may be potentially responsible for part of the AR signalling activation 
observed, HCM additives other than the insulin component in B27 may have also been 
activating the AR signalling pathway. Pathway exploration predicted androgen-like effects 
on the VCaP AR though additives within androgen deprived HCM, which may be suggestive 
of potential pathway to therapeutic resistance (Figure 4.29).  
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5.2 HCM and potential pathways to therapeutic resistance 
 One of the objectives of this thesis was to investigate possible pathways 
responsible for the development of therapeutic resistance PCa, in HCM. Several processes, 
discussed below, have been identified that may account for this ability to proliferate even 
in androgen deprived environments and therefore could suggest possible pathways to 
therapeutic resistance in PCa.  
5.2.1 Androgen independent pathways and HCM 
 Previous research articulates that VCaP cells display amplified expression of AR, 
compared to LNCaP cells, and have a TMPRSS2-ERG gene fusion, a mutation that has been 
linked to an increased propensity in the development of CRPC (Makkonen et al., 2011). 
These factors may intrinsically have allowed VCaP cells grown in HCM to activate pathways 
normally activated through androgen stimulation, possibly explaining the identification of 
pathways involved cell cycle and proliferation in VCaP cells cultured in androgen deprived 
HCM (Figure 4.18 & Appendix Table 16). As it is accepted that the AR signalling pathway is 
crucial for PCa cell survival and proliferation, this potentially suggests the AR signalling 
pathway was activated (Tan et al., 2015). The VCaP genes identified in both androgen-
enriched and depleted HCM were found to be involved in cell survival and proliferation 
pathways/processes (Table 4.21a & b). Expression of these genes was antagonized by 
androgens, suggesting they may be involved in the regulation of cell survival and 
proliferation in an androgen deplete environment (Table 4.20). These results suggest that 
androgen-deplete HCM may be able to promote or, at least regulate expression of genes 
involved in cell proliferation and survival potentially identifying a pathway behind the 
development of therapeutic resistant PCa.  
As HCM is a defined-media that does not contain androgens, the androgen-like 
gene responses must be due to one, or a combination of the additives present in the 
media, either directly or through intermediaries. Tyrosine kinase receptor-activating 
ligands, such as growth factors (EGF, FGF2) or cytokines (IL-6), have the capacity to induce 
non-genomic AR activation and potentially ‘outlaw’ activation (Tan et al., 2015). HCM 
contains a number of potent growth factors and that could potentially promote non-
specific activation of AR (Table 3.1 & 3.2). Pathway exploration identified a possible 
mechanism of non-specific AR activation via FGF2 through FOS (Figure 4.20). FOS 
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expression is regulated by a number of mechanisms, one being MAPK cascade, which was 
identified in the HCM treated LNCaP cells (O’Donnell, Odrohawaz, & Sharrocks, 2011). The 
expression of FOS was upregulated by HCM treatment in both PCa cell datasets potentially 
increasing the possibly of non-genomic activation of AR by MAPK cascade (Table 4.24a & b; 
Appendix Table 1). In addition to MAPK activation, STAT3 signalling was predicted to be 
activated with HCM treatment, and potentially this mechanism may produce non-genomic 
AR signalling (Figure 4.20) (Liao, R., et al., 2013). Although HCM provides an androgen-
deplete environment, it is possible that it may still allow AR signalling pathways to be 
regulated through non-canonical ligand binding and non-genomic action pathways. 
5.2.2  Neuroendocrine-like activation  
There is a large body of research regarding the importance of neuroendocrine-like 
differentiation in the adaption and progression of PCa after ADT (Terry & Beltran, 2014). 
The neuroendocrine-like activity found across both PCa cell lines to androgen-deprived 
HCM treatment this study is consistent with this research, and may indicate a potential 
pathway in the development of therapeutic resistant PCa, in HCM. 
Specific genes used in the diagnosis of NEPCa were differentially expressed in both 
LNCaP and VCaP cells cultured in androgen-deplete HCM (Table 4.25). Androgen treatment 
of LNCaP cells in HCM showed no effect on expression of NED related genes. Unlike the 
LNCaP cells, the addition of androgens to HCM resulted in inhibitory effects on some of the 
identified VCaP NED genes (Table 4.25). The difference in expression of NED genes in the 
PCa cell comparison may be due to the higher basal level of neuroendocrine expression in 
the VCaP cells as compared to LNCaP cells. These finding are observed with varying 
baseline expression levels of CHGA. Highlighted in Figure 4.31, CHGA, a well-established 
neuroendocrine gene, was expressed almost 50 thousand times more in androgen-deplete 
RPMI for VCaP cells as compared to LNCaP cells (Li et al., 2016).  Along with a higher basal 
level of NED, current literature indicates VCaP cells have amplified AR, relative to LNCaP 
cells, and a TMPRSS2-ERG fusion (Makkonen et al., 2011; Terry & Beltran, 2014). These 
findings suggest VCaP cells are possibly susceptible to both CRPC and NED.   
Along with the identified NED markers, gene ontology analysis identified the 
enrichment of neuroendocrine biological processes, however a clear neuroendocrine 
related pathway response was not observed (Figure 4.2, Appendix Table 1 & 2). Of the 
identified NED-like pathways in LNCaP cells, “TREM1 Signalling” was identified to a near 
significant activation state in HCM and excluding androgen regulated genes increased the 
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activation state, suggesting androgens were inhibiting this pathway (Figure 4.3 & 4.13). This 
pathway is associated with cytokines, specifically IL-6 and IL-8, which contribute to the 
survival and proliferation of PCa and are possibly mechanisms behind PCa transitioning to 
NEPCa, as well as to CRPC (Beltran et al., 2013; Ford & McVicar, 2009; Karagiannis et al., 
2014; Zhu et al., 2014). The gene that codes for IL-8, CXCL8, was amplified in both HCM 
treated LNCaP and VCaP cells datasets, suggesting this gene may have played a role in cell 
survival and proliferation in androgen-deprived HCM (Culig, 2013).  
The literature suggests that neuroendocrine-like differentiation of prostate 
adenocarcinoma and CRPC are closely associated and this may be due to the common 
pathways in which these diseases influence cell regulation (Beltran et al., 2013; Tan et al., 
2015; Terry & Beltran, 2014). The STAT3 signalling pathway has been implicated in PCa cell 
hormone-free survival for both neuroendocrine-like differentiation of prostate 
adenocarcinoma and CRPC, and our data predicted STAT3 signalling was activated in both 
HCM treated PCa cell lines (Figure 4.20) (Beltran et al., 2013; Tan et al., 2015).  This finding 
potentially identifies how HCM enables both LNCaP and VCaP cells to survive and grow in 
androgen-deplete environments.     
A potential explanation for the observed NED-like responses observed could be 
due to B27, a HCM additive, which is used in the in vitro culture of neuronal cells and 
therefore provides a stimulus that may promote NED (Thermo Fisher Scientific, 2015).  
Although certain NED-like genes were differentially expressed, we were unable to 
definitively identify NED induced by HCM. However, previous research has tracked the 
progression of NED of PCa over 3 to 12 months, whereas the neuroendocrine-like profile in 
our datasets was observed after only two days of HCM treatment, providing a possible 
explanation for non-definitive findings (Terry & Beltran, 2014; Terry et al., 2013; Wafa et 
al., 2007). Further the differentiation of pre-existing adenocarcinoma prostate cells to cells 
displaying a neuroendocrine-like phenotype is an adaptation to meet cellular needs in an 
androgen-deprived environment and therefore varies (Terry & Beltran, 2014). 
5.2.3  Summary of androgen independent pathways 
AR signalling may be crucial to maintaining PCa, however, this pathway is 
susceptible to alternative activation. HCM is a defined media that enabled LNCaP and VCaP 
cells to utilise innate mechanisms to influence AR signalling to grow and survive in an 
androgen-free environment. LNCaP cells express mutant AR that was potentially activated 
by non-androgen steroids, such as progesterone, which is present in the B27 component of 
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HCM. Compared to LNCaP cells this study identified a considerably weaker androgen-like 
response in VCaP cells treated in HCM. Though this response did not result in the 
expression of well-characterized androgen-regulated genes, the response shared 
expression and directionality of expression with a considerable number of genes whose 
expression is regulated by DHT in RPMI media. This androgen-like response profile was not 
completely explained by the exclusion of insulin-regulated genes, suggesting other 
components of HCM might be involved in ligand-independent mechanisms and/or possible 
AR signalling bypass pathways, for example the growth factors or cytokines. The results of 
this project, supported by current literature, demonstrated AR signalling activation through 
growth factors in the HCM. Functional analysis identified this mechanism may involve 
STAT3, which was predicted to be activated. Current literature suggests STAT3 is involved 
in NED and the expression of several additional markers of NED were detected, however, 
pathways analysis could not definitively identify any active pathways that might be 
specifically causing NED (Liao, R., et al., 2013; Tan et al., 2015). Potentially part of the 
suspected NED response was the identification of androgen deprivation therapy pathways 
of resistance.  
Taken together, these results highlight factors within HCM that may provide PCa 
cells with the ability to bypass the AR in androgen-depleted environments, and provide 
alternate pathways for cells to survive and grow in non-conducive environments, as found 
in vivo during the evolution to treatment resistant PCa. In this way, HCM may provide not 
only the ability to growth and survive PCa cell lines, but also to better observe and 
understand the progression to CPRC.   
5.3 Lipid metabolism and HCM 
5.3.1  Mechanisms behind lipid response in HCM 
Lipid metabolism dysregulation is associated with PCa and therefore it is 
unsurprising that we identified lipid-related pathways in both the HCM and androgen-
enriched RPMI treatments in both PCa cell lines. Although androgens have a profound 
effect on lipid metabolism, other molecules such as insulin are also key regulators of lipid 
metabolism (Butler et al., 2016; Wu, Daniels, Lee, & Monaco, 2014; Wuttke et al., 2015). 
One of the HCM additives is B27, which contains many components including insulin 
(Thermo Scientific Fischer, 2015). There was a high degree of common differential 
expression with congruent directionality between HCM enriched LNCaP genes and insulin 
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regulated genes. The insulin content of HCM, as it is only one of many components of HCM, 
is not often discussed, therefore, the above finding, although intuitive, is nevertheless, 
important to consider when using HCM and other culturing systems with similar 
ingredients.  
When insulin and androgen regulated genes were excluded most of the lipid-
related pathways were unidentifiable in LNCaP cells grown in HCM, suggesting the majority 
of lipid-related pathways identified following HCM treatment were regulated by insulin or 
androgen-like activity (Figure 4.16).  
Lipid-related genes, processes and pathways were identified in both HCM treated 
LNCaP and VCaP cells, however, the activation status of these pathways were generally not 
identified (Figure 4.2 & 4.18). Detailed manual transcript identification, revealed HCM 
upregulated the expression of genes involved in de novo cholesterol synthesis, including 
the rate limiting step, HMG-CoA reductase (HMGCR), and downregulation of genes 
involved in lipid efflux from the cell (Baenke et al., 2013) (Figure 4.32 & 4.33). The 
combination of these two effects suggests possible ongoing intracellular lipid metabolism 
in response to culture in HCM.  
To verify the accuracy of these transcriptomic observations, preliminary 
investigation of the HCM effects on LNCaP lipid metabolism at a cellular and organelle 
(mitochondria, LD) level were conducted, and revealed no accumulation or growth of 
neutral LD (Figure 4.35), suggesting lipids were being taken up by cells but were not being 
stored or being used for energy. In the HCM treatment, the LNCaP LDs and mitochondria 
localized away from the nucleus, which is generally a sign of energy stress, however, as the 
LDs and the mitochondria were not in contact, it was unlikely PCa cells were in an energy 
depleted state (Gao & Goodman, 2015; Herms et al., 2015) (Figure 4.36f). Furthermore, 
pathway analysis indicated the “AMPK Signalling” pathway was predicted to be inactivated 
in LNCaP cells grown in HCM (Table 4.28), suggesting the environment was not nutrient 
deplete (Brownsey, Boone, Elliott, Kulpa, & Lee 2006; Herms et al., 2015). An energy 
depleted state was unlikely as HCM is supplemented with GlutaMax (Gao et al., 2014).  
GlutaMax contains a stabilized form of glutamine that can act as a substitute for glucose 
metabolism thereby reducing the need to shunt energy production to fatty acid oxidation 
from glycolysis (Corbet et al., 2015; Herm et al., 2015; Thermo Fisher Scientific 2015).  
5.3.2  HCM specific lipid response in VCaP cells 
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 “AMPK Signalling” and “Protein Kinase A Signalling” pathways are involved in the 
phosphorylation of Acetyl-CoA carboxylase (ACC), ultimately resulting in the inhibition of 
fatty acid biosynthesis and increased FA beta-oxidation (Brownsey et al., 2006; Tong, 2005). 
The inactivation of these pathways in VCaP cells by HCM suggests a reduction in FA 
breakdown and potentially increased FA synthesis (Figure 4.19). Further supporting this 
theory, ketogenesis is associated with FA breakdown (Foster & McGarry 1982) and the 
“Ketogenesis” pathway was identified from enriched gene expression in HCM treated VCaP 
cells (Appendix Table 18).  The direction of activation could not be determined, however, 
after analysis the genes associated with FA breakdown were downregulated and those 
associated with cholesterol synthesis were upregulated further suggesting lipid 
accumulation (Table 4.13) although this remains to be confirmed. These findings suggest 
HCM growth conditions in VCaP cells were similar to those observed in LNCaP cells. 
5.3.3  HCM specific Phospholipid Synthesis 
Previous research has shown that HCM’s efficacy in promoting self-organisation in 
cells may be a significant mechanism behind the primary PCa cell culturing capabilities of 
the novel media (Gao et al., 2014), however it is unclear how this may occur. Results from 
the current study suggest a possible mechanism behind HCM’s facilitation of cell 
organisation.  In-house phenotypic analysis of cells cultured in HCM showed a propensity to 
form clusters, when compared to the control conditions, possibly indicating a move to self-
organisation. The results of this study indicating the lack of contact between LDs and 
mitochondria, coupled with transcriptomic data suggests the LNCaP cells cultured in HCM 
were not energy starved while simultaneously not storing neutral lipids. As our results 
showed that at least transcriptomically, lipid synthesis was ongoing and experimentally 
neutral lipids synthesis was not detected, this may be potentially indicative of phospholipid 
synthesis and thus ultimately cell membrane growth (Baenke et al., 2013). This membrane 
growth is supported phenotypically, with cells cultured in HCM displaying seemingly more 
depth and complexity than the controls. Gene expression data suggested the ‘Kennedy 
Pathway’ of phospholipid synthesis (Figure 4.34), appeared to be activated in HCM, 
suggesting the synthesis of phosphatidylcholine, a major constituent of the cell membrane, 
was possibly amplified (Pol et al., 2014). In addition, analysis of genes involved in the Land 
Cycle identified phosphatidylcholine conversion of phosphatidylcholine to Phosphatidic 
Acid (PA) was downregulated suggesting further phosphatidylcholine accumulation (Pol et 
al., 2014). Furthermore, Acyl-CoA was predicted to be available through the HCM additive 
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GlutaMax suggesting ample FA for phosphatidylcholine synthesis to occur (Gao et al., 2014; 
Pol et al., 2014; Thermo Fischer Scientific, 2015).  
Subsequently, together these results indicate that the synthesis of phospholipids 
may be facilitated by HCM. With these phospholipids, particularly PC, being a major 
element in the creation of cell membranes, and as these results were specific to HCM, it 
could be inferred that HCM could facilitate the formation of more cellular membrane. 
Therefore, this thesis proposes that HCM, or more specifically certain additives therein, 
may increase phospholipid synthesis, and thus may be a driving factor behind in the 
reported increase in self-organisation as organoids and thus present a possible explanation 
for one of the media’s most innovative properties. 
5.4 Limitations  
Although the physiochemical environment was kept as constant as possible, 
inevitably there are the typical cell culturing limitations of biological reproducibility. Those 
range from serum batch-to-batch variability to subtle variations in seeding cell density and 
cell viability (Rolleston, 1999). ‘This variability may have affected the number of identified 
differentially expressed LNCaP genes to treatment, which was found to be less than what 
was observed in the VCaP dataset. It is also possible that VCaP cells have a more active 
treatment response or there is greater diversity in the transcriptome, as compared to 
LNCaP cells. However, there was robust differential expression of LNCaP genes across 
treatment groups, and the expression was consistent with previous in-house findings by 
the APCRC-Q. 
A further limitation of this project the use of two biological replicates to generate 
the RNA sequencing data that was used to analyse the pathways expressed with HCM 
treatment. To minimise variability, the biological replicates were generated from three 
technical replicates. Each technical replicate underwent quality control testing and the 
expression response to well-characterised genes was measured to ensure there was a 
treatment response. 
 Due to the preliminary nature of this field, a further limitation is the analytical tools 
available at the current time. Primarily, all transcriptomic analytical tools are limited by the 
current knowledge base. Additionally, due to the complexity of this project no one tool was 
able to complete the required analysis. Specifically, while IPA is generally capable of 
meeting the depth of analysis needed, unfortunately it is unable to handle the breadth of 
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data generated. Due to the complexity of biological systems, IPA occasionally lacks specify 
with results. For instance, pathways analyses identified the “Sperm Motility” pathway 
(Figure 4.4) in the androgen enriched RPMI LNCaP dataset. Individual datasets were able to 
be analysed, however, individual datasets could not be compared against the background 
dataset (Ingenuity Systems, 2016). GOrilla allows analysis using the background dataset, 
but identifies enriched functional processes and does not identify specific pathways and 
does not assign directionality or measure of activity to these processes (Eden, et al. 2009). 
To bridge the gap between these analytical tool required detailed manual gene 
identification analysis with reference to current literature to be undertaken. In some cases, 
cellular level analysis was used to verify transcriptomic response (see section 3.10).  
 The neutral lipid assay used in the analysis of lipid droplet parameters, while much 
more detailed than phospholipid assays in determining lipid parameters, cannot detect 
phospholipids. Therefore, phospholipid assay is required to support the transcriptomic 
phospholipid analysis.  Only the LNCaP cell line was used in the lipid droplet assays, but as 
these cells are a well-established cell line the experimenters were able to verify the 
controls behaved as predicted. 
5.5 Implications and Recommendations  
 The results of this study have provided greater clarity in the mechanism of HCM in 
the growth of PCa cells. These findings have important implications on the field of PCa 
research. Primarily, by providing the research community with insight into the complex 
effects that HCM, and similar novel defined medias, have on PCa cells and therefore 
possible interactions with current and future treatments. Further, these findings will aid 
research into this new culturing system, by providing more specifics about its mechanisms. 
Therefore, allowing for increased exploitation of the media system, as well as the capacity 
for more patient tailored systems and treatments.  It was also demonstrated that 
transcriptomic analysis can interrogate thousands of genes and identify pathways and 
process, which could allow researchers to select targets of interest and investigate the 
ultimate product with protein analysis. 
With these newly identified complexities in mind, it is recommended that further 
research is conducted utilising primary PCa cells and PCa CTCs as well as established cell 
lines in HCM. Specifically, in order to identify, through transcriptomic analysis, the 
pathways behind CRCP and additional pathways susceptible to therapeutic treatments.  
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Future investigations into AR knockout/knockdown/inhibitors could provide 
additional evidence to distinguish if the genes regulated by androgen stimulation and 
shared between HCM and androgen enriched RPMI are the result of direct androgen 
stimulation or via indirect/non-classical AR stimulation. Additionally, analysis suing AR ChIP 
sequencing data could be investigated, which potentially could further distinguish between 
different subsets of androgen stimulated genes, specifically the difference between genes 
directly regulated by AR and those genes only regulated within the androgen pathway. 
5.6 Conclusion  
As intended, this study has revealed much of the media specific transcriptomic 
responses to the HCM culture system. This was achieved through the use of pathway 
exploration on RNA sequencing data from LNCaP and VCaP cells cultured with HCM, 
identifying the differentially expressed genes and pathways. An androgenic response was 
induced with DHT on these cell lines, in order to explore the effect of HCM on androgen 
regulated pathways. These transcriptomic responses were compared across both cell lines 
as well as the standard RPMI media, used as a control. 
 Several novel finders were identified in this study. It was found that HCM by itself 
activates the AR, of both cell lines, through a number of different mechanisms. It is 
suggested that both AR mediated and ligand independent mechanisms may be responsible 
for this activation. A possible neuroendocrine-like response was additionally detected 
through the amplification of associated genes. From these findings it is suggested that HCM 
may facilitate certain processes involved in PCa cell survival and growth in androgen 
depleted environments. Furthermore, HCM has been found to have a significant impact on 
the lipid metabolism transcriptomically and at a cellular level, which potentially suggests a 
basis for the media’s efficacy in cell self-organisation. In addition to these findings, this 
study adds support to the efficacy of HCM in the propagation of PCa cell lines and the value 
of transcriptomic pathway analysis. The primary findings of this study will aid in future 
research through the greater ability to discern effects of the HCM culture system from 
experimentally induced responses, furthering the field of precision medicine and PCa 
research. Further research on the transcriptomic pathways of primary PCa cells and PCa 
CTCs cultured in HCM is recommended in order to further the evolution of this new field of 
research.  
  
 94 
Reference List  
Adeniji, A., Chen, M., & Penning, T. (2013). AKR1C3 as a target in castrate resistant prostate 
cancer. The Journal of Steroid Biochemistry and Molecular Biology, 137, 136-149. 
http://dx.doi.org/10.1016/j.jsbmb.2013.05.012 
Antonarakis, E., Lu, C., Wang, H., Luber, B., Nakazawa, M., & Roeser, J. et al. (2014). AR-V7 
and resistance to enzalutamide and abiraterone in prostate cancer. New England 
Journal of Medicine, 371(11), 1028-1038. http://dx.doi.org/10.1056/nejmoa1315815 
Armandari, I., Hamid, A., Verhaegh, G., & Schalken, J. (2014). Intratumoral steroidogenesis 
in castration-resistant prostate cancer: A target for therapy. Prostate International, 
2(3), 105-113. http://dx.doi.org/10.12954/pi.14063 
Attard, G., Parker, C., Eeles, R., Schröder, F., Tomlins, S., Tannock, I., … Bono, J. S. (2016). 
Prostate cancer. The Lancet, 387(10013), 70-82. http://dx.doi.org/10.1016/s0140-
6736(14)61947-4 
Awwad, H., Geisel, J., & Obeid, R. (2012). The role of choline in prostate cancer. Clinical 
Biochemistry, 45(18), 1548-1553. 
http://dx.doi.org/10.1016/j.clinbiochem.2012.08.012 
Baenke F., Peck, B., Meiss, H., & Schulze, A. (2013). Hooked on fat: The role of lipid 
synthesis in cancer metabolism and tumour development. Disease Models & 
Mechanisms. 6(6):1353-63. http://dx.doi.org/10.1242/dmm.011338 
Bambury, R., & Scher, H. (2015). Enzalutamide: Development from bench to bedside. 
Urologic Oncology: Seminars and Original Investigations, 33(6), 280-288. 
http://dx.doi.org/10.1016/j.urolonc.2014.12.017 
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A., Kim, S., … Garraway, 
L. A. (2012). The Cancer Cell Line Encyclopedia enables predictive modelling of 
anticancer drug sensitivity. Nature, 483(7391), 603-307. 
http://dx.doi.org/10.1038/nature11003 
 95 
Beltran, H., Mosquera, J. M., & Rubin, M. A. (2013). Neuroendocrine prostate cancer. In A. 
Tewari (Ed.), Prostate cancer: A comprehensive perspective (pp. 277-282). New York, 
NY: Springer. doi:10.1007/978-1-4471-2864-9 
Brimo, F., Montironi, R., Egevad, L., Erbersdobler, A., Lin, D., Nelson, J., … Epstein, J. I. 
(2013). Contemporary grading for prostate cancer: implications for patient care. 
European Urology, 63(5), 892-901. http://dx.doi.org/10.1016/j.eururo.2012.10.015 
Brownsey, R., Boone, A., Elliott, J., Kulpa, J., & Lee W. (2006). Regulation of acetyl-CoA 
carboxylase. Biochemical Society Transactions, 34(2), 223-228. 
http://doi.org/10.1042/BST20060223 
Brunner, D., Frank, J., Appl, H., Schöffl, H., Pfaller, W., & Gstraunthaler, G. (2010). Serum 
free cell culture: The serum free interactive online database. ALTEX, 27(1), 53-62. 
Received from http://www.altex.ch/ 
Bryce, A. & Antonarakis, E. (2016). Androgen receptor splice variant 7 in castration-
resistant prostate cancer: Clinical considerations. International Journal of Urology, 
23(8), 646-653. http://dx.doi.org/10.1111/iju.13134  
Butler, L., Centenera, M., & Swinnen, J. (2016). Androgen control of lipid metabolism in 
prostate cancer: Novel insights and future applications. Endocrine-Related Cancer, 
23(5), R219-R227. http://dx.doi.org/10.1530/erc-15-0556 
Cai, C., Chen, S., Ng, P., Bubley, G., Nelson, P., Mostaghel, E., … Balk, S. P. (2011a). 
Intratumoral de novo steroid synthesis activates androgen receptor in castration-
resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. 
Cancer Research, 71(20), 6503-6513. http://dx.doi.org/10.1158/0008-5472.can-11-
0532 
Cai, C., He, H., Chen, S., Coleman, I., Wang, H., Fang, Z., … Balk, S. P (2011b). Androgen 
receptor gene expression in prostate cancer is directly suppressed by the androgen 
receptor through recruitment of lysine-specific demethylase 1. Cancer Cell, 20(4), 457-
471. http://dx.doi.org/10.1016/j.ccr.2011.09.001 
 96 
Cancer Council Australia. (2016). Understanding Prostate Cancer. Retrieved from 
http://www.cancer.org.au/ 
Cancer Council Australia, & Prostate Cancer Foundation of Australia. (2015). Clinical 
Practice Guidelines PSA Testing and Early Management of Test-Detected Prostate 
Cancer. Sydney: Cancer Council Australia. Retrieved from http://wiki.cancer.org.au/ 
Chandrasekar, T., Yang, J., Gao, A., & Evans, C. (2015). Mechanisms of resistance in 
castration-resistant prostate cancer (CRPC). Translational Andrology and Urology, 
4(3), 365-380. http://dx.doi.org/10.3978/j.issn.2223-4683.2015.05.02 
Chen, Y. & Li, P. (2016). Fatty acid metabolism and cancer development. Science Bulletin, 1-
7. http://dx.doi.org/10.1007/s11434-016-1129-4 
Chu, Y. & Corey, D. (2012). RNA sequencing: Platform selection, experimental design, and 
data interpretation. Nucleic Acid Therapeutics, 22(4), 271-274. 
http://dx.doi.org/10.1089/nat.2012.0367 
Cookson, M., Lowrance, W., Murad, M., & Kibel, A. (2015). Castration-resistant prostate 
cancer: AUA guideline amendment. The Journal of Urology, 193(2), 491-499. 
http://dx.doi.org/10.1016/j.juro.2014.10.104 
Corbet, C., & Feron, O. (2015) Metabolic and mind shifts: from glucose to glutamine and 
acetate addictions in cancer. Current Opinion in Clinical Nutrition & Metabolic Care, 
18(4), 346-353. http://dx.doi.org/ 10.1097/MCO.0000000000000178. 
Crona, D., Milowsky, M., & Whang, Y. (2015). Androgen receptor targeting drugs in 
castration-resistant prostate cancer and mechanisms of resistance. Clinical 
Pharmacology & Therapeutics, 98(6), 582-589. http://dx.doi.org/10.1002/cpt.256 
Culig, Z. (2013). CXCL8, an underestimated “bad guy” in prostate cancer. European Urology, 
64(2), 189-190. http://dx.doi.org/10.1016/j.eururo.2012.09.024 
 
 97 
Cunha, G. R., Alarid, E., Turner, T., Donjacour, A. A., Boutin, E. L., &  Foster, B. A. (1992). 
Normal and abnormal development of the male urogenital tract: Role of androgens, 
mesenchymal-epithelial interactions and growth factors. Journal of Andrology, 13(6), 
465-475. http://doi.org/10.1002/j.1939-4640.1992.tb00338.x 
Cunningham, D., & You, Z. (2015). In vitro and in vivo model systems used in prostate 
cancer research. Biological Methods, 2(1), 17. 
http://dx.doi.org/10.14440/jbm.2015.63 
Drost, J., Karthaus, W., Gao, D., Driehuis, E., Sawyers, C., Chen, Y., & Clevers, H. (2016). 
Organoid culture systems for prostate epithelial and prostate cancer tissue. Nature 
Protocols, 11(2), 347-358. http://dx.doi.org/10.1038/nprot.2016.006 
Eden, E., Navon, R., Steinfeld, I., Lipson, D., & Yakhini, Z. (2009). GOrilla: A tool for discovery 
and visualization of enriched GO terms in ranked gene lists. BMC Bioinformatics, 10(1), 
48. http://dx.doi.org/10.1186/1471-2105-10-48 
Edwards, P., Tabor, D., Kast, H., & Venkateswaran, A. (2000). Regulation of gene expression 
by SREBP and SCAP. Biochemica et Biophysica Acta, 1529(1-3), 103-113. 
http://doi:10.1016/S1388-1981(00)00140-2 
Eisermann, K., Wang, D., Jing, Y., Pascal, L. E., & Wang, Z. (2013). Androgen receptor gene 
mutation, rearrangement, polymorphism. Translational Andrology and Urology, 2(3), 
137–147. http://doi.org/10.3978/j.issn.2223-4683.2013.09.15 
Ellis, G., Desjardins, C., & Fraser, H. (1983). Control of pulsatile LH release in male rats. 
Neuroendocrinology, 37(3), 177-183. http://dx.doi.org/10.1159/000123540 
Fenner, A. (2015). Prostate cancer: ERG fusion and AKR1C3 form AR signalling feed-forward 
loop. Nature Reviews Urology, 12(5), 239-239. 
http://dx.doi.org/10.1038/nrurol.2015.61 
Ford, J. & McVicar, D. (2009). TREM and TREM-like receptors in inflammation and disease. 
Current Opinion in Immunology, 21(1), 38-46. 
http://dx.doi.org/10.1016/j.coi.2009.01.009 
 98 
Foster, D. W., &  McGarry, J. D. (1982). The regulation of ketogenesis. In R. Porter & G. 
Lawrenson(Eds.), Ciba foundation symposium 87 - metabolic acidosis (pp. 120-144). 
Chichester, UK: John Wiley & Sons, Ltd. doi: 10.1002/9780470720691.ch7 
Gao, D., Vela, I., Sboner, A., Iaquinta, P., Karthaus, W.,  Gopalan, A., … Chen, Y. (2014). 
Organoid cultures derived from patients with advanced prostate cancer. Cell, 159(1), 
176-187. http://dx.doi.org/10.1016/j.cell.2014.08.016 
Gao, Q. & Goodman, J. (2015). The lipid droplet—A well-connected organelle. Frontiers in 
Cell and Developmental Biology, 3, 49. http://dx.doi.org/10.3389/fcell.2015.00049 
Gong, Y., Chippada-Venkata, U., Galsky, M., Huang, J., & Oh, W. (2015). Elevated circulating 
tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with 
neuroendocrine differentiation in castration resistant prostate cancer. The Prostate, 
75(6), 616-627. http://dx.doi.org/10.1002/pros.22945 
Graham, L., & Schweizer, M. (2016). Targeting persistent androgen receptor signaling in 
castration-resistant prostate cancer. Medical Oncology, 33(5), 44. 
http://dx.doi.org/10.1007/s12032-016-0759-3 
Grigore, A., Ben-Jacob, E., & Farach-Carson, M. (2015). Prostate cancer and neuroendocrine 
differentiation: More neuronal, less endocrine?. Frontiers in Oncology, 5, 35. 
http://dx.doi.org/10.3389/fonc.2015.00037 
Hamid, A. R. A. H., Pfeiffer, M. J., Verhaegh, G. W., Schaafsma, E., Brandt, A., Sweep, F. C. G. 
J., … Schalken, J. A. (2012). Aldo-keto Reductase Family 1 Member C3 (AKR1C3) Is a 
Biomarker and Therapeutic Target for Castration-Resistant Prostate Cancer. Molecular 
Medicine, 18(1), 1449–1455. http://doi.org/10.2119/molmed.2012.00296 
Herms, A., Bosch, M., Reddy, B., Schieber, N., Fajardo, A., Rupérez, C., … Pol, A. (2015). 
AMPK activation promotes lipid droplet dispersion on detyrosinated microtubules to 
increase mitochondrial fatty acid oxidation. Nature Communications, 6 (7176). 
http://dx.doi.org/10.1038/ncomms8176 
Huggins, C., Stevens, R., & Hodges, C. (1941). Studies on prostatic cancer. Archives of 
Surgery, 43(2), 209-223. http://dx.doi.org/10.1001/archsurg.1941.01210140043004 
 99 
Ingenuity Systems. (2016a). Calculating and Interpreting the p-values for Functions, 
Pathways and Lists in IPA (p. 5). Retrieved from https://www.ingenuity.com/wp-
content/themes/ingenuity-qiagen/pdf/ipa/functions-pathways-pval-whitepaper.pdf 
Ingenuity Systems.(2016b) Target Explorer: LXR/RXR Activation. Retrieved from 
https://targetexplorer 
.ingenuity.com/pathway/ING/ING:1nili#!/api/rest/v1/client/searchPathwayNodes?pat
hwayId=ING:1nili&rows=0&facetLimit=5000&responseType=default 
Ippolito, J. (2006). Current concepts in neuroendocrine cancer metabolism. Pituitary, 9(3), 
193-202. http://doi.org/10.1007/s11102-006-0264-3 
Karagiannis, G., Saraon, P., Jarvi, K., & Diamandis, E. (2014). Proteomic signatures of 
angiogenesis in androgen-independent prostate cancer. The Prostate, 74(3), 260-272. 
http://dx.doi.org/10.1002/pros.22747 
Karantanos, T., Corn, P., & Thompson, T. (2013). Prostate cancer progression after 
androgen deprivation therapy: Mechanisms of castrate resistance and novel 
therapeutic approaches. Oncogene, 32(49), 5501-5511. 
http://dx.doi.org/10.1038/onc.2013.206 
Katafigiotis, I., Sfoungaristos, S., Duvdevani, M., Mitsos, P., Roumelioti, E., Stravodimos,… 
Constantinides, C. A. (2016). Primary adenocarcinoma of the seminal vesicles. A 
review of the literature. Archivio Italiano Di Urologia E Andrologia, 88(1), 47. 
http://dx.doi.org/10.4081/aiua.2016.1.47 
Katsogiannou, M., Ziouziou, H., Karaki, S., Andrieu, C., Henry de Villeneuve, M., & Rocchi, P. 
(2015). The hallmarks of castration-resistant prostate cancers. Cancer Treatment 
Reviews, 41(7), 588-597. http://dx.doi.org/10.1016/j.ctrv.2015.05.003 
Katzenwadel, A., & Wolf, P. (2015). Androgen deprivation of prostate cancer: Leading to a 
therapeutic dead end. Cancer Letters, 367(1), 12-17. 
http://dx.doi.org/10.1016/j.canlet.2015.06.021 
 100 
Kim, J., Cox, M., & Wasan, K. (2014). Effect of simvastatin on castration-resistant prostate 
cancer cells. Lipids in Health and Disease, 13(1), 56. http://dx.doi.org/10.1186/1476-
511x-13-56 
Kirby, M., Hirst, C., & Crawford, E. (2011). Characterising the castration-resistant prostate 
cancer population: A systematic review. International Journal of Clinical Practice, 
65(11), 1180-1192. http://dx.doi.org/10.1111/j.1742-1241.2011.02799.x 
Knudsen, K., & Penning, T. (2010). Partners in crime: Deregulation of AR activity and 
androgen synthesis in prostate cancer. Trends in Endocrinology & Metabolism, 21(5), 
315-324. http://dx.doi.org/10.1016/j.tem.2010.01.002 
Krause, C., Guzman, A., & Knaus, P. (2011). Noggin. The International Journal of 
Biochemistry & Cell Biology, 43(4), 478-481. 
http://dx.doi.org/10.1016/j.biocel.2011.01.007 
Kridel, S., Axelrod, F., Rozenkrantz, N., & Smith, J. (2004). Orlistat is a novel inhibitor of 
fatty acid synthase with antitumor activity. Cancer Research, 64(6), 2070-2075. 
http://dx.doi.org/10.1158/0008-5472.can-03-3645 
Kumagai, J., Hofland, J., Erkens-Schulze, S., Dits, N., Steenbergen, J., & Jenster, G. et al. 
(2013). Intratumoral conversion of adrenal androgen precursors drives androgen 
receptor-activated cell growth in prostate cancer more potently than de novo 
steroidogenesis. The Prostate, 73(15),1636-1650. 
http://dx.doi.org/10.1002/pros.22655 
Labrie, F., Cusan, L., Gomez, J., Martel, C., Bérubé, R., & Bélanger, P. et al. (2009). 
Comparable amounts of sex steroids are made outside the gonads in men and 
women: Strong lesson for hormone therapy of prostate and breast cancer. The Journal 
Of Steroid Biochemistry And Molecular Biology, 113(1-2), 52-56. 
http://dx.doi.org/10.1016/j.jsbmb.2008.11.004 
Lee, Y., Kim, J., & Song, G. (2014). Genome-wide pathway analysis in neuroblastoma. Tumor 
Biology, 35(4), 3471-3485. http://dx.doi.org/10.1007/s13277-013-1459-7 
 101 
Lee, Y. G., Korenchuk, S., Lehr, J., Whitney, S., Vessela, R., & Pienta, K. J. (2001). 
Establishment and characterization of a new human prostatic cancer cell line: DuCaP. 
In Vivo, 15(2), 157-62. Retrieved from http://iv.iiarjournals.org/ 
Li, Q., Zhang, C., & Zhang, Y. (2016). Molecular aspects of prostate cancer with 
neuroendocrine differentiation. Chinese Journal of Cancer Research, 28(1), 122-129. 
http://dx.doi.org/10.3978/j.issn.1000-9604.2016.01.02. 
Liao, R., Ma, S., Miao, L., Li, R., Yin, Y., & Raj, G. (2013). Androgen receptor-mediated non-
genomic regulation of prostate cancer cell proliferation. Translational Andrology and 
Urology, 2(3), 187-196. http://dx.doi.org/10.3978/j.issn.2223-4683.2013.09.07  
Lin, Y., & Wang, F. (2010). FGF signalling in prostate development, tissue homoeostasis and 
tumorigenesis. Bioscience Reports, 30(5), 285-291. 
http://dx.doi.org/10.1042/bsr20100020 
Longo, D. (2010). New therapies for castration-resistant prostate cancer. New England 
Journal of Medicine, 363(5), 479-481. http://dx.doi.org/10.1056/nejme1006300 
Lu, N., Wardell, S., Burnstein, K., Defranco, D., Fuller, P., Giguere, V., Cidlowski, J. A. (2006). 
International union of pharmacology. LXV. The pharmacology and classification of the 
nuclear receptor superfamily: Glucocorticoid, mineralocorticoid, progesterone, and 
androgen receptors. Pharmacological Reviews, 58(4), 782-797. 
http://dx.doi.org/10.1124/pr.58.4.9 
Luu-The, V. (2013). Assessment of steroidogenesis and steroidogenic enzyme functions. 
Journal of Steroid Biochemistry & Molecular Biology. (137), 176-183. 
http://dx.doi.org/10.1016/j.jsbmb.2013.05.017 
Makkonen, H., Kauhanen, M., Jääskeläinen, T., & Palvimo, J. (2011). Androgen receptor 
amplification is reflected in the transcriptional responses of vertebral-cancer of the 
prostate cells. Molecular and Cellular Endocrinology, 331(1), 57-65. 
http://dx.doi.org/10.1016/j.mce.2010.08.008 
 
 102 
Malinowska, K., Neuwirt, H., Cavarretta, I., Bektic, J., Steiner, H., Dietrich, H., … Culig, Z. 
(2009). Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo 
through activation of the androgen receptor. Endocrine Related Cancer, 16(1), 155-
169. http://dx.doi.org/10.1677/erc-08-0174 
Montgomery, R., Mostaghel, E., Vessella, R., Hess, D., Kalhorn, T., Higano, C., … Nelson, P. S. 
(2008). Maintenance of intratumoral androgens in metastatic prostate cancer: A 
mechanism for castration-resistant tumor growth. Cancer Research, 68(11), 4447-
4454. http://dx.doi.org/10.1158/0008-5472.can-08-0249 
National Cancer Institute. (2016). Prostate Cancer Treatment. Retrieved 28 July 2016, from 
http://www.cancer.gov/types/prostate/patient/prostate-treatment-pdq 
Nelson, W., De Marzo, A., & Isaacs, W. (2003). Prostate cancer. New England Journal of 
Medicine, 349(4), 366-381. http://dx.doi.org/10.1056/nejmra021562 
O’Donnell, A., Odrowaz, Z., & Sharrock, A. (2011). Immediate-early gene activation by the 
MAPK pathways: what do and don't we know?. Biochemical Society Transactions, 
40(1), 58-66. http://dx. Doi.org/10.1042/BST20110636 
Oliveros, J.C. (2007-2015). Venny. An interactive tool for comparing lists with Venn's 
diagrams. http://bioinfogp.cnb.csic.es/tools/venny/index.html 
Parimi, V., Goyal, R., Poropatich, K., & Yang, X. (2014). Neuroendocrine differentiation of 
prostate cancer: A review. American Journal of Clinical and Experimental Urology, 
2(4), 273-285. Retrieved from 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4297323/ 
Pedersen, T., & Tobert, J. (2004). Simvastatin: A review. Expert Opinion On 
Pharmacotherapy, 5(12), 2583-2596. http://dx.doi.org/10.1517/14656566.5.12.2583 
Penning, T. (2014). Androgen biosynthesis in castration-resistant prostate cancer. 
Endocrine Related Cancer, 21(4), T67-T78. http://dx.doi.org/10.1530/erc-14-0109 
 103 
Pol, A., Gross, S., & Parton, R. (2014). Biogenesis of the multifunctional lipid droplet: Lipids, 
proteins, and sites.  Cell Biology, 204(5), 635-646. 
http://dx.doi.org/10.1083/jcb.201311051 
Pospihalj, B. (2015). Staging of prostate cancer: A review with reference for further 
refinement. Analytical and Quantitative Cytology and Histology, 37(1), 69-74. 
Retrieved from http://www.aqch.com/ 
Priemer, D., Montironi, R., Wang, L., Williamson, S., Lopez-Beltran, A., & Cheng, L. (2016). 
Neuroendocrine tumors of the prostate: Emerging insights from molecular data and 
updates to the 2016 World Health Organization classification. Endocrine Pathology. 
27(2), 123–135. http://doi.org/10.1007/s12022-016-9421-z 
Ramadan, W., Kabbara, W., & Al Basiouni Al Masri, H. (2015). Enzalutamide for patients 
with metastatic castration-resistant prostate cancer. OncoTargets and Therapy, 8, 
871-876. http://dx.doi.org/10.2147/ott.s80488 
Robinson, D., Van Allen, E., Wu, Y., Schultz, N., Lonigro, R., Mosquera, J., … Chinnaiyan A. 
M. (2015). Integrative clinical genomics of advanced prostate cancer. Cell, 161(5), 
1215–1228. http://dx.doi.org/10.1016/j.cell.2015.05.001 
Rolleston, W. (1999). Bovine serum: reducing the variables through the use of donor herds. 
Developments in Biological Standardization, 99, 79-86. Retrieved from 
https://www.researchgate.net/publication/12894280_Bovine_serum_Reducing_the_
variables_through_the_use_of_donor_herds 
Salles, A., Romano, A., & Freudenthal, R. (2014). Synaptic NF-kappa B pathway in neuronal 
plasticity and memory. Journal of Physiology – Paris. 108(4-6), 256-262. 
http://dx.doi.org/10.1016/j.jphysparis.2014.05.002 
Salomonis, N., Pico, A., Hanspers, K., Kelder, A., Bohler, Conklin, B.,… Sklar S. (2016). Statin 
Pathway (Homo sapiens). http://www.wikipathways.org/index.php/Pathway:WP430 
Saltiel, A. (2016). Insulin Signaling in the Control of Glucose and Lipid Homeostasis. 
Handbook Expert Pharmacology. 233, 51-71. http://dx.doi.org/10.1007/164_2015_14. 
 104 
Santoni, M., Conti, A., Burattini, L., Berardi, R., Scarpelli, M., Cheng, L., … Montironi, R. 
(2014). Neuroendocrine differentiation in prostate cancer: Novel morphological 
insights and future therapeutic perspectives. Biochimica Et Biophysica Acta, 1846(2), 
630-637. http://dx.doi.org/10.1016/j.bbcan.2014.10.008 
Sato, T., Vries, R. G., Snippert, H. J., van de Wetering, M., Barker, N., Stange, D. E., & ... 
Clevers, H. (2009). Single Lgr5 stem cells build crypt-villus structures in vitro without a 
mesenchymal niche. Nature, 459, 262-265. 
Schalken, J., & Fitzpatrick, J. (2016). Enzalutamide: targeting the androgen signalling 
pathway in metastatic castration-resistant prostate cancer. BJU International, 117(2), 
215-225. http://dx.doi.org/10.1111/bju.13123 
Scher, H., Solo, K., Valant, J., Todd, M., & Mehra, M. (2015). Prevalence of prostate cancer 
clinical states and mortality in the United States: Estimates using a dynamic 
progression model. PLOS ONE, 10(10), e0139440. 
http://dx.doi.org/10.1371/journal.pone.0139440 
Sharifi, N., Gulley, J., & Dahut, W. (2005). Androgen deprivation therapy for prostate 
cancer. Journal of the American Medical Association, 294(2), 238-244. 
http://dx.doi.org/10.1001/jama.294.2.238 
Surcel, C., van Oort, I., Sooriakumaran, P., Briganti, A., De Visschere, P., Fütterer, J., … 
Ploussard, G. (2015). Prognostic effect of neuroendocrine differentiation in prostate 
cancer: A critical review. Urologic Oncology: Seminars and Original Investigations, 
33(6), 265.e1-265.e7. http://dx.doi.org/10.1016/j.urolonc.2014.08.007 
Tan, M., Li, J., Xu, H., Melcher, K., & Yong, E. (2015). Androgen receptor: Structure, role in 
prostate cancer and drug discovery. Acta Pharmacologica Sinica, 36(1), 3-23. 
http://dx.doi.org/10.1038/aps.2014.18 
Terry, S. & Beltran, H. (2014). The many faces of neuroendocrine differentiation in prostate 
cancer progression. Frontiers in Oncology., 4, 60. 
http://dx.doi.org/10.3389/fonc.2014.00060 
 105 
Terry, S., Maillé, P., Baaddi, H., Kheuang, L., Soyeux, P., Nicolaiew, N., ... & De La Taille, A. 
(2013). Cross modulation between the androgen receptor axis and protocadherin-PC 
in mediating neuroendocrine transdifferentiation and therapeutic resistance of 
prostate cancer. Neoplasia, 15(7), 761-IN22 
Thermo Fisher Scientific. (2015). GlutaMAX media. Retrieved from 
http://tools.thermofisher.com/content/sfs/brochures/glutamax-product-
brochure.pdf 
Thermo Fisher Scientific. (2016). B-27 Serum-Free Supplement (50X) liquid. Retrieved 19 
June 2016, from https://www.thermofisher.com/us/en/home/technical-
resources/media-formulation.250.html 
Thiam, A., Farese Jr, R., & Walther, T. (2013). The biophysics and cell biology of lipid 
droplets. Nature Reviews Molecular Cell Biology, 14(12), 775-786. 
http://dx.doi.org/10.1038/nrm3699 
Tian, X., He, Y., & Zhou, J. (2015). Progress in antiandrogen design targeting hormone 
binding pocket to circumvent mutation based resistance. Frontiers in Pharmacology, 
6, 57. http://dx.doi.org/10.3389/fphar.2015.00057 
Tong, L. (2005). Acetyl-coenzyme A carboxylase: crucial metabolic enzyme and attractive 
target for drug discovery. Cellular and Molecular Life Sciences., 62(16), 1784-1803. 
http://dx.doi.org/10.1007/s00018-005-5121-4 
Tuch, B., Laborde, R., Xu, X., Gu, J., Chung, C., Monighetti, C., … Smith, D. I. (2010). Tumor 
transcriptome sequencing reveals allelic expression imbalances associated with copy 
number alterations. Plos ONE, 5(2), e9317. 
http://dx.doi.org/10.1371/journal.pone.0009317 
Turró, S., Ingelmo-Torres, M., Estanyol, J., Tebar, F., Fernández, M., Albor, C., … Pol, A. 
(2006). Identification and characterization of associated with lipid droplet protein 1: A 
novel membrane-associated protein that resides on hepatic lipid droplets. Traffic, 
7(9), 1254-1269. http://dx.doi.org/10.1111/j.1600-0854.2006.00465.x 
 106 
van der Valk, J., Brunner, D., De Smet, K., Fex Svenningsen, Å., Honegger, P., & Knudsen, L. 
et al. (2010). Optimization of chemically defined cell culture media – Replacing fetal 
bovine serum in mammalian in vitro methods. Toxicology In Vitro, 24(4), 1053-1063. 
http://dx.doi.org/10.1016/j.tiv.2010.03.016  
Veldscholte, J., Berrevoets, C., Ris-Stalpers, C., Kuiper, G., Jenster, G., Trapman, J., … 
Mulder, E. (1992). The androgen receptor in LNCaP cells contains a mutation in the 
ligand binding domain which affects steroid binding characteristics and response to 
antiandrogens. The Journal of Steroid Biochemistry and Molecular Biology, 41(3-8), 
665-669. http://dx.doi.org/10.1016/0960-0760(92)90401-4 
Volante, M., Tota, D., Giorcelli, J., Bollito, E., Napoli, F., Vatrano, S., … Rapa, I. (2016). 
Androgen deprivation modulates gene expression profile along prostate cancer 
progression. Human Pathology, (56), 81-88. 
http://dx.doi.org/10.1016/j.humpath.2016.06.004 
Wafa, L. A., Palmer, J., Fazli, L., Hurtado-Coll, A., Bell, R. H., Nelson, C. C., ... & Rennie, P. S. 
(2007). Comprehensive expression analysis of L-dopa decarboxylase and established 
neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleason 
grade prostate tumors. Human pathology, 38(1), 161-170 
Waller, A., Sharrard, R., Berthon, P., & Maitland, N. (2000). Androgen receptor localisation 
and turnover in human prostate epithelium treated with the antiandrogen, casodex. 
Journal of Molecular Endocrinology, 24(3), 339-351. 
http://dx.doi.org/10.1677/jme.0.0240339 
Walther, T., & Farese, R. (2012). Lipid Droplets and Cellular Lipid Metabolism. The Annual 
Review of Biochemistry, 81(1), 687-714. http://dx.doi.org/10.1146/annurev-biochem-
061009-102430 
Wians, F. H., Jr. (2016). Blood test: Normal values. In Merck manual online (professional). 
Retrieved from http://www.merckmanuals.com/professional/ 
Wilfling, F., Haas, J., Walther, T., & Jr, R. (2014). Lipid droplet biogenesis. Current Opinion in 
Cell Biology, 29, 39-45. http://dx.doi.org/10.1016/j.ceb.2014.03.008 
 107 
Wilson, J. (1996). Role of dihydrotestosterone in androgen action. The Prostate, 29(S6), 88-
92. http://dx.doi.org/10.1002/(sici)1097-0045(1996)6+<88::aid-pros17>3.0.co;2-n 
Wu, X., Daniels, G., Lee, P., & Monaco, M. (2014). Lipid metabolism in prostate cancer. 
American Journal of Clinical and Experimental Urology, 2(2), 111–120. Retrieved from 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4219300/ 
Wuttke, A. (2015). Lipid signalling dynamics at the β-cell plasma membrane. Basic and 
Clinical Pharmocology and Technology, 116(4), 281-290. 
http://dx.doi.org/10.1111/bcpt.12369 
Zehmer, J., Bartz, R., Liu, P., & Anderson, R. (2008). Identification of a novel N-terminal 
hydrophobic sequence that targets proteins to lipid droplets. Journal of Cell Science, 
121(11), 1852-1860. http://dx.doi.org/10.1242/jcs.012013 
Zhu, M., & Kyprianou, N. (2008). Androgen receptor and growth factor signaling cross-talk 
in prostate cancer cells. Endocrine Related Cancer, 15(4), 841-849. 
http://dx.doi.org/10.1677/erc-08-0084 
Zhu, Y., Liu, C., Cui, Y., Nadiminty, N., Lou, W., & Gao, A. (2014). Interleukin-6 induces 
neuroendocrine differentiation (NED) through suppression of RE-1 silencing 
transcription factor (REST). The Prostate, 74(11), 1086-1094. 
http://dx.doi.org/10.1002/pros.22819 
  
 108 
Appendix  
 
 
 
Appendix Figure 1. Lipid Metabolism Pathways and LD formation (Pol et al., 2014).  
Note: LD biogenesis requires coordination of fatty acid activation by Acyl-CoA synthetises (green box), de novo synthesis of 
neutral lipids (orange box), the Lands cycle of phospholipid remodelling (purple box), the Kennedy pathway of phospholipid 
synthesis (blue box), and the function of accessory proteins (grey box). The enzymes involved in these pathways are indicated 
with red (mammal) and yellow letters (yeast), the Acyl-CoA with purple letters, the lipid intermediates with black letters, and 
other required molecules with blue letters (Pol et al., 2014). 
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Appendix Figure 2. Gene O
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ap Highlighting specific biological processes for Lipid-like processes LN
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Appendix Figure 3. Gene O
ntology M
ap Highlighting specific biological processes for Neuroendocrine-like processes LN
CaP Cells Cultured in HCM
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Appendix Figure 5. Gene Ontology Map Highlighting specific biological processes for Structural Developments for LNCaP 
Cells Cultured in HCM  
Appendix Figure 4. Gene Ontology Map Highlighting specific biological processes for Amino Acid Transport for LNCaP Cells Cultured in 
HCM  
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Appendix Figure 6. Gene Ontology Map Highlighting specific biological processes for MAPK related processes LNCaP 
Cells Cultured in HCM  
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Appendix Table 1. The comprehensive list of gene ontology processes for LNCaP cells cultured in HCM (HCM vs 
RPMI) with a statically signification P-value. Ranked by lowest P-value 
Description P-value 
single-organism process 1.64E-20 
single-organism cellular process 2.52E-19 
lipid biosynthetic process 4.14E-12 
lipid metabolic process 1.02E-11 
cholesterol biosynthetic process 1.36E-11 
secondary alcohol biosynthetic process 1.36E-11 
sterol biosynthetic process 1.71E-11 
cellular process 3.66E-10 
cellular lipid metabolic process 1.18E-09 
developmental process 1.33E-09 
alcohol metabolic process 1.48E-09 
steroid biosynthetic process 5.7E-09 
alcohol biosynthetic process 1E-08 
single-organism developmental process 1.68E-08 
response to chemical 2.16E-08 
anatomical structure development 2.53E-08 
single-organism metabolic process 2.64E-08 
response to organic substance 6.88E-08 
cholesterol metabolic process 1.07E-07 
secondary alcohol metabolic process 1.87E-07 
organic hydroxy compound metabolic process 1.95E-07 
small molecule biosynthetic process 2.2E-07 
organic hydroxy compound biosynthetic process 2.69E-07 
single-organism biosynthetic process 2.69E-07 
sterol metabolic process 3.36E-07 
steroid metabolic process 3.85E-07 
response to endogenous stimulus 6.05E-07 
positive regulation of biological process 9.91E-07 
regulation of multicellular organismal process 1.19E-06 
synapse assembly 1.31E-06 
positive regulation of cellular process 1.78E-06 
system development 2.14E-06 
regulation of developmental process 2.3E-06 
animal organ development 2.78E-06 
cell adhesion 2.99E-06 
biological adhesion 3.76E-06 
cellular response to chemical stimulus 4.36E-06 
cellular response to organic substance 4.51E-06 
cell-cell adhesion 4.87E-06 
regulation of multicellular organismal development 5.69E-06 
anterograde trans-synaptic signalling 6.23E-06 
chemical synaptic transmission 6.23E-06 
synaptic signalling 6.23E-06 
trans-synaptic signalling 6.23E-06 
negative regulation of cellular process 7.3E-06 
response to organonitrogen compound 1.09E-05 
small molecule metabolic process 1.15E-05 
cellular response to endogenous stimulus 1.16E-05 
cell communication 0.000012 
cognition 1.22E-05 
organic acid transport 1.25E-05 
response to nitrogen compound 1.29E-05 
negative regulation of biological process 1.38E-05 
regulation of anatomical structure morphogenesis 1.45E-05 
response to hormone 1.72E-05 
pattern specification process 0.000023 
cholesterol biosynthetic process via desmosterol 2.43E-05 
cholesterol biosynthetic process via lathosterol 2.43E-05 
regulation of signalling 2.72E-05 
cellular response to stimulus 2.91E-05 
regulation of cell communication 3.29E-05 
learning 3.48E-05 
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multicellular organismal process 3.66E-05 
fatty acid metabolic process 3.81E-05 
single-multicellular organism process 4.07E-05 
synapse organization 0.000043 
single organism signalling 4.69E-05 
organic acid metabolic process 5.15E-05 
regulation of cell differentiation 5.24E-05 
signalling 5.45E-05 
amino acid transport 6.27E-05 
homophilic cell adhesion via plasma membrane adhesion molecules 6.41E-05 
response to organic cyclic compound 6.95E-05 
carboxylic acid metabolic process 0.000071 
regulation of cell proliferation 7.79E-05 
oxoacid metabolic process 8.15E-05 
regulation of cell projection organization 8.15E-05 
response to stress 0.000091 
cellular response to nitrogen compound 0.000102 
response to oxygen-containing compound 0.000106 
positive regulation of cell differentiation 0.000115 
learning or memory 0.000116 
regulation of neuron projection development 0.000116 
regulation of signal transduction 0.000132 
organ morphogenesis 0.000134 
regulation of phosphorylation 0.000134 
phospholipid metabolic process 0.000135 
associative learning 0.000141 
anatomical structure morphogenesis 0.000143 
response to drug 0.000145 
L-amino acid transport 0.000151 
movement of cell or subcellular component 0.000158 
monocarboxylic acid metabolic process 0.00016 
regulation of cell migration 0.000172 
negative regulation of multicellular organismal process 0.000173 
cellular response to oxygen-containing compound 0.00018 
cell-cell signalling 0.000182 
carboxylic acid transmembrane transport 0.000185 
cellular response to peptide 0.00019 
amino acid transmembrane transport 0.000205 
cell-cell adhesion via plasma-membrane adhesion molecules 0.000206 
response to peptide 0.000209 
positive regulation of developmental process 0.000215 
regulation of neuron differentiation 0.000229 
cellular response to organonitrogen compound 0.00026 
response to abiotic stimulus 0.000268 
phospholipid translocation 0.000286 
phosphatidylcholine acyl-chain remodelling 0.00029 
regulation of nervous system development 0.000308 
organic acid transmembrane transport 0.000312 
protein localization to axon 0.000325 
positive regulation of nervous system development 0.000328 
single-organism localization 0.000328 
positive regulation of multicellular organismal process 0.000333 
response to peptide hormone 0.000358 
lipid translocation 0.000404 
regulation of axon extension involved in axon guidance 0.000428 
regulation of cellular component movement 0.000464 
cellular response to insulin stimulus 0.000465 
single-organism behaviour 0.000485 
phosphatidylserine metabolic process 0.000509 
regulation of biological quality 0.000546 
neuron projection guidance 0.000554 
blood vessel development 0.000569 
cellular response to peptide hormone stimulus 0.000628 
cell cycle process 0.000637 
response to extracellular stimulus 0.000639 
cell migration 0.000643 
cellular response to hormone stimulus 0.000644 
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regulation of chemotaxis 0.000649 
regulation of vasculature development 0.000671 
skeletal muscle cell differentiation 0.000692 
monocarboxylic acid biosynthetic process 0.000705 
cell motility 0.000712 
positive regulation of axon extension involved in axon guidance 0.000716 
positive regulation of axon guidance 0.000716 
phosphatidylethanolamine acyl-chain remodelling 0.000751 
locomotion 0.000761 
single-organism transport 0.000774 
long-chain Fatty-Acyl-CoA metabolic process 0.000779 
glycerolipid metabolic process 0.000793 
carboxylic acid transport 0.000794 
regulation of phosphate metabolic process 0.00082 
regulation of MAPK cascade 0.00083 
positive regulation of neuron projection development 0.000832 
regulation of intracellular signal transduction 0.000832 
regulation of phosphorus metabolic process 0.000841 
response to insulin 0.000853 
kidney morphogenesis 0.000888 
PERK-mediated unfolded protein response 0.000888 
regulation of locomotion 0.000909 
behaviour 0.000921 
regulation of response to stimulus 0.000946 
Acyl-CoA biosynthetic process 0.000974 
thioester biosynthetic process 0.000974 
anatomical structure formation involved in morphogenesis 0.000988 
isoprenoid biosynthetic process 0.000997 
 
Appendix Table 2. Canonical Pathways for LNCaP cells treated in HCM (HCM vs RPMI). Ranked by –
log (p-value) 
Ingenuity Canonical Pathways  -log(p-value) z-score 
Superpathway of Cholesterol Biosynthesis 1.35E+01 NaN 
Cholesterol Biosynthesis I 9.68E+00 NaN 
Cholesterol Biosynthesis II (via 24,25-dihydrolanosterol) 9.68E+00 NaN 
Cholesterol Biosynthesis III (via Desmosterol) 9.68E+00 NaN 
LXR/RXR Activation 7.01E+00 0.943 
Atherosclerosis Signalling 4.57E+00 NaN 
Superpathway of Geranylgeranyldiphosphate Biosynthesis I (via Mevalonate) 4.39E+00 NaN 
TR/RXR Activation 4.19E+00 NaN 
Mevalonate Pathway I 4.16E+00 NaN 
Sperm Motility 3.75E+00 1.213 
Triacylglycerol Biosynthesis 3.65E+00 NaN 
IL-6 Signalling 3.52E+00 0 
p38 MAPK Signalling 3.47E+00 -0.728 
γ-linolenate Biosynthesis II (Animals) 3.40E+00 NaN 
Fatty Acid β-oxidation I 3.21E+00 NaN 
Granulocyte Adhesion and Diapedesis 3.16E+00 NaN 
Agranulocyte Adhesion and Diapedesis 3.13E+00 NaN 
Acute Phase Response Signalling 3.06E+00 0 
Acetate Conversion to Acetyl-CoA 3.03E+00 NaN 
CCR3 Signalling in Eosinophils 3.02E+00 NaN 
Hepatic Fibrosis / Hepatic Stellate Cell Activation 2.96E+00 NaN 
Role of Hypercytokinemia/hyperchemokinemia in the Pathogenesis of 
Influenza 2.94E+00 NaN 
Gαs Signalling 2.92E+00 0 
LPS/IL-1 Mediated Inhibition of RXR Function 2.85E+00 1.134 
UVB-Induced MAPK Signalling 2.84E+00 -0.707 
Role of IL-17A in Arthritis 2.77E+00 NaN 
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TNFR2 Signalling 2.77E+00 1.633 
Toll-like Receptor Signalling 2.70E+00 -1.667 
CD40 Signalling 2.67E+00 0 
Inhibition of Matrix Metalloproteases 2.61E+00 NaN 
Endothelin-1 Signalling 2.60E+00 -1.606 
Role of Tissue Factor in Cancer 2.46E+00 NaN 
IL-17A Signalling in Gastric Cells 2.43E+00 NaN 
Epoxysqualene Biosynthesis 2.41E+00 NaN 
Zymosterol Biosynthesis 2.37E+00 NaN 
Tec Kinase Signalling 2.36E+00 -0.5 
IL-9 Signalling 2.35E+00 0 
Oxidative Ethanol Degradation III 2.28E+00 NaN 
FXR/RXR Activation 2.28E+00 NaN 
Stearate Biosynthesis I (Animals) 2.21E+00 NaN 
Fatty Acid Activation 2.16E+00 NaN 
VEGF Family Ligand-Receptor Interactions 2.13E+00 0.302 
RAR Activation 2.10E+00 NaN 
Glutamate Receptor Signalling 2.08E+00 -2.236 
UVA-Induced MAPK Signalling 2.07E+00 -1.508 
Antioxidant Action of Vitamin C 2.07E+00 0.632 
γ-glutamyl Cycle 2.04E+00 NaN 
Communication between Innate and Adaptive Immune Cells 2.03E+00 NaN 
IL-10 Signalling 2.03E+00 NaN 
Neuropathic Pain Signalling in Dorsal Horn Neurons 2.03E+00 -1.941 
Nitric Oxide Signalling in the Cardiovascular System 2.03E+00 0.577 
Phospholipases 2.03E+00 NaN 
Relaxin Signalling 1.99E+00 0 
Role of Osteoblasts, Osteoclasts and Chondrocytes in Rheumatoid Arthritis 1.99E+00 NaN 
Airway Pathology in Chronic Obstructive Pulmonary Disease 1.97E+00 NaN 
Histidine Degradation III 1.97E+00 NaN 
Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid 
Arthritis 1.95E+00 NaN 
IL-8 Signalling 1.95E+00 0.471 
Ethanol Degradation IV 1.91E+00 NaN 
MIF Regulation of Innate Immunity 1.90E+00 1.134 
Colorectal Cancer Metastasis Signalling 1.89E+00 0 
G Protein Signalling Mediated by Tubby 1.88E+00 NaN 
Molecular Mechanisms of Cancer 1.88E+00 NaN 
IL-17 Signalling 1.86E+00 NaN 
Axonal Guidance Signalling 1.84E+00 NaN 
Dendritic Cell Maturation 1.83E+00 -1.698 
Mismatch Repair in Eukaryotes 1.82E+00 NaN 
MIF-mediated Glucocorticoid Regulation 1.82E+00 0.816 
Phosphatidylethanolamine Biosynthesis II 1.81E+00 NaN 
Antiproliferative Role of Somatostatin Receptor 2 1.80E+00 -1.342 
Eicosanoid Signalling 1.76E+00 0 
HMGB1 Signalling 1.75E+00 0.535 
TREM1 Signalling 1.75E+00 1.897 
Nicotine Degradation III 1.74E+00 NaN 
Role of IL-17F in Allergic Inflammatory Airway Diseases 1.74E+00 0.816 
Mitochondrial L-carnitine Shuttle Pathway 1.73E+00 NaN 
TGF-β Signalling 1.71E+00 0.707 
BMP signalling pathway 1.71E+00 0.333 
Thrombopoietin Signalling 1.69E+00 0 
Ketogenesis 1.68E+00 NaN 
Pentose Phosphate Pathway 1.68E+00 NaN 
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Altered T Cell and B Cell Signalling in Rheumatoid Arthritis 1.68E+00 NaN 
Xenobiotic Metabolism Signalling 1.67E+00 NaN 
Arsenate Detoxification I (Glutaredoxin) 1.67E+00 NaN 
Pentose Phosphate Pathway (Oxidative Branch) 1.67E+00 NaN 
VDR/RXR Activation 1.64E+00 0 
Cholecystokinin/Gastrin-mediated Signalling 1.63E+00 -0.577 
Hepatic Cholestasis 1.62E+00 NaN 
Cell Cycle Control of Chromosomal Replication 1.62E+00 NaN 
Melatonin Degradation I 1.61E+00 NaN 
CXCR4 Signalling 1.55E+00 0.277 
Graft-versus-Host Disease Signalling 1.54E+00 NaN 
Aryl Hydrocarbon Receptor Signalling 1.54E+00 0 
Thrombin Signalling 1.54E+00 -1 
April Mediated Signalling 1.54E+00 0.816 
PPAR Signalling 1.52E+00 0.302 
TNFR1 Signalling 1.50E+00 0.816 
tRNA Charging 1.49E+00 NaN 
Tetrahydrofolate Salvage from 5,10-methenyltetrahydrofolate 1.46E+00 NaN 
Trans, trans-farnesyl Diphosphate Biosynthesis 1.46E+00 NaN 
Mouse Embryonic Stem Cell Pluripotency 1.46E+00 -2.111 
Fc Epsilon RI Signalling 1.43E+00 -1.155 
Superpathway of Melatonin Degradation 1.42E+00 NaN 
IL-12 Signalling and Production in Macrophages 1.41E+00 NaN 
Human Embryonic Stem Cell Pluripotency 1.39E+00 NaN 
Phospholipase C Signalling 1.38E+00 0.243 
4-1BB Signalling in T Lymphocytes 1.38E+00 1.342 
Leukocyte Extravasation Signalling 1.38E+00 -1.213 
IL-15 Signalling 1.38E+00 NaN 
Nicotine Degradation II 1.38E+00 NaN 
Amyotrophic Lateral Sclerosis Signalling 1.38E+00 NaN 
Protein Kinase A Signalling 1.37E+00 0.209 
Role of IL-17A in Psoriasis 1.36E+00 NaN 
Oleate Biosynthesis II (Animals) 1.36E+00 NaN 
UDP-N-Acetyl-D-glucosamine Biosynthesis II 1.31E+00 NaN 
Lymphotoxin β Receptor Signalling 1.30E+00 -0.447 
Role of Cytokines in Mediating Communication between Immune Cells 1.30E+00 NaN 
Note: a positive z-score indicated the pathway is activated, a negative z-score indicates the pathway is 
inactivated, NaN indicates it is unknown to IPA pathway activation or inactivation state. 
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Appendix Table 3. Top 10* Canonical Pathways for DE genes from LNCaP cells grown in HCM compared to 
RPMI (HCM vs RPMI) 
Ingenuity Canonical Pathways -log (p-value) Ratio z-score 
Superpathway of Cholesterol Biosynthesis 13.5 17/28 NaN 
LXR/RXR Activation 7.01 25/120 0.943 
Atherosclerosis Signalling 4.57 21/124 NaN 
TR/RXR Activation 4.19 16/85 NaN 
Sperm Motility 3.75 19/121 1.213 
Triacylglycerol Biosynthesis 3.65 9/35 NaN 
IL-6 Signalling 3.52 18/116 0 
p38 MAPK Signalling 3.47 17/110 -0.728 
γ-linolenate Biosynthesis II (Animals) 3.40 6/17 NaN 
Fatty Acid β-oxidation I 3.21 8/32 NaN 
Note: Ranked by –log (p-value), -log (p-value) > 1.3 is significant, Ratio (target genes/IPA identified pathway 
genes), a positive z-score indicates the pathway is activated, a negative z-score indicates the pathway is 
inactivated, a 0 z-score indicates the pathway is neither activated or inactivated, NaN indicates it is by the 
IPA database if the result indicates an activation or inactivation state.  
*Appendix Table 4. Canonical Pathways for LNCaP cells treated in HCM that share all genes with 
“Superpathway of Cholesterol Biosynthesis” pathway 
 
Appendix Table 4. Canonical Pathways that share all DE genes with “Superpathway of Cholesterol Biosynthesis” 
pathway for LNCaP cells treated in HCM (LNCaP.DMSO.HCMvRPMI). 
Canonical Pathways  -log (p-value) Ratio z-score 
Cholesterol Biosynthesis I,  9.68  10/13 NaN 
Cholesterol Biosynthesis II (via 24,25-dihydrolanosterol),  9.68  10/13 NaN 
Cholesterol Biosynthesis III (via Desmosterol) 9.68  10/13 NaN 
Superpathway of Geranylgeranyldiphosphate Biosynthesis 
I (via Mevalonate) 4.39   7/17 NaN 
Mevalonate Pathway I 4.16   6/13 NaN 
Note: Ranked by –log (p-value), -log (p-value) > 1.3 is significant, Ratio (target genes/IPA identified pathway 
genes), a positive z-score indicates the pathway is activated, a negative z-score indicates the pathway is 
inactivated, a 0 z-score indicates the pathway is neither activated or inactivated, NaN indicates it is unknown to 
IPA pathway activation or inactivation state. 
 
Appendix Table 5. Canonical Pathways for LNCaP cells cultured in HCM as compared to RPMI (HCM vs RPMI) 
with significant or near significant z-scores. 
Canonical Pathways  -log (p-value) Ratio z-score 
TREM1 Signalling 1.75 10/75 1.897 
Mouse Embryonic Stem Cell Pluripotency 1.46 11/95 -2.111 
Glutamate Receptor Signalling 2.08 9/57 -2.236 
Note: Ranked by z-score, -log (p-value) > 1.3 is significant, Ratio (target genes/IPA identified 
pathway genes), a positive z-score indicates the pathway is activated, a negative z-score indicates 
the pathway is inactivated, a 0 z-score indicates the pathway is neither activated or inactivated, NaN 
indicates it is by the IPA database if the result indicates an activation or inactivation state. 
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Appendix Table 6. Canonical Pathways for androgen-enriched RPMI treated LNCaP cells (RPMI+DHT vs RPMI) 
Ranked by -log (p-value) 
Ingenuity Canonical Pathways -log(p-value) z-score 
Protein Kinase A Signalling 5.21E+00 0.174 
GPCR-Mediated Nutrient Sensing in Enteroendocrine Cells 4.29E+00 NaN 
Sperm Motility 4.10E+00 1.5 
Phospholipase C Signalling 4.00E+00 0.243 
Superpathway of Cholesterol Biosynthesis 3.51E+00 NaN 
Breast Cancer Regulation by Stathmin1 3.36E+00 NaN 
Molecular Mechanisms of Cancer 3.30E+00 NaN 
Type II Diabetes Mellitus Signalling 3.29E+00 0 
GNRH Signalling 3.26E+00 -0.5 
Axonal Guidance Signalling 3.14E+00 NaN 
LXR/RXR Activation 3.09E+00 2.714 
TR/RXR Activation 3.08E+00 NaN 
CDK5 Signalling 2.99E+00 -0.832 
γ-linolenate Biosynthesis II (Animals) 2.99E+00 NaN 
Mitochondrial L-carnitine Shuttle Pathway 2.99E+00 NaN 
CMP-N-acetylneuraminate Biosynthesis I (Eukaryotes) 2.97E+00 NaN 
Role of NFAT in Cardiac Hypertrophy 2.92E+00 -0.471 
Triacylglycerol Biosynthesis 2.89E+00 NaN 
Gap Junction Signalling 2.82E+00 NaN 
Cellular Effects of Sildenafil (Viagra) 2.81E+00 NaN 
Remodelling of Epithelial Adherens Junctions 2.79E+00 0 
UDP-N-Acetyl-D-glucosamine Biosynthesis II 2.68E+00 NaN 
Dopamine-DARPP32 Feedback in cAMP Signalling 2.64E+00 0.258 
Putrescine Biosynthesis III 2.62E+00 NaN 
RAR Activation 2.61E+00 NaN 
Renin-Angiotensin Signalling 2.60E+00 -0.832 
Oleate Biosynthesis II (Animals) 2.55E+00 NaN 
Cholesterol Biosynthesis I 2.55E+00 NaN 
Cholesterol Biosynthesis II (via 24,25-dihydrolanosterol) 2.55E+00 NaN 
Cholesterol Biosynthesis III (via Desmosterol) 2.55E+00 NaN 
CXCR4 Signalling 2.51E+00 0.775 
α-Adrenergic Signalling 2.48E+00 -0.632 
Calcium-induced T Lymphocyte Apoptosis 2.43E+00 0.378 
UVB-Induced MAPK Signalling 2.41E+00 1.134 
Huntington's Disease Signalling 2.38E+00 -0.447 
VDR/RXR Activation 2.35E+00 NaN 
Factors Promoting Cardiogenesis in Vertebrates 2.29E+00 NaN 
Thrombin Signalling 2.26E+00 -0.243 
Phospholipases 2.17E+00 NaN 
Gαs Signalling 2.16E+00 0.632 
Stearate Biosynthesis I (Animals) 2.13E+00 NaN 
GPCR-Mediated Integration of Enteroendocrine Signalling Exemplified by an 
L Cell 2.13E+00 NaN 
UDP-N-Acetyl-D-galactosamine Biosynthesis II 2.11E+00 NaN 
Corticotrophin Releasing Hormone Signalling 2.10E+00 -0.302 
Neuropathic Pain Signalling in Dorsal Horn Neurons 2.02E+00 -0.905 
Nitric Oxide Signalling in the Cardiovascular System 2.02E+00 0.632 
eNOS Signalling 2.02E+00 0 
Endothelin-1 Signalling 2.00E+00 -0.258 
Netrin Signalling 1.96E+00 NaN 
CCR3 Signalling in Eosinophils 1.93E+00 NaN 
Colorectal Cancer Metastasis Signalling 1.93E+00 -0.943 
PPARα/RXRα Activation 1.89E+00 0.905 
P2Y Purigenic Receptor Signalling Pathway 1.87E+00 -0.905 
AMPK Signalling 1.86E+00 -0.775 
Nicotine Degradation III 1.81E+00 NaN 
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UVC-Induced MAPK Signalling 1.81E+00 1.633 
GABA Receptor Signalling 1.80E+00 0 
Endoplasmic Reticulum Stress Pathway 1.76E+00 NaN 
Atherosclerosis Signalling 1.74E+00 NaN 
Acute Phase Response Signalling 1.73E+00 -0.333 
IGF-1 Signalling 1.70E+00 -0.816 
Lysine Degradation V 1.67E+00 NaN 
Synaptic Long Term Depression 1.67E+00 0.832 
Antioxidant Action of Vitamin C 1.65E+00 0 
Fatty Acid Activation 1.64E+00 NaN 
NAD Phosphorylation and Dephosphorylation 1.64E+00 NaN 
Mevalonate Pathway I 1.64E+00 NaN 
IL-9 Signalling 1.63E+00 NaN 
Basal Cell Carcinoma Signalling 1.63E+00 -1.89 
Cardiac Hypertrophy Signalling 1.60E+00 0.728 
Hepatic Cholestasis 1.58E+00 NaN 
Thyroid Hormone Metabolism II (via Conjugation and/or Degradation) 1.58E+00 NaN 
Glioblastoma Multiforme Signalling 1.58E+00 -0.577 
Epithelial Adherens Junction Signalling 1.58E+00 NaN 
Ovarian Cancer Signalling 1.58E+00 NaN 
UVA-Induced MAPK Signalling 1.56E+00 0 
Sertoli Cell-Sertoli Cell Junction Signalling 1.55E+00 NaN 
Androgen Biosynthesis 1.55E+00 NaN 
Cardiac β-adrenergic Signalling 1.53E+00 -0.632 
NRF2-mediated Oxidative Stress Response 1.52E+00 1.897 
Human Embryonic Stem Cell Pluripotency 1.51E+00 NaN 
BMP signalling pathway 1.50E+00 1.134 
Nicotine Degradation II 1.48E+00 NaN 
Hepatic Fibrosis / Hepatic Stellate Cell Activation 1.46E+00 NaN 
Aldosterone Signalling in Epithelial Cells 1.46E+00 -1.134 
Pyridoxal 5'-phosphate Salvage Pathway 1.45E+00 NaN 
Dopamine Receptor Signalling 1.44E+00 -0.816 
RhoA Signalling 1.44E+00 1 
Estrogen Biosynthesis 1.44E+00 NaN 
fMLP Signalling in Neutrophils 1.42E+00 -0.333 
Role of Osteoblasts, Osteoclasts and Chondrocytes in Rheumatoid Arthritis 1.40E+00 NaN 
CREB Signalling in Neurons 1.39E+00 -1.387 
Ceramide Signalling 1.39E+00 0.447 
Role of Tissue Factor in Cancer 1.37E+00 NaN 
Pregnenolone Biosynthesis 1.37E+00 NaN 
GDP-glucose Biosynthesis 1.37E+00 NaN 
LPS/IL-1 Mediated Inhibition of RXR Function 1.37E+00 1.414 
Serotonin Degradation 1.36E+00 NaN 
Integrin Signalling 1.33E+00 1.069 
Unfolded protein response 1.33E+00 NaN 
Superpathway of Geranylgeranyldiphosphate Biosynthesis I (via 
Mevalonate) 1.33E+00 NaN 
Sorbitol Degradation I 1.31E+00 NaN 
Growth Hormone Signalling 1.30E+00 0 
TNFR2 Signalling 1.30E+00 NaN 
Intrinsic Prothrombin Activation Pathway 1.30E+00 1 
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Appendix Table 7. Top 10 Canonical Pathways for LNCaP cells cultured in RPMI+DHT and compared to RPMI 
and control (DMSO) (RPMI+DHT vs RPMI) 
Ingenuity Canonical Pathways -log (p-value) Ratio z-score 
Protein Kinase A Signalling 5.21 42/403 0.174 
GPCR-Mediated Nutrient Sensing in Enteroendocrine Cells 4.29 14/84 NaN 
Sperm Motility 4.10 17/121 1.5 
Phospholipase C Signalling 4.00 27/245 0.243 
Superpathway of Cholesterol Biosynthesis 3.51 7/28 NaN 
Breast Cancer Regulation by Stathmin1 3.36 22/200 NaN 
Molecular Mechanisms of Cancer 3.30 24/376 NaN 
Type II Diabetes Mellitus Signalling 3.29 15/116 0 
GNRH Signalling 3.26 16/129 -0.5 
Axonal Guidance Signalling 3.14 38/445 NaN 
Note: Ranked by –log (p-value), -log (p-value) > 1.3 is significant, Ratio (target genes/IPA identified 
pathway genes), a positive z-score indicates the pathway is activated, a negative z-score indicates 
the pathway is inactivated, a 0 z-score indicates the pathway is neither activated or inactivated, NaN 
indicates it is by the IPA database if the result indicates an activation or inactivation state.  
 
Appendix Table 8. Exhaustive list of the predicted Upstream Regulators for DHT+RPMI treated LNCaP cells  
Upstream 
Regulator Exp FC Molecule Type 
Predicted 
Activation 
State 
Activation z-
score 
p-value of 
overlap 
DHT - chemical - endogenous  Activated 6.963 2.37E-23 
metribolone - chemical reagent Activated 6.806 1.99E-29 
AR - ligand-dependent nuclear receptor Activated 5.982 4.75E-22 
XBP1 - transcription regulator Activated 4.08 0.000138 
PKD1 - ion channel Activated 2.887 0.000876 
SREBF2 - transcription regulator Activated 2.742 3.49E-07 
SCAP - other Activated 2.608 0.0095 
beta-oestradiol - chemical - endogenous  Activated 2.471 4.56E-11 
SREBF1 - transcription regulator Activated 2.444 3.55E-06 
PCGEM1 - other Activated 2.408 0.00866 
FBXO32 - enzyme Activated 2.35 4.83E-06 
KRAS - enzyme Activated 2.304 0.00469 
CD38 - enzyme Activated 2.291 0.00482 
ATP7B - transporter Activated 2.236 0.00765 
MITF - transcription regulator Activated 2.236 0.00238 
Insulin - group Activated 2.206 3.68E-06 
TCF7L2 - transcription regulator Activated 2.191 1.13E-05 
ERN1 2.163 kinase Activated 2.173 0.00329 
androgen - chemical drug Activated 2.107 6.75E-08 
STAT4 - transcription regulator Activated 2.101 0.00514 
CYP27A1 - enzyme Activated 2 0.00934 
CYP51A1 - enzyme Inhibited -2 0.00214 
HTT - transcription regulator Inhibited -2.058 0.000181 
PA2G4 - transcription regulator Inhibited -2.183 9.35E-06 
ZMPSTE24 - peptidase Inhibited -2.219 0.00164 
N-cor - group Inhibited -2.219 0.00349 
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NKX2-3 - transcription regulator Inhibited -2.236 0.00177 
STAG1 - transcription regulator Inhibited -2.236 9.35E-06 
HOXB13 - transcription regulator Inhibited -2.236 0.00899 
CCND1 - transcription regulator Inhibited -2.273 3.89E-13 
25-
hydroxycholesterol - chemical reagent Inhibited -2.424 0.000432 
methylselenic acid - chemical reagent Inhibited -2.742 2.64E-10 
cholesterol - chemical - endogenous  Inhibited -3.908 0.00105 
Note: Ranked determined by activation z-score. A positive activation z-score indicates the pathway is 
predicted to be activated, p-val >0.01, Expression Fold Change (Exp FC) listed if the gene is DE in the 
dataset. 
 
Appendix Table 9. Gene Ontology Analysis Identified Neuronal or Endocrine Associated Biological Processes for 
LNCaP cells Cultured in HCM compared to RPMI media (HCM vs RPMI).  
 Description P-value 
 synapse assembly 1.31E-06 
 anterograde trans-synaptic signalling 6.23E-06 
 chemical synaptic transmission 6.23E-06 
 synaptic signalling 6.23E-06 
 trans-synaptic signalling 6.23E-06 
 cognition 1.22E-05 
 regulation of signalling 2.72E-05 
 learning 3.48E-05 
 synapse organization 4.30E-05 
 learning or memory 1.16E-04 
 regulation of neuron projection development 1.16E-04 
 regulation of signal transduction 1.32E-04 
 associative learning 1.41E-04 
 regulation of neuron differentiation 2.29E-04 
 regulation of nervous system development 3.08E-04 
 protein localization to axon 3.25E-04 
 positive regulation of nervous system development 3.28E-04 
 regulation of axon extension involved in axon guidance 4.28E-04 
 neuron projection guidance 5.54E-04 
 positive regulation of axon extension involved in axon guidance 7.16E-04 
 positive regulation of axon guidance 7.16E-04 
 positive regulation of neuron projection development 8.32E-04 
 behaviour 9.21E-04 
 Note: Listed with Process p-value  
 
Appendix Table 10. Canonical Pathways with Neuroendocrine Association for LNCaP cells cultured in 
HCM (Table for Figure 4.10) 
Ingenuity Canonical Pathways -log(p-value) Ratio z-score 
Neuropathic Pain Signalling in Dorsal 
Horn Neurons 2.03 13/100 -1.941 
Glutamate Receptor Signalling 2.08 9/57 -2.236 
Note: Ranked by –log (p-value); -log (p-value) > 1.3 is significant, Ratio (target genes/IPA 
identified pathway genes), a positive z-score indicates the pathway is activated, a negative 
z-score indicates the pathway is inactivated, a 0 z-score indicates the pathway is neither 
activated or inactivated, NaN indicates it is unknown to IPA pathway activation or 
inactivation state. 
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Appendix Table 11. The total list of gene ontology processes for non-androgen LNCaP cells treated with HCM 
(Table for Figure 4.4) 
Description P-value 
single-organism process 7.55E-08 
single-organism cellular process 1.64E-06 
homophilic cell adhesion via plasma membrane adhesion molecules 3.53E-06 
lipid biosynthetic process 5.23E-06 
lipid metabolic process 5.25E-06 
cholesterol biosynthetic process 2.40E-05 
secondary alcohol biosynthetic process 2.40E-05 
alcohol metabolic process 2.47E-05 
cell-cell adhesion via plasma-membrane adhesion molecules 2.95E-05 
single organism signaling 3.55E-05 
system development 3.86E-05 
signaling 3.88E-05 
cholesterol metabolic process 4.79E-05 
cholesterol biosynthetic process via desmosterol 4.94E-05 
cholesterol biosynthetic process via lathosterol 4.94E-05 
developmental process 5.48E-05 
sterol biosynthetic process 5.54E-05 
response to chemical 5.62E-05 
secondary alcohol metabolic process 6.15E-05 
regulation of neutrophil migration 6.94E-05 
response to organic substance 7.17E-05 
response to endogenous stimulus 8.93E-05 
sterol metabolic process 1.44E-04 
cell communication 1.45E-04 
single-organism developmental process 2.25E-04 
steroid metabolic process 2.33E-04 
cellular lipid metabolic process 2.81E-04 
response to hormone 2.92E-04 
positive regulation of hormone secretion 3.35E-04 
positive regulation of neutrophil migration 3.55E-04 
regulation of neutrophil chemotaxis 3.55E-04 
regulation of endocrine process 3.98E-04 
cell-cell signaling 4.05E-04 
response to oxygen-containing compound 4.65E-04 
regulation of brain-derived neurotrophic factor receptor signaling pathway 5.42E-04 
cell recognition 6.34E-04 
positive regulation of transport 6.45E-04 
anatomical structure morphogenesis 6.80E-04 
small molecule metabolic process 6.97E-04 
phosphatidylcholine metabolic process 7.03E-04 
regulation of cell projection organization 7.37E-04 
regulation of hormone secretion 7.49E-04 
fat cell differentiation 7.78E-04 
organic hydroxy compound metabolic process 7.86E-04 
cell adhesion 8.08E-04 
cellular response to oxygen-containing compound 8.57E-04 
biological adhesion 8.65E-04 
steroid biosynthetic process 8.91E-04 
positive regulation of cyclic nucleotide metabolic process 8.91E-04 
response to abiotic stimulus 9.19E-04 
neuron recognition 9.30E-04 
positive regulation of cAMP metabolic process 9.54E-04 
anatomical structure development 9.61E-04 
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Appendix Table 12. Top 10 Canonical Pathways for HCM treated LNCaP cells excluding androgen regulated 
genes (HCM vs RPMI) vs (RPMI+DHT vs RPMI)  (Table for Figure 4.10) 
Canonical Pathways  -log (p-value) z-score Ratio 
Superpathway of Cholesterol Biosynthesis 7.00 NaN 10/28 
LXR/RXR Activation 4.36 -0.577 16/121 
IL-6 Signalling 4.02 0.775 15/116 
Role of IL-17A in Arthritis 3.44 NaN 9/54 
Agranulocyte Adhesion and Diapedesis 3.44 NaN 19/188 
Granulocyte Adhesion and Diapedesis 3.35 NaN 18/176 
Atherosclerosis Signalling 3.17 NaN 14/124 
TR/RXR Activation 3.10 NaN 11/85 
RAR Activation 2.99 NaN 17/179 
Zymosterol Biosynthesis 2.88 NaN 3/6 
Note: Ranked by –log (p-value), -log (p-value) > 1.3 is significant, Ratio (target genes/IPA identified pathway 
genes), a positive z-score indicates the pathway is activated, a negative z-score indicates the pathway is 
inactivated, a 0 z-score indicates the pathway is neither activated or inactivated, NaN indicates it is unknown to 
IPA pathway activation or inactivation state. 
 
Appendix Table 14. Top 10 Canonical Pathways for LNCaP cells treated in HCM excluding androgen 
and insulin regulated genes (HCM vs RPMI) vs ((RPMI+DHT vs RPMI) & Insulin 1). (Table for Figure 
4.16) 
Canonical Pathways  -log (p-value) Ratio z-score 
LXR/RXR Activation 6.66 14/121 -0.632 
Granulocyte Adhesion and Diapedesis 4.06 13/177 NaN 
IL-6 Signalling 3.82 10/116 1.897 
Acute Phase Response Signalling 3.66 12/169 1.508 
Role of Hypercytokinemia/hyperchemokinemia in 
the Pathogenesis of Influenza 3.61 6/43 NaN 
Atherosclerosis Signalling 3.58 10/124 NaN 
Toll-like Receptor Signalling 3.07 7/74 0 
April Mediated Signalling 2.97 5/38 1.342 
FXR/RXR Activation 2.90 9/126 NaN 
IL-17A Signalling in Gastric Cells 2.79 4/25 NaN 
Note: Ranked by –log (p-value); -log (p-value) > 1.3 is significant, Ratio (target genes/IPA identified pathway 
genes), A positive z-score indicates the pathway is activated, a negative z-score indicates the pathway is 
inactivated, a 0 z-score indicates the pathway is neither activated or inactivated, NaN indicates it is unknown to 
IPA pathway activation or inactivation state. 
 
Appendix Table 13. Canonical Pathways with significant z-scores for LNCaP treated with HCM excluding DHT 
regulated genes ((HCM vs RPMI) vs (RPMI+DHT vs RPMI) (Figure 4.11) 
Canonical Pathways  -log (p-value) z-score Ratio 
TREM1 Signalling 2.41 2.333 16/133 
Role of NANOG in Mammalian Embryonic 
Stem Cell Pluripotency 1.35 -2 10/119 
Mouse Embryonic Stem Cell Pluripotency 1.37 -2.121 16/197 
Note: Ranked by z-score, -log (p-value) > 1.3 is significant, Ratio (target genes/IPA identified pathway genes), a 
positive z-score indicates the pathway is activated, a negative z-score indicates the pathway is inactivated, a 0 
z-score indicates the pathway is neither activated or inactivated, NaN indicates it is unknown to IPA pathway 
activation or inactivation state. 
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Appendix Table 15. The gene ontology analysis identified processes for HCM treated VCaP cells 
Description P-value 
DNA metabolic process 2.95E-22 
DNA replication 5.21E-22 
cell cycle process 9.09E-22 
mitotic cell cycle phase transition 1.35E-19 
cell cycle phase transition 1.73E-19 
mitotic cell cycle process 2.49E-19 
single-organism process 6.72E-17 
single-organism cellular process 1.63E-16 
telomere maintenance via recombination 3.83E-16 
DNA repair 4.50E-16 
cell cycle G1/S phase transition 4.72E-16 
G1/S transition of mitotic cell cycle 4.72E-16 
mitotic recombination 5.28E-16 
cellular response to DNA damage stimulus 7.28E-16 
chromosome organization 1.18E-14 
cellular response to stimulus 2.08E-14 
DNA recombination 2.86E-13 
cellular component organization 5.43E-13 
cellular process 8.73E-13 
cellular component organization or biogenesis 1.36E-12 
recombinational repair 4.72E-12 
regulation of cell cycle 7.95E-12 
double-strand break repair via homologous recombination 1.83E-11 
cell cycle checkpoint 3.81E-11 
developmental process 6.32E-11 
cellular response to stress 6.42E-11 
DNA replication initiation 6.75E-11 
DNA synthesis involved in DNA repair 3.15E-10 
organelle organization 5.39E-10 
cell division 1.02E-09 
DNA strand elongation involved in DNA replication 1.08E-09 
DNA integrity checkpoint 1.18E-09 
single-organism developmental process 1.37E-09 
regulation of DNA metabolic process 2.80E-09 
DNA biosynthetic process 2.84E-09 
organelle fission 4.19E-09 
DNA strand elongation 7.16E-09 
double-strand break repair 9.24E-09 
nuclear division 9.36E-09 
anatomical structure development 1.93E-08 
telomere maintenance 2.37E-08 
DNA damage response, detection of DNA damage 3.08E-08 
DNA duplex unwinding 3.12E-08 
response to endogenous stimulus 4.15E-08 
mitotic nuclear division 4.90E-08 
response to hormone 5.06E-08 
DNA conformation change 7.15E-08 
nucleotide-excision repair, DNA gap filling 8.61E-08 
regulation of DNA replication 8.92E-08 
DNA geometric change 1.02E-07 
DNA damage checkpoint 1.03E-07 
regulation of signaling 1.67E-07 
regulation of cell proliferation 2.19E-07 
response to organic substance 2.36E-07 
G2/M transition of mitotic cell cycle 2.70E-07 
movement of cell or subcellular component 2.84E-07 
regulation of biological quality 3.01E-07 
regulation of cell communication 3.06E-07 
centriole replication 3.24E-07 
regulation of developmental process 3.70E-07 
regulation of cell morphogenesis 3.79E-07 
cell cycle G2/M phase transition 3.99E-07 
interstrand cross-link repair 4.13E-07 
regulation of DNA-dependent DNA replication 4.89E-07 
negative regulation of cellular process 5.03E-07 
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strand displacement 5.76E-07 
telomere organization 6.11E-07 
centriole assembly 6.33E-07 
centrosome organization 7.79E-07 
positive regulation of cellular process 9.46E-07 
response to oxygen-containing compound 1.39E-06 
microtubule organizing center organization 1.62E-06 
cellular response to hormone stimulus 1.72E-06 
sister chromatid cohesion 1.78E-06 
positive regulation of biological process 1.84E-06 
negative regulation of biological process 1.84E-06 
regulation of cell cycle process 2.37E-06 
regulation of cell differentiation 2.88E-06 
cell projection organization 3.02E-06 
negative regulation of cell cycle 3.38E-06 
response to chemical 3.77E-06 
sterol biosynthetic process 3.96E-06 
DNA replication-independent nucleosome organization 4.57E-06 
DNA replication-independent nucleosome assembly 4.57E-06 
postreplication repair 4.57E-06 
positive regulation of DNA metabolic process 4.82E-06 
anatomical structure homeostasis 4.88E-06 
regulation of cell development 4.97E-06 
response to nutrient 5.11E-06 
cellular response to endogenous stimulus 5.72E-06 
positive regulation of macromolecule metabolic process 6.40E-06 
error-prone translesion synthesis 6.67E-06 
error-free translesion synthesis 6.67E-06 
base-excision repair 6.85E-06 
translesion synthesis 7.09E-06 
regulation of intracellular signal transduction 7.43E-06 
regulation of transcription involved in G1/S transition of mitotic 
cell cycle 7.50E-06 
cellular component assembly 7.67E-06 
regulation of mitotic cell cycle 8.05E-06 
response to lipid 8.81E-06 
positive regulation of cell cycle 1.03E-05 
response to organonitrogen compound 1.16E-05 
positive regulation of metabolic process 1.18E-05 
regulation of signal transduction 1.19E-05 
response to radiation 1.22E-05 
regulation of cellular component organization 1.24E-05 
regulation of multicellular organismal development 1.36E-05 
regulation of phosphorylation 1.39E-05 
chromatin assembly or disassembly 1.53E-05 
regulation of double-strand break repair 1.81E-05 
cholesterol biosynthetic process 1.81E-05 
secondary alcohol biosynthetic process 1.81E-05 
positive regulation of developmental process 1.96E-05 
animal organ development 2.36E-05 
second-messenger-mediated signaling 2.44E-05 
nucleotide-excision repair, DNA incision 2.55E-05 
microtubule-based process 2.78E-05 
regulation of signal transduction by p53 class mediator 2.80E-05 
regulation of kinase activity 2.88E-05 
regulation of anatomical structure morphogenesis 3.17E-05 
biological_process 3.80E-05 
response to peptide hormone 3.87E-05 
negative regulation of mitotic cell cycle 4.00E-05 
regulation of protein phosphorylation 4.34E-05 
single-organism organelle organization 4.37E-05 
positive regulation of cell differentiation 4.41E-05 
regulation of multicellular organismal process 4.82E-05 
response to ionizing radiation 5.13E-05 
locomotion 5.19E-05 
regulation of cyclin-dependent protein kinase activity 5.76E-05 
G2 DNA damage checkpoint 5.87E-05 
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anatomical structure morphogenesis 6.15E-05 
nucleotide-excision repair, DNA incision, 5'-to lesion 6.42E-05 
response to peptide 6.58E-05 
regulation of centrosome cycle 6.58E-05 
regulation of cyclin-dependent protein serine/threonine kinase 
activity 6.80E-05 
regulation of cellular component movement 7.09E-05 
alcohol metabolic process 7.14E-05 
cell motility 7.17E-05 
sterol metabolic process 7.33E-05 
positive regulation of DNA-directed DNA polymerase activity 7.35E-05 
regulation of DNA-directed DNA polymerase activity 7.35E-05 
homeostatic process 7.58E-05 
regulation of microtubule-based process 7.66E-05 
regulation of phosphate metabolic process 7.93E-05 
regulation of phosphorus metabolic process 8.24E-05 
DNA-dependent DNA replication maintenance of fidelity 8.59E-05 
regulation of transferase activity 8.63E-05 
positive regulation of cell cycle process 8.73E-05 
regulation of response to stimulus 8.83E-05 
response to abiotic stimulus 9.07E-05 
cell migration 9.73E-05 
lipid metabolic process 9.78E-05 
positive regulation of cellular metabolic process 1.11E-04 
regulation of neurogenesis 1.16E-04 
chromatin remodeling at centromere 1.17E-04 
cellular response to organic substance 1.19E-04 
mitotic DNA integrity checkpoint 1.19E-04 
regulation of catalytic activity 1.21E-04 
response to stress 1.25E-04 
double-strand break repair via break-induced replication 1.27E-04 
regulation of nervous system development 1.28E-04 
organic hydroxy compound metabolic process 1.32E-04 
chromosome segregation 1.41E-04 
positive regulation of DNA replication 1.42E-04 
replication fork processing 1.51E-04 
mismatch repair 1.51E-04 
neuron projection guidance 1.58E-04 
response to nitrogen compound 1.58E-04 
regulation of centrosome duplication 1.60E-04 
cilium movement 1.60E-04 
response to mineralocorticoid 1.60E-04 
regulation of cell morphogenesis involved in differentiation 1.71E-04 
negative regulation of cell cycle process 1.78E-04 
negative regulation of cell proliferation 1.79E-04 
response to corticosterone 1.91E-04 
alcohol biosynthetic process 1.91E-04 
biological regulation 1.93E-04 
regulation of protein kinase activity 1.96E-04 
regulation of DNA repair 1.98E-04 
mitotic cell cycle checkpoint 2.01E-04 
negative regulation of pathway-restricted SMAD protein 
phosphorylation 2.05E-04 
tube development 2.10E-04 
negative regulation of cell differentiation 2.17E-04 
protein-DNA complex assembly 2.18E-04 
cellular response to chemical stimulus 2.22E-04 
negative regulation of cell communication 2.28E-04 
regulation of protein modification process 2.30E-04 
isoprenoid metabolic process 2.46E-04 
negative regulation of hemostasis 2.56E-04 
negative regulation of blood coagulation 2.56E-04 
cyclic-nucleotide-mediated signaling 2.56E-04 
regulation of centriole replication 2.63E-04 
axon guidance 2.68E-04 
negative regulation of signaling 2.69E-04 
CENP-A containing nucleosome assembly 2.77E-04 
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response to extracellular stimulus 3.02E-04 
anatomical structure formation involved in morphogenesis 3.06E-04 
cell proliferation 3.13E-04 
regulation of cell projection organization 3.21E-04 
regulation of microtubule cytoskeleton organization 3.22E-04 
negative regulation of phosphorus metabolic process 3.40E-04 
negative regulation of phosphate metabolic process 3.40E-04 
carbohydrate derivative catabolic process 3.48E-04 
regulation of cell migration 3.51E-04 
regulation of mitotic cell cycle phase transition 3.54E-04 
regulation of molecular function 3.76E-04 
organic substance metabolic process 3.76E-04 
response to organic cyclic compound 3.81E-04 
cholesterol metabolic process 3.95E-04 
mitotic DNA damage checkpoint 3.96E-04 
regulation of response to DNA damage stimulus 4.04E-04 
cell-substrate adhesion 4.04E-04 
negative regulation of coagulation 4.12E-04 
negative regulation of mitotic cell cycle phase transition 4.20E-04 
regulation of localization 4.31E-04 
DNA replication checkpoint 4.48E-04 
system development 4.57E-04 
meiotic cell cycle process 4.70E-04 
organic hydroxy compound biosynthetic process 4.88E-04 
epithelial tube morphogenesis 5.11E-04 
cellular response to peptide hormone stimulus 5.39E-04 
phosphate-containing compound metabolic process 5.52E-04 
negative regulation of phosphorylation 5.71E-04 
de novo centriole assembly 5.80E-04 
secondary alcohol metabolic process 6.00E-04 
regulation of locomotion 6.34E-04 
phosphorus metabolic process 6.64E-04 
regulation of organelle assembly 6.67E-04 
positive regulation of molecular function 6.78E-04 
cellular response to peptide 6.81E-04 
positive regulation of kinase activity 6.84E-04 
positive regulation of mitotic cell cycle 6.86E-04 
regulation of epithelial to mesenchymal transition 7.05E-04 
negative regulation of cell cycle phase transition 7.14E-04 
regulation of cilium assembly 7.25E-04 
regulation of peptide secretion 7.35E-04 
positive regulation of protein kinase activity 7.37E-04 
steroid biosynthetic process 7.37E-04 
nucleotide-excision repair 7.37E-04 
positive regulation of DNA-dependent DNA replication 7.46E-04 
regulation of insulin secretion 7.55E-04 
regulation of cell motility 7.86E-04 
cellular lipid metabolic process 8.12E-04 
cellular response to oxygen-containing compound 8.47E-04 
response to nutrient levels 8.57E-04 
regulation of peptide transport 8.87E-04 
regulation of cellular process 8.91E-04 
regulation of peptide hormone secretion 9.00E-04 
adipose tissue development 9.69E-04 
circulatory system process 9.73E-04 
histone exchange 9.78E-04 
inactivation of MAPK activity 9.79E-04 
response to organophosphorus 9.89E-04 
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Appendix Table 16. Canonical Pathways for DE genes from VCaP cells cultured in RPMI+DHT 
Ingenuity Canonical Pathways  -log(p-value) Ratio z-score 
EIF2 Signaling 28.10 4.85E-01 -5.547 
Regulation of eIF4 and p70S6K Signaling 11.30 3.69E-01 1.698 
Superpathway of Cholesterol Biosynthesis 8.50 6.43E-01 NaN 
mTOR Signaling 7.24 2.96E-01 1.789 
Axonal Guidance Signaling 7.00 2.41E-01 NaN 
Molecular Mechanisms of Cancer 5.64 2.38E-01 NaN 
Unfolded protein response 4.90 3.89E-01 NaN 
Cholesterol Biosynthesis I 4.87 6.92E-01 NaN 
Cholesterol Biosynthesis II (via 24,25-
dihydrolanosterol) 4.87 6.92E-01 NaN 
Cholesterol Biosynthesis III (via Desmosterol) 4.87 6.92E-01 NaN 
Cardiac β-adrenergic Signaling 4.35 2.81E-01 0.378 
CDK5 Signaling 4.20 3.03E-01 -0.577 
Cell Cycle: G2/M DNA Damage Checkpoint 
Regulation 3.90 3.67E-01 1.291 
tRNA Splicing 3.90 4.05E-01 NaN 
Relaxin Signaling 3.64 2.60E-01 NaN 
Superpathway of Geranylgeranyldiphosphate 
Biosynthesis I (via Mevalonate) 3.58 5.29E-01 NaN 
Neuregulin Signaling 3.53 2.95E-01 1.147 
Mitotic Roles of Polo-Like Kinase 3.44 3.18E-01 -1.807 
Caveolar-mediated Endocytosis Signaling 3.39 3.10E-01 NaN 
Basal Cell Carcinoma Signaling 3.30 3.06E-01 -2.065 
ATM Signaling 3.24 3.22E-01 0.243 
P2Y Purigenic Receptor Signaling Pathway 3.17 2.58E-01 -0.18 
Sonic Hedgehog Signaling 3.17 4.00E-01 -1.265 
Agrin Interactions at Neuromuscular Junction 3.15 3.04E-01 1.134 
Ephrin Receptor Signaling 3.14 2.41E-01 1.225 
Protein Kinase A Signaling 3.10 2.08E-01 0.855 
Breast Cancer Regulation by Stathmin1 3.01 2.32E-01 NaN 
Mevalonate Pathway I 2.94 5.38E-01 NaN 
Purine Nucleotides Degradation II (Aerobic) 2.93 4.50E-01 NaN 
Endoplasmic Reticulum Stress Pathway 2.74 4.29E-01 NaN 
Tetrahydrofolate Salvage from 5,10-
methenyltetrahydrofolate 2.68 8.00E-01 NaN 
Epithelial Adherens Junction Signaling 2.66 2.40E-01 NaN 
Glioma Signaling 2.64 2.55E-01 3.266 
Purine Nucleotides De Novo Biosynthesis II 2.61 5.45E-01 NaN 
IL-1 Signaling 2.56 2.64E-01 1.886 
Gustation Pathway 2.54 2.46E-01 NaN 
Virus Entry via Endocytic Pathways 2.50 2.55E-01 NaN 
5-aminoimidazole Ribonucleotide Biosynthesis I 2.49 1.00E+00 NaN 
NRF2-mediated Oxidative Stress Response 2.47 2.23E-01 3.4 
Remodeling of Epithelial Adherens Junctions 2.43 2.79E-01 1.414 
G Beta Gamma Signaling 2.42 2.61E-01 1.091 
Dopamine-DARPP32 Feedback in cAMP Signaling 2.39 2.28E-01 1.257 
Synaptic Long Term Potentiation 2.36 2.42E-01 1.3 
Small Cell Lung Cancer Signaling 2.35 2.62E-01 NaN 
Clathrin-mediated Endocytosis Signaling 2.30 2.18E-01 NaN 
GDP-glucose Biosynthesis 2.28 5.56E-01 NaN 
Folate Transformations I 2.28 5.56E-01 NaN 
UDP-N-acetyl-D-glucosamine Biosynthesis II 2.25 6.67E-01 NaN 
UVC-Induced MAPK Signaling 2.22 3.10E-01 1.941 
Non-Small Cell Lung Cancer Signaling 2.14 2.60E-01 1.807 
Gap Junction Signaling 2.13 2.20E-01 NaN 
Colorectal Cancer Metastasis Signaling 2.12 2.06E-01 0.885 
Oxidative Ethanol Degradation III 2.12 3.81E-01 NaN 
γ-linolenate Biosynthesis II (Animals) 2.12 4.12E-01 NaN 
Adenosine Nucleotides Degradation II 2.12 4.12E-01 NaN 
phagosome maturation 2.08 2.33E-01 NaN 
HGF Signaling 2.06 2.35E-01 1.8 
Glioblastoma Multiforme Signaling 2.04 2.20E-01 1.915 
Glucose and Glucose-1-phosphate Degradation 2.03 5.00E-01 NaN 
p53 Signaling 1.99 2.34E-01 -0.853 
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Corticotropin Releasing Hormone Signaling 1.99 2.34E-01 0.894 
Androgen Signaling 1.99 2.34E-01 0.258 
Role of NANOG in Mammalian Embryonic Stem 
Cell Pluripotency 1.98 2.30E-01 0.632 
Role of Tissue Factor in Cancer 1.98 2.30E-01 NaN 
Ovarian Cancer Signaling 1.97 2.22E-01 NaN 
Adenine and Adenosine Salvage III 1.94 5.71E-01 NaN 
Glutathione Redox Reactions II 1.94 7.50E-01 NaN 
Acetate Conversion to Acetyl-CoA 1.94 7.50E-01 NaN 
Stearate Biosynthesis I (Animals) 1.91 3.06E-01 NaN 
Pancreatic Adenocarcinoma Signaling 1.91 2.29E-01 1.706 
IL-8 Signaling 1.87 2.08E-01 2.466 
Reelin Signaling in Neurons 1.87 2.39E-01 NaN 
α-Adrenergic Signaling 1.85 2.41E-01 0.775 
Role of NFAT in Cardiac Hypertrophy 1.84 2.08E-01 2 
ErbB Signaling 1.83 2.35E-01 NaN 
Glycogen Degradation II 1.83 4.55E-01 NaN 
UDP-N-acetyl-D-galactosamine Biosynthesis II 1.83 4.55E-01 NaN 
Xenobiotic Metabolism Signaling 1.81 1.96E-01 NaN 
CXCR4 Signaling 1.79 2.12E-01 2.268 
Regulation of Cellular Mechanics by Calpain 
Protease 1.79 2.63E-01 1.265 
Cyclins and Cell Cycle Regulation 1.76 2.44E-01 0.5 
Aldosterone Signaling in Epithelial Cells 1.76 2.11E-01 1.789 
Integrin Signaling 1.71 2.01E-01 1.441 
ILK Signaling 1.70 2.04E-01 1.441 
Sphingosine and Sphingosine-1-phosphate 
Metabolism 1.69 5.00E-01 NaN 
Pyridoxal 5'-phosphate Salvage Pathway 1.66 2.50E-01 NaN 
Cell Cycle: G1/S Checkpoint Regulation 1.66 2.50E-01 -2.138 
GNRH Signaling 1.66 2.17E-01 2.268 
Epoxysqualene Biosynthesis 1.66 1.00E+00 NaN 
Wnt/β-catenin Signaling 1.64 2.07E-01 0 
Triacylglycerol Biosynthesis 1.64 2.73E-01 NaN 
Chondroitin Sulfate Biosynthesis (Late Stages) 1.64 2.65E-01 NaN 
IL-17A Signaling in Gastric Cells 1.63 3.20E-01 NaN 
Ethanol Degradation IV 1.63 3.20E-01 NaN 
Cellular Effects of Sildenafil (Viagra) 1.62 2.15E-01 NaN 
Endothelin-1 Signaling 1.62 2.03E-01 2.271 
NF-κB Activation by Viruses 1.62 2.33E-01 1.147 
Macropinocytosis Signaling 1.60 2.35E-01 0.277 
Sperm Motility 1.59 2.16E-01 1.4 
CMP-N-acetylneuraminate Biosynthesis I 
(Eukaryotes) 1.59 6.00E-01 NaN 
Trans, trans-farnesyl Diphosphate Biosynthesis 1.59 6.00E-01 NaN 
G-Protein Coupled Receptor Signaling 1.59 1.93E-01 NaN 
Ephrin A Signaling 1.59 2.50E-01 NaN 
Antioxidant Action of Vitamin C 1.59 2.23E-01 -2.357 
BMP signaling pathway 1.58 2.37E-01 0.243 
Signaling by Rho Family GTPases 1.57 1.94E-01 1.441 
Renin-Angiotensin Signaling 1.57 2.17E-01 NaN 
Gαs Signaling 1.56 2.20E-01 -0.655 
CREB Signaling in Neurons 1.53 2.01E-01 0 
Dopamine Receptor Signaling 1.53 2.34E-01 -0.302 
RAR Activation 1.52 2.00E-01 NaN 
HER-2 Signaling in Breast Cancer 1.52 2.27E-01 NaN 
Germ Cell-Sertoli Cell Junction Signaling 1.51 2.02E-01 NaN 
Prostate Cancer Signaling 1.49 2.23E-01 NaN 
MIF Regulation of Innate Immunity 1.49 2.68E-01 1.508 
Glycogen Degradation III 1.49 3.85E-01 NaN 
Guanosine Nucleotides Degradation III 1.49 3.85E-01 NaN 
Assembly of RNA Polymerase I Complex 1.49 4.44E-01 NaN 
Ketolysis 1.49 4.44E-01 NaN 
cAMP-mediated signaling 1.47 1.95E-01 -0.801 
Rac Signaling 1.46 2.14E-01 2.041 
Ephrin B Signaling 1.45 2.33E-01 -1 
STAT3 Pathway 1.45 2.33E-01 2.183 
Aryl Hydrocarbon Receptor Signaling 1.45 2.07E-01 0.229 
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Cell Cycle Control of Chromosomal Replication 1.43 2.96E-01 NaN 
ERK/MAPK Signaling 1.42 1.96E-01 1.441 
Ethanol Degradation II 1.42 2.70E-01 NaN 
PCP pathway 1.41 2.38E-01 0 
Gα12/13 Signaling 1.40 2.08E-01 3.138 
Paxillin Signaling 1.40 2.12E-01 2.236 
Chondroitin Sulfate Biosynthesis 1.40 2.41E-01 NaN 
PTEN Signaling 1.38 2.10E-01 -2.449 
Putrescine Degradation III 1.37 3.04E-01 NaN 
Role of Macrophages, Fibroblasts and 
Endothelial Cells in Rheumatoid Arthritis 1.36 1.84E-01 NaN 
p70S6K Signaling 1.36 2.06E-01 0.962 
Urate Biosynthesis/Inosine 5'-phosphate 
Degradation 1.35 3.57E-01 NaN 
Colanic Acid Building Blocks Biosynthesis 1.35 3.57E-01 NaN 
LPS-stimulated MAPK Signaling 1.35 2.21E-01 2.065 
Zymosterol Biosynthesis 1.34 5.00E-01 NaN 
Circadian Rhythm Signaling 1.34 2.73E-01 NaN 
Myc Mediated Apoptosis Signaling 1.33 2.29E-01 NaN 
Ketogenesis 1.32 4.00E-01 NaN 
Calcium Transport I 1.32 4.00E-01 NaN 
fMLP Signaling in Neutrophils 1.31 2.07E-01 1.706 
Note: Ranked by –log (p-value), -log (p-value) > 1.3 is significant, Ratio (target genes/IPA identified pathway genes), a 
positive z-score indicates the pathway is activated, a negative z-score indicates the pathway is inactivated, a 0 z-score 
indicates the pathway is neither activated or inactivated, NaN indicates it is by the IPA database if the result indicates an 
activation or inactivation state. 
 
Appendix Table 17. Top 10* Canonical Pathways for HCM cultured VCaP cells ranked by -log (p-value) (Table for 
Figure 4.18) 
Ingenuity Canonical Pathways -log (p-value) z-score Ratio 
Role of BRCA1 in DNA Damage Response 10.5 2.236 29/78 
Cell Cycle Control of Chromosomal Replication 9.75 NaN 16/27 
Superpathway of Cholesterol Biosynthesis 8.34 NaN 15/28 
Mismatch Repair in Eukaryotes 7.84 NaN 11/16 
Role of CHK Proteins in Cell Cycle Checkpoint 
Control 7.25 1.508 20/55 
Hereditary Breast Cancer Signalling 5.58 NaN 30/129 
ATM Signalling 5.32 3.357 18/59 
Superpathway of Geranylgeranyldiphosphate 
Biosynthesis I (via Mevalonate) 4.16 NaN 7/13 
nNOS Signalling in Neurons 4.14 -0.816 14/47 
Sperm Motility 3.86 -0.655 25/121 
Note: A positive z-score indicates the pathway is activated, a negative z-score indicates the pathway is 
inactivated, NaN indicates it is unknown to IPA pathway activation or inactivation state, the higher or lower the 
z-score the great activation or inactivation, significance is determined by – log (p-value) > 1.3, *See Appendix 
Table 10 
 
Appendix Table 18. Canonical Pathways that share all DE genes with Superpathway of Cholesterol Biosynthesis 
for VCaP cells treated in HCM. Ranked by –log (p-value)  
Canonical Pathways  -log (p-value) ratio z-score 
Cholesterol Biosynthesis I 4.17  7/13 NaN 
Mevalonate Pathway I 4.17 7/13 NaN 
Cholesterol Biosynthesis II (via 24,25-dihydrolanosterol) 4.17 7/13 NaN 
Cholesterol Biosynthesis III (via Desmosterol) 4.17 7/13 NaN 
Ketogenesis 2.9 5/10 NaN 
Note: -log (p-value) > 1.3 is significant, Ratio (target genes/IPA identified pathway genes); A positive z-score indicates the 
pathway is activated, a negative z-score indicates the pathway is inactivated, a 0 z-score indicates the pathway is neither 
activated or inactivated, NaN indicates it is unknown to IPA pathway activation or inactivation state. 
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Appendix Table 19. Canonical Pathways for HCM cultured VCaP cells with significant or near significant z-
scores. (Table for Figure 4.19) 
Ingenuity Canonical Pathways -log (p-value) z-score Ratio 
ATM Signalling 5.32 3.357 18/59 
Estrogen-mediated S-phase Entry 2.27 2.646 7/24 
Role of BRCA1 in DNA Damage Response 10.5 2.236 29/78 
AMPK Signalling 1.54 -1.886 26/186 
Cardiac β-adrenergic Signalling 2.18 -2.183 22/133 
Protein Kinase A Signalling 3.34 -2.429 59/399 
Note: a positive z-score indicates the pathway is activated, a negative z-score indicates the pathway 
is inactivated, NaN indicates it is unknown to IPA pathway activation or inactivation state, the higher 
or lower the z-score the great activation or inactivation, significance is determined by – log (p-value) 
> 1.3 
 
 
Appendix Table 20. Top 10 Canonical Pathways for genes common between VCaP cells cultured in HCM treated 
+/- DHT and in RPMI + DHT. (Table for Figure 4.22) 
Canonical Pathways  -log (p-
value) z-score Ratio 
Cell Cycle Control of Chromosomal Replication 4.93 NaN 5/27 
Role of BRCA1 in DNA Damage Response 2.72 2 5/78 
Pyrimidine Deoxyribonucleotides De Novo Biosynthesis I 2.67 NaN 3/23 
Guanosine Nucleotides Degradation III 2.04 NaN 2/13 
DNA Double-Strand Break Repair by Homologous 
Recombination 1.97 NaN 2/14 
Urate Biosynthesis/Inosine 5'-phosphate Degradation 1.97 NaN 2/14 
Adenosine Nucleotides Degradation II 1.81 NaN 2/17 
Cell Cycle: G2/M DNA Damage Checkpoint Regulation 1.74 NaN 3/49 
Purine Nucleotides Degradation II (Aerobic) 1.67 NaN 2/20 
Glutamate Biosynthesis II 1.65 NaN 1/2 
Note: a positive z-score indicates the pathway is activated, a negative z-score indicates the pathway 
is inactivated, NaN indicates it is unknown to IPA pathway activation or inactivation state, the higher 
or lower the z-score the great activation or inactivation, significance is determined by – log (p-value) 
> 1.3 
 
Appendix Table 21. 497 common VCaP Genes between (HCM vs RPMI) & (RPMI+DHT vs RPMI) 
Genes HCM vs RPMI RPMI+DHT vs RPMI 
RP11-599B13.9 136.824 191.641 
ETV5 120.125 -39.125 
HSD17B2 84.979 57.502 
SLC5A1 78.302 48.814 
PLA2G4E 69.21 492.483 
ITGB3 49.112 28.826 
PSORS1C1 34.765 28.117 
NRGN 23.876 -5.737 
INSIG1 18.678 34.837 
HES1 15.293 31.912 
DNAH7 15.113 8.163 
LIPG 14.852 13.016 
ABCG2 14.661 6.231 
CDKN2B 14.657 5.839 
PHOSPHO1 13.4 48.51 
NPR1 13.322 16.681 
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EPHA7 11.721 8.564 
LINC00883 11.455 3.235 
EFEMP1 11.31 17.472 
STARD4 11.091 27.543 
LMO2 10.909 -12.343 
MAK 10.378 11.393 
CPM 9.865 5.728 
IER5 9.747 -4.233 
PLEKHD1 9.7 8.533 
C3orf14 9.69 51.46 
PPIC 9.54 3.703 
NPPC 9.038 19.646 
SEMA3C 8.54 8.749 
TESC 7.927 7.621 
HMGCS1 7.867 10.63 
TBXAS1 7.832 6.216 
HIST2H2AC 7.62 6.428 
MED12L 7.534 4.281 
C4orf19 7.349 4.167 
CITED1 7.213 15.115 
HLA-DQB1 7.178 -10.662 
LINC00263 7.053 24.424 
GDF15 6.858 10.508 
RARB 6.853 5.192 
FAM129A 6.512 3.162 
RP11-91J19.3 6.455 6.495 
SPRED1 6.329 3.505 
CYP46A1 6.133 3.309 
SCD 6.013 7.995 
MVD 5.939 3.804 
ANKRD42 5.847 3.607 
ASPHD2 5.712 4.935 
CHST2 5.696 5.449 
EBP 5.517 5.479 
RP11-303E16.2 5.502 6.139 
MITF 5.497 3.918 
SLC12A2 5.426 3.957 
CASC5 5.403 -3.695 
TNFRSF19 5.397 7.036 
LINC00472 5.278 3.623 
NEIL3 5.212 -5.937 
ZNF703 5.09 2.566 
B3GNT2 5.01 9.01 
SKA3 4.94 -3.414 
UBTD1 4.923 3.857 
NCAPH 4.874 -2.804 
ATRNL1 4.843 5.433 
C16orf93 4.817 3.049 
RP11-150O12.3 4.783 5.859 
ANXA2 4.752 5.674 
MPV17L2 4.703 2.893 
SOX9 4.701 3.698 
CCDC15 4.66 2.777 
MSMO1 4.614 10.899 
BHLHE40 4.536 2.309 
TNFAIP8 4.442 3.194 
DNAJB5 4.431 2.668 
RP11-680F8.3 4.269 5.208 
GDA 4.24 4.21 
CENPI 4.108 -4.331 
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WDR62 4.106 -3.21 
SQLE 4.08 3.715 
FDFT1 4.004 3.824 
STOX1 3.908 -4.697 
RAB9B 3.827 2.632 
FOXM1 3.809 -3.112 
P4HA2 3.761 6.471 
MANF 3.706 2.733 
DHCR7 3.684 3.078 
FZD1 3.672 4.807 
KIAA0513 3.672 4.203 
POPDC3 3.636 3.144 
GSG2 3.633 -3.326 
KIF18B 3.578 -3.713 
MYCL 3.57 3.795 
GLIPR2 3.499 5.609 
BAHD1 3.449 1.789 
SERTAD4 3.446 -3.453 
CENPN 3.445 5.808 
CYB5B 3.444 2.188 
AP4E1 3.443 4.283 
GK 3.415 1.81 
CCND1 3.408 2.842 
FAM151B 3.4 3.359 
WDR66 3.394 4.497 
CETN2 3.392 2.1 
CCDC69 3.376 2.945 
MORN2 3.361 2.624 
KIF20B 3.34 -2.919 
CCNE1 3.332 -3.186 
CYP51A1 3.277 3.234 
MIDN 3.222 1.864 
MTCL1 3.194 3.3 
ACAT2 3.163 3.038 
C1orf210 3.136 2.473 
EHD4 3.128 3.515 
CNKSR2 3.123 4.972 
SGK3 3.113 2.306 
STK17A 3.092 2.43 
KIAA1841 3.091 3.506 
FAM118B 3.087 1.971 
HABP4 3.08 2.711 
SLC1A4 3.074 2.719 
CCND3 3.071 2.508 
INCENP 3.058 -2.662 
ZNF519 3.055 -2.938 
FDPS 3.041 3.5 
ZDHHC16 3.038 2.582 
DGKH 3.033 -4.139 
AC018766.4 3.024 2.897 
ABCA7 3.008 2.878 
PARPBP 2.992 -3.223 
C5orf34 2.932 -3.697 
HMGCR 2.925 4.151 
GDF11 2.821 1.961 
KIAA1524 2.803 -2.912 
DYNC1I1 2.774 5.473 
PDK3 2.752 2.634 
MARVELD3 2.75 4.431 
FGFR1 2.715 2.052 
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CLGN 2.691 6.615 
JAG1 2.612 2.12 
GREB1L 2.612 -2.178 
TAOK3 2.61 3.416 
PBX3 2.562 1.922 
DBF4B 2.56 -2.465 
PLA2G16 2.548 2.283 
PDIA4 2.547 2.638 
ZNF487 2.542 2.688 
AAGAB 2.528 2.458 
DNAJB11 2.526 3.019 
STK17B 2.477 3.929 
IFT22 2.442 2.109 
NPC1 2.419 2.297 
STK33 2.413 -5.092 
GCH1 2.411 6.86 
TEX2 2.373 3.137 
ANXA5 2.35 3.203 
ACVR1 2.329 2.206 
RRBP1 2.309 4.281 
MORC4 2.292 2.915 
TJP2 2.29 3.071 
TTC30B 2.286 2.046 
HYOU1 2.285 2.607 
PKP4 2.279 -2.559 
MMD 2.274 2.516 
SORT1 2.27 1.676 
KAT2B 2.266 3.308 
STX3 2.259 2.482 
FNIP2 2.252 1.936 
TUBB4B 2.238 3.216 
CDK2AP2 2.232 2.998 
TUBG1 2.222 3.737 
WDR19 2.221 -2.571 
GMPPB 2.206 4.202 
PHTF1 2.199 3.413 
MPHOSPH9 2.186 3.284 
CCDC34 2.18 -2.002 
PI4K2A 2.179 1.761 
ENTPD7 2.175 3.881 
PIK3R3 2.165 2.018 
SUCO 2.158 3.112 
CHSY1 2.155 3.66 
PAQR4 2.152 3.194 
CREB3L2 2.148 2.834 
ITGA3 2.136 3.144 
GRK5 2.099 3.238 
LRCH4 2.085 2.091 
GOT1 2.078 2.104 
SPDL1 2.065 -1.965 
PDIA6 2.034 2.202 
SYNE2 2.02 2.684 
TMEM19 1.977 2.36 
RSPH3 1.97 1.818 
SNX19 1.955 2.183 
SLC31A1 1.949 2.301 
ACSS2 1.943 1.909 
TMEM1 1.941 1.828 
ZNF682 1.939 1.997 
USP6NL 1.924 2.11 
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ZFYVE19 1.912 1.846 
C14orf1 1.903 2.052 
STPG1 1.901 2.325 
CALM1 1.891 3.021 
KIAA1522 1.862 1.898 
NEO1 1.849 1.683 
ZSWIM8 1.837 2.308 
OGDH 1.814 2.747 
MYO9B 1.788 1.618 
FUT11 1.779 1.946 
RPN1 1.771 2.576 
ZNF701 1.764 1.896 
ZNF589 1.762 2.622 
DLG5 1.75 1.875 
NEK4 1.724 1.611 
ARPC5 1.709 1.621 
HIATL1 1.692 1.702 
MAGT1 1.682 2.087 
WDR1 1.617 1.75 
ELMOD2 1.612 1.647 
C1QBP -1.547 -1.746 
TRUB2 -1.607 -1.815 
SUPV3L1 -1.675 -1.767 
CYP4V2 -1.718 -1.892 
ESD -1.749 -1.65 
REXO2 -1.756 -1.865 
RPS13 -1.858 -3.006 
TOMM20 -1.86 -2.124 
KIF13A -1.862 2.884 
ADAM10 -1.863 1.881 
MAPKAPK5-AS1 -1.891 -1.654 
MRRF -1.896 -2.48 
XBP1 -1.916 2.65 
BCKDHB -1.917 -1.724 
ACOT13 -1.921 2.206 
GABPB1-AS1 -1.925 -3.159 
MRPL15 -1.947 -1.982 
HSPD1 -1.978 -1.883 
PARVA -1.979 2.165 
PCBD2 -1.985 -2.02 
HDGF -2 -2.107 
RSL1D1 -2.02 -2.607 
TTC12 -2.036 3.267 
AMER1 -2.066 -3.873 
FAM134B -2.072 -1.724 
TTC27 -2.079 -2.11 
CD97 -2.088 -2.228 
RP11-3P17.3 -2.12 -2.782 
RCCD1 -2.122 -2.675 
KAT2A -2.132 -2.92 
RP11-379H18.1 -2.134 -1.984 
RPS23 -2.146 -3.588 
RILPL1 -2.157 -1.71 
TYSND1 -2.205 -2.743 
THEM4 -2.208 -2.531 
RPL41 -2.223 -2.322 
RPL22 -2.229 -2.95 
SLC25A25-AS1 -2.241 -2.728 
RPL30 -2.26 -2.703 
PRKD1 -2.273 -1.863 
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CNDP2 -2.333 2.127 
FOXN3 -2.338 -2.243 
POLR2I -2.349 -2.664 
SYT17 -2.365 1.977 
C15orf52 -2.381 2.294 
SNX22 -2.403 -2.124 
TMEM136 -2.405 -1.932 
BBS4 -2.414 2.311 
POLR2M -2.421 -3.469 
GLTSCR2 -2.436 -4.904 
NACA -2.45 -2.355 
KB-431C1.4 -2.47 -2.815 
RPL10A -2.475 -3.938 
RP11-136K7.2 -2.508 2.274 
SEPT7P2 -2.522 -3.473 
EIF3J-AS1 -2.534 -2.184 
MCTP1 -2.534 -4.133 
LRRC37A3 -2.56 -2.925 
TTC39A -2.57 2.514 
SNHG8 -2.586 -2.564 
PTCH1 -2.591 -3.49 
C5orf30 -2.592 -2.851 
CBR4 -2.62 -2.938 
CAMKK1 -2.622 -3.182 
PSD4 -2.627 -1.92 
RASA3 -2.632 -2.666 
NDRG2 -2.633 -2.146 
DDX31 -2.637 -1.837 
LTB4R -2.662 -3.102 
C11orf95 -2.69 -2.505 
RARG -2.693 -2.727 
LINC00869 -2.693 -3.271 
RPS18 -2.742 -4.227 
DUXAP8 -2.748 -4.341 
CTC-459F4.3 -2.749 -1.895 
NEFL -2.767 -2.42 
RP11-159N11.4 -2.768 3.741 
CLMN -2.8 -2.289 
CD101 -2.855 -2.79 
NRXN1 -2.866 -4.419 
LHX6 -2.93 -4.01 
SNHG20 -2.938 -2.618 
RPL3 -2.956 -3.56 
CCDC78 -2.968 -3.427 
N4BP3 -2.992 -2.882 
COL6A1 -2.996 -3.473 
FAM47E-STBD1 -3.002 -2.164 
DGAT2 -3.033 -2.437 
KCNJ12 -3.054 -3.285 
PRKAR1B -3.073 -4.935 
PCDHB15 -3.074 -4.241 
TNRC6C-AS1 -3.085 2.811 
C5orf66 -3.088 -5.248 
LRRC75A-AS1 -3.175 -5.342 
EDA -3.185 -2.915 
DIXDC1 -3.2 -4.235 
EBPL -3.243 -2.151 
CMBL -3.283 -4.58 
RP11-16P6.1 -3.341 -3.435 
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UNC93B1 -3.359 -3.593 
SFTPA2 -3.37 -1.813 
BMF -3.414 -2.653 
DPY19L2 -3.417 -4.692 
INPP4B -3.492 3.34 
ZNF276 -3.512 -2.68 
RGS11 -3.513 -2.867 
NEIL1 -3.528 -5.7 
BFSP1 -3.531 -3.935 
BZRAP1 -3.581 -3.251 
HAGHL -3.61 -2.935 
DLGAP1-AS1 -3.625 -5.338 
CDH26 -3.631 -10.077 
PLEKHN1 -3.646 -2.489 
BTN3A1 -3.797 -3.419 
TGIF2 -3.97 -3.929 
RP11-178H8.7 -3.972 -2.605 
SNED1 -3.989 -2.299 
TDP2 -4.003 2.592 
MOCOS -4.003 -5.176 
PLK2 -4.027 -8.458 
PNMA3 -4.052 -6.142 
RP5-912I13.1 -4.073 -4.147 
ABHD1 -4.115 -3.754 
WNT2B -4.134 -6.668 
PPP1R26-AS1 -4.146 -2.736 
RP11-1391J7.1 -4.263 -5.412 
AC093642.1 -4.334 -5.089 
LINC01138 -4.4 -2.728 
C1QL4 -4.435 -15.246 
FGD3 -4.44 -9.254 
RP11-279F6.1 -4.459 2.595 
DHRS7 -4.509 -1.943 
MESP1 -4.514 5.672 
C1QTNF6 -4.545 -6.274 
BZRAP1-AS1 -4.554 -4.412 
SLC26A10 -4.627 -3.821 
LGI1 -4.685 4.73 
RP11-713C5.1 -4.736 -3.005 
RP11-159D12.2 -4.762 -2.872 
IMMP2L -4.784 -2.682 
DNAH5 -4.828 -2.31 
NTN4 -4.934 -4.079 
RP11-1020A11.2 -4.935 -8.715 
SUSD5 -4.937 -4.759 
RASA4 -4.988 -3.662 
PCNXL4 -5.028 -4.257 
LINC01341 -5.038 -3.091 
WASIR2 -5.096 -5.949 
PRAC1 -5.104 -3.831 
DACT2 -5.108 -4.455 
GAL -5.117 -3.513 
CIART -5.134 -5.091 
ATG9B -5.177 -5.794 
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BAMBI -5.369 -3.958 
GRIN1 -5.415 -4.954 
GARNL3 -5.483 -1.935 
CH17-125A10.2 -5.52 -8.156 
AL133493.2 -5.628 -10.053 
LIN7A -5.897 -3.794 
TMEM51-AS1 -5.921 -24.671 
RP11-339B21.8 -5.932 -6.312 
AIFM3 -5.94 -4.613 
RP11-289H16.1 -5.971 -6.089 
ITGB2 -5.985 -11.265 
RASGRF1 -6.098 -2.757 
FXYD3 -6.166 2.857 
LEPREL1 -6.28 -3.18 
EPB41L3 -6.287 -15.73 
AC011298.2 -6.299 -5.884 
CTC-459F4.1 -6.336 -5.461 
PLXNA4 -6.466 -5.989 
ATP8A1 -6.593 -2.779 
RP11-467L19.16 -6.677 6.379 
VSTM2L -6.835 -3.009 
FAM184B -6.883 -6.238 
NYNRIN -6.962 -4.814 
ANKRD65 -6.996 -2.852 
TRIM38 -7.235 -7.617 
METTL21B -7.265 -2.581 
DSEL -7.31 -4.26 
ABCC6P1 -7.461 -5.464 
GC -7.491 -25.098 
ALB -7.509 -42.185 
CYP4F26P -7.665 -7.875 
RP11-664D7.4 -7.684 -8.012 
SMTNL2 -7.823 -16.91 
PNMA6A -7.913 -7.274 
RIN3 -8.208 -5.934 
NHLRC4 -8.413 -8.395 
LUZP2 -8.433 -6.684 
RP11-627G23.1 -8.619 -2.336 
ANXA3 -8.621 -2.884 
GLIPR1 -9.285 -13.818 
FAM101A -9.354 -6.298 
GPC6 -9.368 -3.88 
CNRIP1 -9.383 -8.446 
CECR1 -9.57 -6.197 
LRRC31 -9.653 -5.672 
LPXN -9.66 3.195 
SELENBP1 -10.017 -6.343 
HOPX -10.03 -17.599 
SLC6A4 -10.286 -65.692 
ADORA2B -10.408 -5.887 
TRIM71 -10.446 -38.121 
CTD-2541J13.2 -10.525 -11.406 
POU5F1B -10.538 -36.705 
ABCC3 -10.596 -11.512 
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LRFN2 -11.019 -51.448 
ABCB5 -11.092 -14.23 
NOS1 -11.352 -9.066 
RP5-1056H1.2 -11.485 -10.288 
RP11-54O7.16 -12.274 -18.727 
RP11-809C18.4 -12.333 -18.666 
CDH10 -12.493 -8.843 
LAMC3 -12.63 -26.182 
RAMP2-AS1 -12.764 -7.832 
FAM222A-AS1 -12.889 -11.901 
PIWIL2 -13.019 -228.033 
GPR110 -13.064 -8.082 
SLC30A10 -13.088 -13.7 
TNFRSF18 -13.258 -6.562 
ARHGDIG -13.343 -4.974 
RP11-1069G10.1 -13.343 -7.914 
MEGF10 -13.639 -26.613 
PLA2G2A -13.837 -39.714 
CPNE7 -15.38 -9.905 
CTA-246H3.12 -16.118 -6.602 
RP4-799P18.2 -16.34 -85 
DNAH11 -16.508 -4.132 
RNF212 -16.518 -12.942 
SPATA3-AS1 -17.24 -18.365 
HMGN2P15 -17.667 -92.058 
RP11-763B22.6 -19.278 -15.318 
COL9A1 -19.309 -8.757 
SLC26A4-AS1 -19.55 -21.043 
CD200 -19.628 -12.281 
HSPA12B -20.282 -4.066 
IGHG3 -20.451 -11.767 
LPPR3 -20.756 -15.117 
ERP27 -20.85 -20.999 
GPR133 -21.172 -13.828 
MXRA8 -22.087 -12.394 
PPFIA2 -22.676 -32.613 
NEB -23.251 -11.674 
IGFBP3 -23.921 -31.349 
AQP12B -24.273 -6.344 
BMX -25.225 -9.01 
DNAH8 -25.464 10.571 
AP000473.8 -26.91 -4.88 
PDIA2 -27.634 -7.467 
ACSS3 -27.926 -15.125 
NTS -32.581 -42.031 
ATP2B2 -33.415 -9.654 
LA16c-381G6.1 -34.362 -12.999 
PDE6B -36.858 -18.543 
RP11-231E6.1 -39.633 -78.575 
TRIM29 -40.455 -7.443 
EPYC -42.003 -42.003 
RP11-90K6.1 -43.098 -17.533 
VWA5B1 -44.642 -7.472 
TRIM49 -47.049 -48.365 
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Appendix 
Table 22. 
Top 10 
Canonical 
Pathways 
for VCaP 
Androgen 
Sensitive 
Genes 
Upregulate
d in HCM 
that are 
insensitive 
to 
additional 
DHT 
Treatment. 
(Table for 
Figure 4.24) 
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(
p
-
v
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l
u
e
) 
z
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r
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R
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1
/
2
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4
.
8
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N
a
N 
5
/
1
7 
PDE7B -47.05 -47.05 
DNAJC15 -50.272 -15.671 
CSPG4P5 -56.253 -56.253 
DAPL1 -61.925 -61.925 
RP13-379L11.1 -80.174 5.379 
ZNF503-AS1 -92.533 -18.649 
B3GNT6 -99.482 -99.482 
AGBL1 -109.308 -109.308 
KCNMB2 -111.31 -9.192 
ZPBP2 -115.743 -115.743 
RP11-54O7.2 -123.16 -123.16 
OLFM4 -123.239 -15.517 
A1CF -143.386 -19.344 
UBTFL1 -164.323 -164.323 
MEP1A -246.434 -49.57 
ADH1B -343.091 -69.217 
UGT2B17 -356.5 -356.5 
ISLR2 -553.811 -111.609 
RP11-315E17.1 -719.563 -719.563 
TRIM49D1 -1468.29 -10.772 
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Note: -log 
(p-value) > 
1.3 is 
significant, 
Ratio 
(target 
genes/IPA 
identified 
pathway 
genes), 
Ranked by 
Ranked by 
HCMvRPMI  
–log (p-
value). 
A positive 
z-score 
indicates 
the 
pathway is 
activated, a 
negative z-
score 
indicates 
the 
pathway is 
inactivated, 
a 0 z-score 
indicates 
the 
pathway is 
neither 
activated 
or 
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inactivated, 
NaN 
indicates it 
is unknown 
to IPA 
pathway 
activation 
or 
inactivation 
state. 
 
Appendix Table 23.  274 genes common between LNCaP and VCaP cells treated in HCM, excluding androgen 
and insulin regulated genes. 
Ranked by LNCaP HCM vs RPMI FC 
Genes LNCaP HCM vs RPMI VCaP HCM vs RPMI 
CXCL8 429.028 18.474 
PLEKHA4 269.604 16.509 
ETV4 231.306 187.333 
TIMP1 121.484 32.455 
ADAMTS6 101.484 191.38 
GSDMA 88.847 459.48 
TRGV9 84.696 -6.637 
MMP10 81.394 6.235 
A2M 76.792 7126.989 
DACT1 74.538 13.824 
EGR2 58.305 120.082 
METTL7B 41.427 1196.6 
TRGC1 30.507 -6.8 
EGR3 26.618 14.33 
ETV5 24.888 120.125 
FOS 24.194 10.088 
HPGD 23.786 -9.46 
LMO2 22.085 10.909 
GCNT3 20.451 12.252 
DUSP6 16.543 41.913 
APOH 16.465 -6.653 
CHRM3 15.758 960.34 
CADPS2 15.748 3.189 
PIP5K1B 12.964 29.213 
NTNG2 12.127 -5.847 
PKHD1 9.588 -6.177 
TLE4 8.912 4.602 
CLDN1 8.716 11.165 
HIST2H3C 8.439 20.839 
HIST2H3A 8.439 20.839 
DNER 8.049 13.583 
CDKN2B-AS1 7.748 88.123 
CDH7 6.862 3.308 
PHLDA2 6.536 2.778 
C14orf37 6.378 5.066 
LY6G6C 6.374 28.316 
UBASH3B 6.154 6.308 
AKAP2 5.839 -3.742 
ATF3 5.485 5.827 
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KLKP1 4.885 -2.788 
SHC4 4.703 5.077 
CENPI 4.478 4.108 
LPIN1 4.315 1.718 
EME1 4.089 6.127 
GSG2 4.037 3.633 
FDPS 4.001 3.041 
NRCAM 3.803 4.412 
HYDIN 3.746 4.804 
LCA5L 3.729 4.1 
NRXN3 3.675 3.656 
KIF24 3.613 8.351 
NFKB2 3.577 2.092 
MALL 3.529 6.262 
MVD 3.286 5.939 
SPRED1 3.221 6.329 
C5orf34 3.132 2.932 
ACAT2 3.071 3.163 
SGK1 3.034 3.633 
PGD 3.031 2.133 
C19orf26 3.023 3.986 
GGCT 2.98 2.206 
ZWILCH 2.955 3.9 
PRIM1 2.925 3.051 
RFC4 2.886 5.854 
GADD45A 2.85 5.077 
ACSS2 2.839 1.943 
ATP8B2 2.809 2.16 
CYP51A1 2.78 3.277 
CENPP 2.742 4.907 
JPH1 2.7 2.576 
CCDC18 2.699 4.302 
SPRED2 2.505 3.04 
GUCY1B3 2.46 3.327 
SLC1A4 2.437 3.074 
IL6R 2.395 2.866 
CKS1B 2.368 3.721 
ICOSLG 2.334 1.879 
KPNA2 2.306 2.453 
JUND 2.254 2.19 
GK 2.225 3.415 
SNRPA1 2.105 1.613 
UCHL3 2.075 1.79 
JOSD1 1.94 1.747 
PDE4DIP 1.908 1.788 
SLC27A2 1.887 2.086 
EZH2 1.857 4.33 
INTS7 1.812 2.539 
TMEM97 1.802 2.036 
GOT1 1.767 2.078 
UBR7 1.621 1.701 
HBP1 -1.663 -1.634 
CACNA1H -1.734 -2.296 
BTG1 -1.735 1.883 
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C1RL -1.82 -1.779 
TMEM59 -1.872 -1.766 
ALAD -1.91 1.654 
RWDD2A -1.912 -3.509 
SKAP2 -1.977 1.89 
TMEM50B -2.029 2.583 
RP11-983P16.4 -2.111 -2.233 
INPP5A -2.133 -2.325 
PIK3R3 -2.162 2.165 
CHD3 -2.187 -2.888 
RAP1GAP2 -2.223 -2.534 
GTF2IP1 -2.251 -1.933 
SQRDL -2.278 -2.12 
C20orf194 -2.367 -3.059 
CASZ1 -2.385 -2.157 
KIAA1467 -2.405 -3.606 
RP11-517B11.7 -2.446 -2.75 
AC013394.2 -2.509 -1.858 
DHRS7 -2.518 -4.509 
OSBP2 -2.521 -2.424 
PRKG2 -2.53 -10.183 
FAM134B -2.55 -2.072 
GLIDR -2.553 -2.836 
FRAT2 -2.56 -2.534 
EEF1A2 -2.573 -3.238 
DGAT2 -2.591 -3.033 
SHANK2 -2.601 -2.893 
RP11-216L13.19 -2.631 -4.333 
GALNT3 -2.666 -1.904 
TMC4 -2.725 -3.041 
LTB4R -2.728 -2.662 
NCALD -2.765 -2.326 
CTD-2377D24.4 -2.81 -3.6 
INHBB -2.877 -3.936 
NDUFB4 -2.906 -2.32 
LRP1 -2.933 -2.763 
CA12 -2.935 -2.803 
GARNL3 -2.951 -5.483 
KRTAP5-AS1 -2.966 -3.058 
RP3-414A15.12 -2.967 -2.995 
CABLES1 -3.128 -5.067 
ZNF185 -3.131 -2.684 
ATP8A1 -3.319 -6.593 
NETO1 -3.362 -4.059 
RGS11 -3.382 -3.513 
MAPRE2 -3.433 2.934 
TMEM229B -3.452 -3.151 
C15orf52 -3.532 -2.381 
LINC01138 -3.545 -4.4 
CTD-2626G11.2 -3.573 -3.684 
PCDHB15 -3.699 -3.074 
FFAR2 -3.792 -3.768 
TEAD2 -3.815 7.108 
CWH43 -4.085 -2.523 
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ELFN2 -4.108 -7.125 
BZRAP1 -4.236 -3.581 
BCAS1 -4.239 -21.876 
RTN1 -4.239 -3.589 
BOC -4.297 -3.878 
EFCAB11 -4.386 -2.56 
GATS -4.413 -2.456 
ADRBK2 -4.553 -2.12 
MYT1 -4.701 -2.057 
MEX3A -4.873 -2.919 
MFSD4 -4.927 -2.701 
RCAN3 -5.031 -2.004 
MTURN -5.194 -3.355 
PIK3IP1 -5.213 -14.46 
FBLN2 -5.3 -13.308 
RP11-396K3.1 -5.316 -2.973 
AP001626.2 -5.383 -11.037 
PLLP -5.387 -3.049 
TIMP2 -5.401 -2.658 
RTN4RL1 -5.504 -5.894 
TTR -5.645 -3.587 
ARHGDIG -5.779 -13.343 
NKPD1 -6.026 -4.617 
SAMD11 -6.069 -9.593 
MB -6.538 -2.368 
FSTL1 -6.652 -4.1 
ODAM -6.717 5.548 
A1CF -7.12 -143.386 
EDN2 -7.418 -7.938 
RP11-449P15.2 -7.569 -7.392 
ESPN -8.818 7.07 
POU3F2 -9.876 65.559 
CAPN12 -10.016 -6.172 
SMAD6 -10.083 -5.099 
UGT2B15 -10.654 -18.393 
HOXC9 -11.204 -2.926 
RP11-400N9.1 -11.514 -18.746 
ABCG1 -12.574 -2.813 
SEMA5B -12.705 7.155 
PLA2G2A -13.182 -13.837 
BPIFB1 -13.856 -7.439 
NTS -14.156 -32.581 
RP11-586D19.1 -18.587 -3.339 
KNG1 -19.029 -7.121 
LRRN1 -19.051 -4.721 
QRFP -23.221 -63.606 
CPLX3 -26.14 -6.019 
LINC00940 -31.823 -9.083 
MATK -36.148 -5.515 
BMX -36.484 -25.225 
RP11-1406H17.1 -38.876 -9.122 
UMODL1 -38.886 -19.179 
ABCC6P1 -40.717 -7.461 
ANO2 -41.879 -93.959 
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LRAT -42.65 3.548 
RP11-90K6.1 -48.271 -43.098 
RAMP2-AS1 -49.561 -12.764 
ALB -51.279 -7.509 
CD200 -51.694 -19.628 
FRMPD2L2 -96.729 -23.601 
VWA5B1 -111.943 -44.642 
NWD1 -120.095 -12.947 
TRIM49 -126.247 -47.049 
SI -133.245 -5.984 
RP11-231E6.1 -180.807 -39.633 
FPR3 -184.526 -15.494 
CPAMD8 -280.074 -7.616 
IGHG3 -767.297 -20.451 
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Appendix Table 24. 468 genes in common between LNCaP and VCaP cells treated in HCM with no DHT. 
Genes VCaP HCM vs RPMI LNCaP HCM vs RPMI 
CXCL8 18.474 429.028 
PLEKHA4 16.509 269.604 
ETV4 187.333 231.306 
EGR1 88.494 154.849 
TIMP1 32.455 121.484 
ADAMTS6 191.38 101.484 
GSDMA 459.48 88.847 
TRGV9 -6.637 84.696 
MMP10 6.235 81.394 
A2M 7126.989 76.792 
DACT1 13.824 74.538 
PLA2G4E 69.21 72.724 
RP1-69M21.2 51.966 61.903 
EGR2 120.082 58.305 
DIRAS3 83.947 46.961 
METTL7B 1196.6 41.427 
TRGC1 -6.8 30.507 
SIPA1L2 11.009 28.078 
EGR3 14.33 26.618 
GPR3 22.213 25.311 
ETV5 120.125 24.888 
FOS 10.088 24.194 
KLK2 -17.281 23.878 
HPGD -9.46 23.786 
LMO2 10.909 22.085 
MAK 10.378 20.779 
GCNT3 12.252 20.451 
CHST1 23.85 18.611 
VGF 9.879 17.929 
DUSP6 41.913 16.543 
APOH -6.653 16.465 
RP11-303E16.2 5.502 15.906 
CHRM3 960.34 15.758 
CADPS2 3.189 15.748 
RP11-599B13.9 136.824 14.017 
PIP5K1B 29.213 12.964 
NTNG2 -5.847 12.127 
GDF15 6.858 11.759 
ANXA2 4.752 10.269 
FAM65B 18.081 9.829 
PKHD1 -6.177 9.588 
DUSP4 5.421 9.519 
CENPN 3.445 9.267 
HSPA2 5.776 9.203 
KLK3 -5.28 9.057 
CXCR4 118.855 9.003 
TLE4 4.602 8.912 
CLDN1 11.165 8.716 
FAM129A 6.512 8.621 
INSIG1 18.678 8.596 
MYBL1 16.975 8.527 
HIST2H3C 20.839 8.439 
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HIST2H3A 20.839 8.439 
DNER 13.583 8.049 
CDKN2B-AS1 88.123 7.748 
KLF5 4.778 7.409 
TGFBR2 8.678 7.342 
DUSP5 9.117 6.945 
CDH7 3.308 6.862 
FDFT1 4.004 6.737 
PHLDA2 2.778 6.536 
BHLHE40 4.536 6.511 
F5 8.695 6.421 
C14orf37 5.066 6.378 
LY6G6C 28.316 6.374 
LAMA1 3.946 6.206 
UBASH3B 6.308 6.154 
PDE4B -4.11 6.056 
FAM111B 9.321 6.009 
AKAP2 -3.742 5.839 
HMGCS1 7.867 5.821 
ATF3 5.827 5.485 
NPTX2 8.852 5.327 
KLKP1 -2.788 4.885 
INPP4B -3.492 4.837 
SHC4 5.077 4.703 
ERCC6L 5.893 4.655 
SGOL1 3.929 4.506 
NEIL3 5.212 4.505 
CENPI 4.108 4.478 
WIPI1 5.474 4.412 
SKA1 4.102 4.319 
LPIN1 1.718 4.315 
DNAH7 15.113 4.304 
HMGCR 2.925 4.2 
ANLN 4.281 4.198 
DHCR7 3.684 4.185 
GPX8 9.28 4.183 
DSCC1 4.78 4.113 
CDC6 8.489 4.091 
EME1 6.127 4.089 
MNS1 8.609 4.082 
DDIAS 7.027 4.067 
RAD51 7.759 4.063 
GSG2 3.633 4.037 
FDPS 3.041 4.001 
MSMO1 4.614 3.993 
BLM 6.381 3.962 
NRCAM 4.412 3.803 
SHCBP1 3.285 3.792 
EBP 5.517 3.772 
HYDIN 4.804 3.746 
LCA5L 4.1 3.729 
FAM46C 23.064 3.71 
NRXN3 3.656 3.675 
GAS2L3 3.775 3.672 
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ORC6 5.521 3.623 
KIF24 8.351 3.613 
LPAR3 5.336 3.59 
NFKB2 2.092 3.577 
SQLE 4.08 3.561 
MALL 6.262 3.529 
HELLS 5.913 3.518 
CDKN2B 14.657 3.505 
CCDC150 6.305 3.468 
MELK 4.746 3.391 
IQCD 5.496 3.338 
CENPK 4.502 3.334 
ATAD2 4.077 3.304 
RFC3 3.596 3.3 
MVD 5.939 3.286 
TICRR 5.299 3.269 
SPRED1 6.329 3.221 
SCD 6.013 3.205 
ARHGAP26 3.572 3.167 
CDC25A 3.012 3.165 
ZGRF1 3.637 3.142 
C5orf34 2.932 3.132 
IER5L 5.462 3.116 
ANKRD32 3.832 3.107 
KBTBD8 4.122 3.106 
CENPH 4.097 3.092 
IDI1 4.463 3.091 
ACAT2 3.163 3.071 
STK17B 2.477 3.051 
CCDC15 4.66 3.039 
SGK1 3.633 3.034 
PGD 2.133 3.031 
C19orf26 3.986 3.023 
IRS2 -2.367 3.022 
CNTNAP2 2.535 2.987 
GGCT 2.206 2.98 
CLGN 2.691 2.957 
ZWILCH 3.9 2.955 
PRIM1 3.051 2.925 
KIF20B 3.34 2.917 
RFC4 5.854 2.886 
GPSM2 3.284 2.877 
GADD45A 5.077 2.85 
ACSS2 1.943 2.839 
PLK4 4.685 2.828 
ATP8B2 2.16 2.809 
CYP51A1 3.277 2.78 
RHOU -2.42 2.776 
FEN1 6.918 2.761 
CENPP 4.907 2.742 
PER1 2.681 2.714 
JPH1 2.576 2.7 
CCDC18 4.302 2.699 
WDHD1 3.609 2.65 
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MPHOSPH9 2.186 2.647 
PGP 4.062 2.647 
EPDR1 -2.267 2.641 
GMNN 2.913 2.583 
TMEM194A 3.444 2.569 
CENPJ 2.973 2.565 
STIL 2.799 2.525 
BTG3 4.387 2.523 
SPRED2 3.04 2.505 
TEX30 3.084 2.482 
CDC7 4.812 2.47 
SFR1 2.114 2.461 
GUCY1B3 3.327 2.46 
STK17A 3.092 2.438 
SLC1A4 3.074 2.437 
VRK1 3.617 2.418 
TMPO 2.109 2.397 
IL6R 2.866 2.395 
IRF2BP2 1.967 2.373 
CKS1B 3.721 2.368 
TTLL4 1.93 2.357 
SMC4 2.664 2.344 
SAP30 2.278 2.344 
ICOSLG 1.879 2.334 
POLD3 4.079 2.326 
KPNA2 2.453 2.306 
SCML2 2.197 2.304 
B4GALT6 2.228 2.283 
FNIP2 2.252 2.255 
JUND 2.19 2.254 
GK 3.415 2.225 
STC2 -2.687 2.218 
NCAPG2 3.275 2.171 
SPDL1 2.065 2.164 
DSN1 2.614 2.119 
ERI1 2.692 2.115 
SNRPA1 1.613 2.105 
UCHL3 1.79 2.075 
C1orf21 2.142 2.073 
MANF 3.706 2.038 
RAD51C 2.363 1.967 
QSOX2 1.728 1.951 
JOSD1 1.747 1.94 
CEP78 2.193 1.917 
PDE4DIP 1.788 1.908 
SLC27A2 2.086 1.887 
RAD18 2.212 1.871 
EZH2 4.33 1.857 
PARP2 2.397 1.833 
INTS7 2.539 1.812 
SLBP 2.3 1.812 
SDCBP 1.732 1.807 
TMEM97 2.036 1.802 
GOT1 2.078 1.767 
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EFTUD1 1.805 1.755 
WARS 1.596 1.719 
C14orf1 1.903 1.706 
UBR7 1.701 1.621 
PHKB -1.798 -1.577 
MUT -1.588 -1.595 
HBP1 -1.634 -1.663 
SYNE2 2.02 -1.723 
CBFA2T2 -1.774 -1.734 
CACNA1H -2.296 -1.734 
BTG1 1.883 -1.735 
FBXO28 -1.975 -1.751 
C1RL -1.779 -1.82 
SPECC1 1.959 -1.835 
TMEM59 -1.766 -1.872 
MAPK13 -2.109 -1.893 
MCCC1 -2.078 -1.905 
ALAD 1.654 -1.91 
RWDD2A -3.509 -1.912 
SRC -1.864 -1.965 
SKAP2 1.89 -1.977 
LPCAT3 -1.731 -2.003 
SRSF8 -2.541 -2.024 
TMEM50B 2.583 -2.029 
CBR3-AS1 -1.944 -2.07 
ST5 1.76 -2.075 
RP11-983P16.4 -2.233 -2.111 
INPP5A -2.325 -2.133 
PIK3R3 2.165 -2.162 
NIPAL2 -3.068 -2.174 
CHD3 -2.888 -2.187 
TTC7B -2.26 -2.22 
RAP1GAP2 -2.534 -2.223 
GTF2IP1 -1.933 -2.251 
SNRK -1.855 -2.268 
PSD4 -2.627 -2.277 
SQRDL -2.12 -2.278 
C20orf194 -3.059 -2.367 
CASZ1 -2.157 -2.385 
GALNT10 2.157 -2.394 
NDRG2 -2.633 -2.398 
KIAA1467 -3.606 -2.405 
RP11-517B11.7 -2.75 -2.446 
SLCO5A1 -4.51 -2.45 
FOSL2 -1.814 -2.491 
AC013394.2 -1.858 -2.509 
DNASE1 -2.176 -2.517 
DHRS7 -4.509 -2.518 
OSBP2 -2.424 -2.521 
PRKG2 -10.183 -2.53 
FAM134B -2.072 -2.55 
GLIDR -2.836 -2.553 
FRAT2 -2.534 -2.56 
EEF1A2 -3.238 -2.573 
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DGAT2 -3.033 -2.591 
SHANK2 -2.893 -2.601 
RP11-216L13.19 -4.333 -2.631 
GALNT3 -1.904 -2.666 
TMC4 -3.041 -2.725 
NEK1 -1.897 -2.728 
LTB4R -2.662 -2.728 
TP73 4.331 -2.734 
GYLTL1B -2.324 -2.763 
GPRC5B 2.291 -2.763 
NCALD -2.326 -2.765 
RABL3 -1.703 -2.787 
PASK -9.168 -2.789 
CCNG2 -2.284 -2.793 
CTD-2377D24.4 -3.6 -2.81 
LCP1 -2.813 -2.817 
YPEL3 -2.716 -2.86 
INHBB -3.936 -2.877 
NDUFB4 -2.32 -2.906 
RP11-658F2.8 -1.956 -2.927 
LRP1 -2.763 -2.933 
RP4-758J24.5 -4.738 -2.934 
CA12 -2.803 -2.935 
NCOA2 -2.898 -2.94 
GARNL3 -5.483 -2.951 
KRTAP5-AS1 -3.058 -2.966 
RP3-414A15.12 -2.995 -2.967 
ZNF703 5.09 -3.013 
ASAP3 -1.859 -3.018 
PRRT2 -4.382 -3.02 
RP11-713C5.1 -4.736 -3.021 
FAM47E-STBD1 -3.002 -3.075 
COBLL1 -2.337 -3.099 
SOX4 1.776 -3.12 
CABLES1 -5.067 -3.128 
ZNF185 -2.684 -3.131 
TTLL3 -2.587 -3.161 
HOXB13 -7.166 -3.171 
CALD1 -2.627 -3.238 
FOXN3 -2.338 -3.261 
COL5A2 3.804 -3.317 
ATP8A1 -6.593 -3.319 
NETO1 -4.059 -3.362 
RGS11 -3.513 -3.382 
MAPRE2 2.934 -3.433 
TMEM229B -3.151 -3.452 
ANKRD65 -6.996 -3.482 
RP11-279F6.1 -4.459 -3.506 
SCAI -2.438 -3.523 
C15orf52 -2.381 -3.532 
LINC01138 -4.4 -3.545 
CTD-2626G11.2 -3.684 -3.573 
EYA2 -3.295 -3.588 
GDPD1 -4.422 -3.651 
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TRPV6 -3.565 -3.684 
PCDHB15 -3.074 -3.699 
PIK3AP1 -2.687 -3.722 
FFAR2 -3.768 -3.792 
PLCH2 -10.313 -3.796 
TEAD2 7.108 -3.815 
SLC16A2 -4.117 -3.901 
RP11-617F23.1 -3.002 -3.934 
C11orf95 -2.69 -3.996 
SMAD9 -5.884 -4.07 
CWH43 -2.523 -4.085 
ELFN2 -7.125 -4.108 
BZRAP1 -3.581 -4.236 
BCAS1 -21.876 -4.239 
RTN1 -3.589 -4.239 
DSEL -7.31 -4.263 
BOC -3.878 -4.297 
EFCAB11 -2.56 -4.386 
BIK -3.611 -4.4 
GATS -2.456 -4.413 
DAPK2 -4.37 -4.415 
ADRBK2 -2.12 -4.553 
OLFM2 -2.737 -4.598 
MYT1 -2.057 -4.701 
CLMN -2.8 -4.857 
MEX3A -2.919 -4.873 
PKNOX2 -4.194 -4.89 
AGO4 -4.626 -4.919 
MFSD4 -2.701 -4.927 
RCAN3 -2.004 -5.031 
MTURN -3.355 -5.194 
PIK3IP1 -14.46 -5.213 
GRIK2 5.831 -5.257 
FBLN2 -13.308 -5.3 
RP11-396K3.1 -2.973 -5.316 
AP001626.2 -11.037 -5.383 
PLLP -3.049 -5.387 
TIMP2 -2.658 -5.401 
COL9A2 -4.278 -5.488 
RTN4RL1 -5.894 -5.504 
RP11-54O7.3 -12.772 -5.589 
TTR -3.587 -5.645 
ARHGDIG -13.343 -5.779 
SH3RF1 -2.013 -5.797 
NKPD1 -4.617 -6.026 
SLIT1 -4.363 -6.047 
SAMD11 -9.593 -6.069 
UPB1 -36.692 -6.381 
MB -2.368 -6.538 
GRIN2D -10.163 -6.594 
FSTL1 -4.1 -6.652 
ODAM 5.548 -6.717 
SMAD7 -4.383 -6.799 
MYRIP -2.262 -6.906 
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LEPREL1 -6.28 -6.944 
A1CF -143.386 -7.12 
CD34 16.178 -7.287 
EDN2 -7.938 -7.418 
RP11-449P15.2 -7.392 -7.569 
MYO15B -3.185 -7.686 
GNG4 -3.378 -7.695 
NEB -23.251 -7.763 
NIPSNAP3A -2.149 -7.837 
DNAH11 -16.508 -8.072 
C1R -3.634 -8.295 
CECR1 -9.57 -8.608 
JAKMIP1 -4.175 -8.767 
ESPN 7.07 -8.818 
GPC6 -9.368 -9.217 
AC141928.1 -6.872 -9.516 
RP11-54O7.1 -10.494 -9.608 
LRRC31 -9.653 -9.643 
POU3F2 65.559 -9.876 
CAPN12 -6.172 -10.016 
SMAD6 -5.099 -10.083 
SELENBP1 -10.017 -10.186 
UGT2B15 -18.393 -10.654 
NAALAD2 -4.77 -10.664 
HOXC9 -2.926 -11.204 
UGT2B17 -356.5 -11.42 
RP11-400N9.1 -18.746 -11.514 
PLXNA4 -6.466 -11.651 
ABCG1 -2.813 -12.574 
SEMA5B 7.155 -12.705 
DNASE1L3 -55.312 -12.774 
PLA2G2A -13.837 -13.182 
BPIFB1 -7.439 -13.856 
NTS -32.581 -14.156 
SEMA6A -8.037 -14.797 
CPNE4 -4.087 -15.294 
RASSF2 -4.535 -16.623 
C5orf66 -3.088 -16.984 
ST6GALNAC5 -4.478 -17.827 
RP11-586D19.1 -3.339 -18.587 
PDIA2 -27.634 -18.703 
LRRN2 -8.168 -18.912 
KNG1 -7.121 -19.029 
LRRN1 -4.721 -19.051 
RASGRF1 -6.098 -19.059 
ACPP -11.087 -20.195 
GPER1 -3.467 -20.198 
UPK1A -6.472 -20.642 
BMF -3.414 -21.953 
EFHD1 -6.332 -22.057 
FAXDC2 -30.2 -22.365 
QRFP -63.606 -23.221 
DDC -4.433 -24.027 
ABCG2 14.661 -24.736 
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CPLX3 -6.019 -26.14 
DAPK1 -5.217 -30.026 
LINC00940 -9.083 -31.823 
IGSF21 -5.963 -36.105 
MATK -5.515 -36.148 
BMX -25.225 -36.484 
ID3 -28.925 -38.392 
RP11-1406H17.1 -9.122 -38.876 
UMODL1 -19.179 -38.886 
ABCC6P1 -7.461 -40.717 
ANO2 -93.959 -41.879 
LRAT 3.548 -42.65 
CACNA1G -7.293 -42.743 
ANO7 -16.966 -43.035 
ID1 -55.446 -43.465 
RP11-90K6.1 -43.098 -48.271 
RAMP2-AS1 -12.764 -49.561 
ALB -7.509 -51.279 
CD200 -19.628 -51.694 
APOL4 -9.605 -58.504 
LRRTM4 -48.619 -60.18 
LA16c-312E8.4 -21.88 -60.815 
HSPA12B -20.282 -85.53 
FRMPD2L2 -23.601 -96.729 
COL8A2 -27.221 -111.014 
VWA5B1 -44.642 -111.943 
NWD1 -12.947 -120.095 
TRIM49 -47.049 -126.247 
SLC6A4 -10.286 -132.699 
SI -5.984 -133.245 
MEGF10 -13.639 -159.406 
RP11-231E6.1 -39.633 -180.807 
FPR3 -15.494 -184.526 
CPAMD8 -7.616 -280.074 
LDLRAD4 -24.149 -285.436 
ATOH8 -62.132 -733.609 
PLA2G2F -195.939 -741.323 
IGHG3 -20.451 -767.297 
 
